EP4603484A2

Compounds for the treatment of bacterial infections and potentiation of antibiotics

Abstract

Provided is a compound of Formula IV or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection or potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection: wherein L2 is selected from v and w are independently selected from 0, 1, 2, 3, and 4; R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano; X8, and X9 are independently selected from O, S, NH, and Se; X10 is selected from Se, S, or NH; R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine; and R6 and R7 are independently at each occurrence selected from the group consisting of:

EP4603484A2, drawing sheet 1 — Sheet 1 of 569

Term

14.2 yearsto projected expiry

Projected expiry 18 December 2040, counted from filing; an application has no term until it is granted.

15 claims: 8 independent, 7 dependent

1
A compound of Formula IV or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection or potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection:wherein L 2 is selected from v and w are independently selected from 0, 1, 2, 3, and 4;R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkanoyl, aliphatic, carbocyclic, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, N(R 3 ) 2 , -NHSO 2 alkyl, -N(alkyl)SO 2 alkyl, -NHSO 2 aryl, -N(alkyl)SO 2 aryl, -NHSO 2 alkenyl, -N(alkyl)SO 2 alkenyl, -NHSO 2 alkynyl, - N(alkyl)SO 2 alkynyl, NO 2 , -COOH, -CONH 2 , -P(O)(OH) 2 , -S(O)R 3 , -SO 2 R 3 , -SO 3 R 3 , - SO 2 N(R 3 ) 2 , -OSO 2 R 3 , -N(R 3 )SO 2 R 3 , azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;X 8 , and X 9 are independently selected from O, S, NH, and Se;X 10 is selected from Se, S, or NH;R 3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkanoyl, carbocyclic, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;and R 6 and R 7 are independently at each occurrence selected from the group consisting of:
5
A compound of Formula VI or a pharmaceutically acceptable salt thereof for use in the treatment of a gram-positive or gram-negative bacterial infection:wherein: R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkanoyl, aliphatic, carbocyclic, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, N(R 3 ) 2 , -NHSO 2 alkyl, -N(alkyl)SO 2 alkyl, -NHSO 2 aryl, -N(alkyl)SO 2 aryl, -NHSO 2 alkenyl, -N(alkyl)SO 2 alkenyl, -NHSO 2 alkynyl, -N(alkyl)SO 2 alkynyl, NO 2 , -COOH, -CONH 2 , -P(O)(OH) 2 , -S(O)R 3 , -SO 2 R 3 , -SO 3 R 3 , -SO 2 N(R 3 ) 2 , -OSO 2 R 3 , -N(R 3 )SO 2 R 3 , azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano R 3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkanoyl, carbocyclic, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine R 9 and R 12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkanoyl, aliphatic, carbocyclic, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, N(R 3 ) 2 , -NHSO 2 alkyl, -N(alkyl)SO 2 alkyl, -NHSO 2 aryl, -N(alkyl)SO 2 aryl, -NHSO 2 alkenyl, -N(alkyl)SO 2 alkenyl, -NHSO 2 alkynyl, -N(alkyl)SO 2 alkynyl, NO 2 , -COOH, -CONH 2 , -P(O)(OH) 2 , -S(O)R 3 , -SO 2 R 3 , -SO 3 R 3 , -SO 2 N(R 3 ) 2 , -OSO 2 R 3 , -N(R 3 )SO 2 R 3 , azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;and R 10 and R 11 are independently at each occurrence selected from the group consisting of hydroxyl, C 1 -C 6 alkanoyl, carbocyclic, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, N(R 3 ) 2 , -NHSO 2 alkyl, -N(alkyl)SO 2 alkyl, -NHSO 2 aryl, -N(alkyl)SO 2 aryl, -NHSO 2 alkenyl, -N(alkyl)SO 2 alkenyl, -NHSO 2 alkynyl, -N(alkyl)SO 2 alkynyl, NO 2 , -COOH, -CONH 2 , - C(O)R, -P(O)(OH) 2 , -S(O)R 3 , -SO 2 R 3 , -SO 3 R 3 , -SO 2 N(R 3 ) 2 , -OSO 2 R 3 , -N(R 3 )SO 2 R 3 , azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano.
8
The compound of any one of claims 1-7 for the use of any one of claims 1 to 7, wherein the host is a human.
9
A compound selected from Compound F - Compound L or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection or of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection:and
11
A pharmaceutical composition comprising a compound selected from Compound F - Compound L or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.
12
A pharmaceutical composition comprising a compound of Formula IV or Formula VI:or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in combination with an effective amount of an antibiotic for the treatment of a bacterial infection in a host in need thereof wherein: m and o are independently selected from 0, 1, 2, or 3;n is 0, 1, 2, 3, or 4;L 2 is selected from v and w are independently selected from 0, 1, 2, 3, and 4;X 1 is O, S, or NR 4 ;X 8 and X 9 are independently selected from O, S, NH, and Se;X 10 is selected from Se, S, or NH;R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkanoyl, aliphatic, carbocyclic, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, N(R 3 ) 2 , -NHSO 2 alkyl, -N(alkyl)SO 2 alkyl, -NHSO 2 aryl, -N(alkyl)SO 2 aryl, -NHSO 2 alkenyl, -N(alkyl)SO 2 alkenyl, -NHSO 2 alkynyl, - N(alkyl)SO 2 alkynyl, NO 2 , -COOH, -CONH 2 , -P(O)(OH) 2 , -S(O)R 3 , -SO 2 R 3 , -SO 3 R 3 , - SO 2 N(R 3 ) 2 , -OSO 2 R 3 , -N(R 3 )SO 2 R 3 , azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;R 3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkanoyl, carbocyclic, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;R 6 and R 7 are independently at each occurrence selected from the group consisting of: R 9 and R 12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkanoyl, aliphatic, carbocyclic, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, N(R 3 ) 2 , -NHSO 2 alkyl, -N(alkyl)SO 2 alkyl, -NHSO 2 aryl, -N(alkyl)SO 2 aryl, -NHSO 2 alkenyl, -N(alkyl)SO 2 alkenyl, -NHSO 2 alkynyl, -N(alkyl)SO 2 alkynyl, NO 2 , -COOH, -CONH 2 , -P(O)(OH) 2 , -S(O)R 3 , -SO 2 R 3 , -SO 3 R 3 , -SO 2 N(R 3 ) 2 , -OSO 2 R 3 , -N(R 3 )SO 2 R 3 , azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;and R 10 and R 11 are independently at each occurrence selected from the group consisting of hydroxyl, C 1 -C 6 alkanoyl, carbocyclic, C 1 -C 6 hydroxyalkyl, C 1 -C 6 haloalkyl, N(R 3 ) 2 , -NHSO 2 alkyl, -N(alkyl)SO 2 alkyl, -NHSO 2 aryl, -N(alkyl)SO 2 aryl, -NHSO 2 alkenyl, -N(alkyl)SO 2 alkenyl, -NHSO 2 alkynyl, -N(alkyl)SO 2 alkynyl, NO 2 , -COOH, -CONH 2 , - C(O)R, -P(O)(OH) 2 , -S(O)R 3 , -SO 2 R 3 , -SO 3 R 3 , -SO 2 N(R 3 ) 2 , -OSO 2 R 3 , -N(R 3 )SO 2 R 3 , azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano.
14
A pharmaceutical composition comprising a compound selected from Compound F - Compound L or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in combination with an effective amount of an antibiotic for the treatment of a bacterial infection in a host in need thereof.
15
A compound selected from Compound F - Compound L or a pharmaceutically acceptable salt thereof.

Independent claims8

486 paragraphs in 15 sections, as filed

CROSS REFERENCE TO PRIORITY APPLICATION

0001This application claims priority to <patcit id="pcit0001" dnum="US62950852"><text>U.S. Provisional Application No. 62/950,852, filed December 19, 2019</text></patcit>, which is incorporated by reference herein in its entirety.

FIELD OF THE INVENTION

0002The invention provides compounds for use in the treatment of medical disorders caused by bacteria or for use as a potentiator of an antibiotic in the treatment of medical disorders caused by bacteria.

BACKGROUND OF THE INVENTION

0003Despite the overall success of antibiotics in diminishing the effects of infectious disease in the modern world, their ease of access has led to overuse, resulting in the development of bacterial resistance. Antibiotic resistance is on the rise globally, leading the World Health Organization to classify antibiotic resistance as a "serious threat [that] is no longer a prediction for the future" ("<nplcit id="ncit0001" npl-type="s"><text>Antimicrobial resistance: global report on surveillance 2014" The World Health Organization, April 2014</text></nplcit>). Antibiotic resistance is linked to inappropriate prescribing of antibiotics, incorrect dosing, and missing doses. In the United States, approximately 2.8 million people become infected with antibiotic resistant bacteria each year and roughly 35,000 die as a result ("Antibiotic/Antimicrobial Resistance (AR/AMR)" Centers for Disease Control and Prevention, https://www.cdc.gov/drugresistance/). Some bacteria harbor a natural resistance to certain types of antibiotics, while others may gain resistance by genetic mutation or horizontal gene transfer from already-resistant species. Bacteria diminish the effectiveness of antibiotics by modifying or inactivating the drug, altering the target or binding site, altering the metabolic pathways that propagate the drug's effects, or reducing accumulation of the drug within the cell by decreasing drug permeability or increasing efflux. Certain bacteria, colloquially known as "superbugs", may eventually develop resistance to multiple types of antibiotics, requiring alternative medications at higher doses, often with higher cost and greater toxicity.

0004Several preventative measures have been proposed to slow bacterial resistance to currently available antibiotics. Proper antibiotic stewardship along with increased hygiene provides significant strides in preventing future resistance. Despite this, new therapeutics are necessary to treat infections caused by currently resistant bacterial strains. The period from the 1950s until the 1970s represented the peak of antibiotic discovery, but since that time no new classes of antibiotics have been discovered, and development of new antibiotics within existing classes has been low. Alternative strategies, such as the development of bacterial vaccines and phage therapy, have not seen the success necessary to become widely used.

0005Investigators in the 1920s discovered that an anti-diabetic drug, Synthalin, had therapeutic activity against Trypanosoma brucei infections in mice. Out of a series of subsequently developed analogs, pentamidine was found to be curative of murine T. rhodesiense infections (<nplcit id="ncit0002" npl-type="s"><text>Yorke W. "Recent work on the chemotherapy of protozoal infections", Trans. R., Soc. Trop. Med. Hyg. 1940, 33:463</text></nplcit>). It was not until the 1960s that pentamidine became available on a restricted basis for use in the treatment of protozoal infections, and only in the 1980s did it see more extensive use as a treatment of pnuemocystis pneumonia in immunocompromised individuals such as HIV patients (<nplcit id="ncit0003" npl-type="s"><text>Sands et al. "Pentamidine: A Review", Reviews of Infectious Diseases 1985, 7(5):625-634</text></nplcit>). In recent years, pentamidine has received renewed interest as a possible therapeutic in the treatment of infections by antibiotic resistant bacteria. For example, pentamidine has been demonstrated to sensitize resistant bacteria to colistin, one of the antibiotics of last resort (<nplcit id="ncit0004" npl-type="s"><text>Stokes et al. "Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance", Nat. Microbiol. 2017, 2:17028</text></nplcit>; <nplcit id="ncit0005" npl-type="s"><text>Bean et al. "Pentamidine: a drug to consider re-purposing in the targeted treatment of multi-drug resistant bacterial infections?" J. Lab. Precis. Med. 2017, 2:49</text></nplcit>). <chemistry id="chem0001" num="0001"><img file="EP4603484A2_D0001.tif" /></chemistry><chemistry id="chem0002" num="0002"><img file="EP4603484A2_D0002.tif" /></chemistry>

0006The use of amidine compounds for biological applications is described in <nplcit id="ncit0006" npl-type="s"><text>Geratz et al. "Novel Bis(benzamidino) Compounds with an Aromatic Central Link. Inhibitors of Thrombin, Pancreatic Kallikrein, Trypsin, and Complement" J. Med. Chem. 1976, 19(5):634</text></nplcit>; <nplcit id="ncit0007" npl-type="s"><text>Parrish et al. "Structure-Activity Relationships for the Inhibition of Acrosin by Benzamidine Derivatives" J. Med. Chem. 1978, 21(11)1132</text></nplcit>; <nplcit id="ncit0008" npl-type="s"><text>Patrick et al. "Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyoxy)naphthalenes" Eur. J. Med. Chem. 2009, 44:3543</text></nplcit>; <nplcit id="ncit0009" npl-type="s"><text>Giordani et al. "Green Fluorescent Diamidine as Diagnostic Probes for Trypanosomes" Antimicrobial Agents and Chemotherapy 2014, 58:1793</text></nplcit>; <nplcit id="ncit0010" npl-type="s"><text>Munde et al. "The Unusual Monomer Recognition of Guanine-Containing Mixed Sequence DNA by a Dithiophene Heterocyclic Diamidine" Biochemistry 2014, 53:1218</text></nplcit>; <nplcit id="ncit0011" npl-type="s"><text>Arafa et al. "Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozoal agents" European Journal of Medicinal Chemistry, 2008, 43:2901</text></nplcit>; <nplcit id="ncit0012" npl-type="s"><text>Stephens et al. "Diguanidino and "Reversed" Diamidino 2,5-Diarylfurans as Antimicrobial Agents" J. Med. Chem, 2001, 44:1741</text></nplcit>; <nplcit id="ncit0013" npl-type="s"><text>Munde et al. "Structure-dependent inhibition of the ETS-family transcription factor PU.1 by novel heterocyclic diamidines" Nucleic Acids Research, 2014, 42: 1379</text></nplcit>; <nplcit id="ncit0014" npl-type="s"><text>Gonzalez, et al. "Synthesis and antiparasitic evaluation of bis-2,5-[4-guanidinophenyl]thiophenes" Eur J Med Chem, 2007, 42: 552</text></nplcit>; and <nplcit id="ncit0015" npl-type="s"><text>Wang et al. "Evaluation of the Influence of Compound Structure on Stacked-Dimer Formation in the DNA Minor Groove" Biochemistry, 2001, 40, 2511</text></nplcit>.

0007University of North Carolina describes the use of amidine compounds to inhibit RSV-induced cell fusion in <patcit id="pcit0002" dnum="US4619942A"><text>U.S. Patent No. 4,619,942</text></patcit> titled "Inhibition of Respiratory Syncytial Virus-Induced Cell Fusion by Amidino Compounds".

0008Eisai Co., Ltd. describes the use of amidine compounds as antifungal, antibacterial, and anti-trichomonal therapeutics in "<patcit id="pcit0003" dnum="US4034010A"><text>U.S. Patent No. 4,034,010</text></patcit> titled "Bis-(Meta-Amidinophenoxy)-Compounds and Pharmacologically Acceptable Acid Addition Salts Thereof".

0009Berlex Laboratories describes the use of amidine compounds as anticoagulants in International Patent Application Publication Nos. <patcit id="pcit0004" dnum="WO9628427A"><text>WO96/28427</text></patcit> titled "Benzamidine Derivatives Their Preparation and Their Use as Anti-Coagulants"; <patcit id="pcit0005" dnum="WO9729067A"><text>WO97/29067</text></patcit> titled "Benzamidine Derivatives Substituted by Amino Acid and Hydroxy Acid Derivatives and Their Use as Anti-Coagulants"; and <patcit id="pcit0006" dnum="WO0031068A"><text>WO00/31068</text></patcit> titled "Polyhydroxylated Heterocyclic Derivatives as Anticoagulants".

0010Georgia State University Research Foundation, Inc. and the University of North Carolina jointly disclosed the use of amidine compounds in amyloidosis and the treatment of microbial infections in International Patent Application Publication Nos. <patcit id="pcit0007" dnum="WO2003103598A"><text>WO2003/103598</text></patcit> titled "Amidine Derivatives for Treating Amyloidosis" and <patcit id="pcit0008" dnum="WO2005033065A"><text>WO2005/033065</text></patcit> titled "Novel Amidine Compounds for Treating Microbial Infections". The use of compounds for the treatment of microbial infections, including protozoa are disclosed in <patcit id="pcit0009" dnum="WO2005086808A"><text>WO 2005/086808</text></patcit> and <patcit id="pcit0010" dnum="WO2005040132A"><text>WO 2005/040132</text></patcit>. Bichalcophenes as antiprotozoal agents are also described in <patcit id="pcit0011" dnum="US20060293540A"><text>US 2006/0293540</text></patcit> assigned to the University of North Carolina and the Georgia State University Research Foundation, Inc.

0011Georgia State University Research Foundation and the Albert Einstein College of Medicine, Inc. disclosed the use of amidine and diamidine compounds for the inhibition of PU.1 and for the treatment of disorders associated with abnormal PU.1 levels in <patcit id="pcit0012" dnum="WO2017223260A"><text>WO 2017/223260</text></patcit>.

0012Georgia State University Research Foundation and the Ohio State Innovation Foundation disclosed the use of amidine compounds for the treatment of fungal infections in <patcit id="pcit0013" dnum="WO2018045106A"><text>WO 2018/045106</text></patcit> and compounds for the treatment of parasites in <patcit id="pcit0014" dnum="WO2018045104A"><text>WO 2018/045104</text></patcit>.

0013Georgia State University Research Foundation, Inc. has also disclosed the use of amidine compounds as DNA-targeting agents in <patcit id="pcit0015" dnum="US20100249175A"><text>US 2010/0249175</text></patcit> and compounds for the use of protozoa in <patcit id="pcit0016" dnum="WO2009051796A"><text>WO 2009/051796</text></patcit> and <patcit id="pcit0017" dnum="WO2005086754A"><text>WO 2005/086754</text></patcit>.

0014Neurochem, Inc. describes the use of amidine compounds in the treatment of amyloidosis in International Patent Application Publication No. <patcit id="pcit0018" dnum="WO03017994A"><text>WO03/017994</text></patcit> titled "Amidine Derivatives for Treating Amyloidosis".

0015Altana Pharma AG describes compounds including amidine derivatives for use as tryptase inhibitors in <patcit id="pcit0019" dnum="US9960588B"><text>U.S. Patent No. 9,960,588</text></patcit> titled "Tryptase Inhibitors".

0016Mpex Pharmaceuticals describes the use of amidine compounds as bacterial efflux inhibitors in International Patent Application Publication No. <patcit id="pcit0020" dnum="WO2005089738A"><text>WO2005/089738</text></patcit> title "Use and Administration of Bacterial Efflux Inhibitors". Bostian et al. also describe a similar use of amidine compounds as bacterial efflux inhibitors in the treatment of ophthalmic and otic infections in U.S. Patent Application Publication No. <patcit id="pcit0021" dnum="US20080132457A"><text>US2008/0132457</text></patcit> titled "Bacterial Efflux Inhibitors for the Treatment of Ophthalmic and Otic Infections".

0017The University of Cincinnati describes the use of amidine compounds for the treatment of pneumonia in International Patent Application Publication No. <patcit id="pcit0022" dnum="WO2006021833A"><text>WO2006/021833</text></patcit> titled "Bisbenzamidines for the Treatment of Pneumonia". Xavier University of Louisiana describes the use of amidine compounds for the treatment of trypanosomiasis in International Patent Application Publication No. <patcit id="pcit0023" dnum="WO2008090831A"><text>WO2008/090831</text></patcit> titled "Bisbenzamidines and Bisbenzamidoximes for the Treatment of Human African Trypanosomiasis".

0018The University of Oregon describes the use of pentamidine and related compounds in the treatment of myotonic dystrophy in International Patent Application Publication No. <patcit id="pcit0024" dnum="WO2009105691A"><text>WO2009/105691</text></patcit> titled "Use of Pentamidine and Related Compounds".

0019Orion Corporation describes the use of amidine compounds as protease inhibitors in Internationla Patent Application Publication No. <patcit id="pcit0025" dnum="WO2010133748A"><text>WO2010/133748</text></patcit> titled "Protease Inhibitors".

0020There remains a need for the development of novel therapeutics and pharmaceutical compositions and their use for the treatment of bacterial infections, including therapeutics that potentiate the effect of antibiotics on bacterial strains, including bacterial strains resistant to certain antibiotics.

SUMMARY OF THE INVENTION

0021The present invention provides compounds for use in the treatment of bacterial infections as well as for the potentiation of the therapeutic effect of antibiotics in the treatment of bacterial infections that comprise administering an effective amount of a compound described herein or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier. The bacterial infection may be caused by gram-positive bacteria, gram-negative bacteria, and/or antibiotic resistant bacteria. In one embodiment, the bacterial infection is caused by mycobacteria. The present invention is defined in the appended claims.

0022In a first aspect, the invention relates to a compound of Formula IV or a <ul id="ul0001" list-style="none" compact="compact"><li>pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection or potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection: <chemistry id="chem0003" num="0003"><img file="EP4603484A2_D0003.tif" /></chemistry></li><li>wherein</li><li>L2 is selected from <chemistry id="chem0004" num="0004"><img file="EP4603484A2_D0004.tif" /></chemistry></li><li>v and w are independently selected from 0, 1, 2, 3, and 4;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>X8, and X9 are independently selected from O, S, NH, and Se;</li><li>X10 is selected from Se, S, or NH;</li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine; and</li><li>R6 and R7 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0005" num="0005"><img file="EP4603484A2_D0005.tif" /></chemistry></li></ul>

0023In a preferred embodiment of the first aspect, the invention relates to the compound of Formula IV for the above-described use, wherein Formula IV is selected from <chemistry id="chem0006" num="0006"><img file="EP4603484A2_D0006.tif" /></chemistry><chemistry id="chem0007" num="0007"><img file="EP4603484A2_D0007.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.

0024In a preferred embodiment of the first aspect, the invention relates to the compound of Formula IV for the above-described use, wherein Formula IV is a compound of the structure: <chemistry id="chem0008" num="0008"><img file="EP4603484A2_D0008.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.

0025In a preferred embodiment of the first aspect, the invention relates to the compound of Formula IV for the above-described use, wherein the bacterial infection is caused by a gram-positive bacterium, a gram-negative bacterium, or a mycobacterium.

0026According to a second aspect of the present invention, described herein is a compound of Formula VI or a pharmaceutically acceptable salt thereof for use in the treatment of a gram-positive or gram-negative bacterial infection: <chemistry id="chem0009" num="0009"><img file="EP4603484A2_D0009.tif" /></chemistry> wherein: <ul id="ul0002" list-style="none" compact="compact"><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano</li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine</li><li>R9 and R12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano; and</li><li>R10 and R11 are independently at each occurrence selected from the group consisting of hydroxyl, C1-C6alkanoyl, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, - C(O)R, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano.</li></ul>

0027In a preferred embodiment of the second aspect, Formula VI is a compound of the formula: <chemistry id="chem0010" num="0010"><img file="EP4603484A2_D0010.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.

0028In a preferred embodiment of the second aspect, Formula VI is a compound selected from the group consisting of: <chemistry id="chem0011" num="0011"><img file="EP4603484A2_D0011.tif" /></chemistry><chemistry id="chem0012" num="0012"><img file="EP4603484A2_D0012.tif" /></chemistry><chemistry id="chem0013" num="0013"><img file="EP4603484A2_D0013.tif" /></chemistry><chemistry id="chem0014" num="0014"><img file="EP4603484A2_D0014.tif" /></chemistry><chemistry id="chem0015" num="0015"><img file="EP4603484A2_D0015.tif" /></chemistry> and <chemistry id="chem0016" num="0016"><img file="EP4603484A2_D0016.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.

0029In a preferred embodiment of the above aspects, the host is a human.

0030According to a third aspect , the present invention relates to a compound selected from Compound F - Compound L or a pharmaceutically acceptable salt thereof for use in the treatment of a bacterial infection or of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection: <chemistry id="chem0017" num="0017"><img file="EP4603484A2_D0017.tif" /></chemistry><chemistry id="chem0018" num="0018"><img file="EP4603484A2_D0018.tif" /></chemistry><chemistry id="chem0019" num="0019"><img file="EP4603484A2_D0019.tif" /></chemistry><chemistry id="chem0020" num="0020"><img file="EP4603484A2_D0020.tif" /></chemistry><chemistry id="chem0021" num="0021"><img file="EP4603484A2_D0021.tif" /></chemistry><chemistry id="chem0022" num="0022"><img file="EP4603484A2_D0022.tif" /></chemistry> and <chemistry id="chem0023" num="0023"><img file="EP4603484A2_D0023.tif" /></chemistry>

0031According to a preferred embodiment of the third aspect, the bacterial infection is caused by a gram-positive bacterium, a gram-negative bacterium, or a mycobacterium.

0032According to a fourth aspect, the present invention relates to a pharmaceutical composition comprising a compound selected from Compound F - Compound L <chemistry id="chem0024" num="0024"><img file="EP4603484A2_D0024.tif" /></chemistry><chemistry id="chem0025" num="0025"><img file="EP4603484A2_D0025.tif" /></chemistry><chemistry id="chem0026" num="0026"><img file="EP4603484A2_D0026.tif" /></chemistry><chemistry id="chem0027" num="0027"><img file="EP4603484A2_D0027.tif" /></chemistry><chemistry id="chem0028" num="0028"><img file="EP4603484A2_D0028.tif" /></chemistry><chemistry id="chem0029" num="0029"><img file="EP4603484A2_D0029.tif" /></chemistry><chemistry id="chem0030" num="0030"><img file="EP4603484A2_D0030.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

0033According to a fifth aspect, the present invention relates to a pharmaceutical composition comprising a compound of Formula IV or Formula VI: <chemistry id="chem0031" num="0031"><img file="EP4603484A2_D0031.tif" /></chemistry><chemistry id="chem0032" num="0032"><img file="EP4603484A2_D0032.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in combination with an effective amount of an antibiotic for the treatment of a bacterial infection in a host in need thereof wherein: <ul id="ul0003" list-style="none" compact="compact"><li>m and o are independently selected from 0, 1, 2, or 3;</li><li>n is 0, 1, 2, 3, or 4;</li><li>L2 is selected from <chemistry id="chem0033" num="0033"><img file="EP4603484A2_D0033.tif" /></chemistry></li><li>v and w are independently selected from 0, 1, 2, 3, and 4;</li><li>X1 is O, S, or NR4;</li><li>X8 and X9 are independently selected from O, S, NH, and Se;</li><li>X10 is selected from Se, S, or NH; R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;</li><li>R6 and R7 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0034" num="0034"><img file="EP4603484A2_D0034.tif" /></chemistry></li><li>R9 and R12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano; and</li><li>R10 and R11 are independently at each occurrence selected from the group consisting of hydroxyl, C1-C6alkanoyl, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, - C(O)R, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano.</li></ul>

0034According to a preferred embodiment of the fifth aspect, the compound of Formula IV is: <chemistry id="chem0035" num="0035"><img file="EP4603484A2_D0035.tif" /></chemistry><chemistry id="chem0036" num="0036"><img file="EP4603484A2_D0036.tif" /></chemistry> or wherein the compound of Formula IV is: <chemistry id="chem0037" num="0037"><img file="EP4603484A2_D0037.tif" /></chemistry> and <chemistry id="chem0038" num="0038"><img file="EP4603484A2_D0038.tif" /></chemistry> and wherein the compound of Formula VI is: <chemistry id="chem0039" num="0039"><img file="EP4603484A2_D0039.tif" /></chemistry><chemistry id="chem0040" num="0040"><img file="EP4603484A2_D0040.tif" /></chemistry><chemistry id="chem0041" num="0041"><img file="EP4603484A2_D0041.tif" /></chemistry><chemistry id="chem0042" num="0042"><img file="EP4603484A2_D0042.tif" /></chemistry><chemistry id="chem0043" num="0043"><img file="EP4603484A2_D0043.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.

0035According to a sixth aspect, the present invention relates to a pharmaceutical composition comprising a compound selected from Compound F - Compound L <chemistry id="chem0044" num="0044"><img file="EP4603484A2_D0044.tif" /></chemistry><chemistry id="chem0045" num="0045"><img file="EP4603484A2_D0045.tif" /></chemistry><chemistry id="chem0046" num="0046"><img file="EP4603484A2_D0046.tif" /></chemistry><chemistry id="chem0047" num="0047"><img file="EP4603484A2_D0047.tif" /></chemistry><chemistry id="chem0048" num="0048"><img file="EP4603484A2_D0048.tif" /></chemistry><chemistry id="chem0049" num="0049"><img file="EP4603484A2_D0049.tif" /></chemistry><chemistry id="chem0050" num="0050"><img file="EP4603484A2_D0050.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in combination with an effective amount of an antibiotic for the treatment of a bacterial infection in a host in need thereof.

0036According to a seventh aspect, the present invention relates to a compound selected from Compound F - Compound L <chemistry id="chem0051" num="0051"><img file="EP4603484A2_D0051.tif" /></chemistry><chemistry id="chem0052" num="0052"><img file="EP4603484A2_D0052.tif" /></chemistry><chemistry id="chem0053" num="0053"><img file="EP4603484A2_D0053.tif" /></chemistry><chemistry id="chem0054" num="0054"><img file="EP4603484A2_D0054.tif" /></chemistry><chemistry id="chem0055" num="0055"><img file="EP4603484A2_D0055.tif" /></chemistry><chemistry id="chem0056" num="0056"><img file="EP4603484A2_D0056.tif" /></chemistry><chemistry id="chem0057" num="0057"><img file="EP4603484A2_D0057.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.

0037Further described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: <chemistry id="chem0058" num="0058"><img file="EP4603484A2_D0058.tif" /></chemistry> wherein: <ul id="ul0004" list-style="none" compact="compact"><li>m and o are independently selected from 0, 1, 2, or 3;</li><li>n is 0, 1, 2, 3, or 4;</li><li>X1 is O, S, or NR4;</li><li>X3 is independently at each occurrence selected from the group consisting of C(R3)2, O, S, and NR4;</li><li>X4 is independently at each occurrence selected from the group consisting of CR3 and N;</li><li>X5 is C(R3)2, O, or S;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R1 and R2 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0059" num="0059"><img file="EP4603484A2_D0059.tif" /></chemistry> and <chemistry id="chem0060" num="0060"><img file="EP4603484A2_D0060.tif" /></chemistry></li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine; and</li><li>R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl.</li></ul>

0038In another aspect, a method is provided for treating a bacterial infection in a host, typically a human, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

0039In another aspect, a method is provided for potentiating the effect of a bacterial infection in a host, typically a human, comprising administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in combination with an antibiotic.

0040A pharmaceutical composition is also provided comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier either alone or in combination with an effective amount of an additional antibiotic.

0041In another aspect, a method is provided for treating a bacterial infection comprising administering an effective amount of a compound of Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof to a host in need thereof: <chemistry id="chem0061" num="0061"><img file="EP4603484A2_D0061.tif" /></chemistry><chemistry id="chem0062" num="0062"><img file="EP4603484A2_D0062.tif" /></chemistry> wherein <ul id="ul0005" list-style="none" compact="compact"><li>L1 is selected from <chemistry id="chem0063" num="0063"><img file="EP4603484A2_D0063.tif" /></chemistry></li><li>L2 is selected from <chemistry id="chem0064" num="0064"><img file="EP4603484A2_D0064.tif" /></chemistry></li><li>v and w are independently selected from 0, 1, 2, 3, and 4;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>X6, X7, X8, and X9 are independently selected from O, S, NH, and Se;</li><li>X10 is selected from Se, S, or NH;</li><li>R6 and R7 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0065" num="0065"><img file="EP4603484A2_D0065.tif" /></chemistry> and</li><li>X3, X4, R4, and R5 are as defined herein.</li></ul>

0042In some embodiments of Formula II, Formula III, Formula IV, and/or Formula V, X10 is not S.

0043In some embodiments of Formula II, Formula III, Formula IV, and/or Formula V, X10 is not NH.

0044In some embodiments of Formula II, Formula III, Formula IV and/or Formula V, L2 is not <chemistry id="chem0066" num="0066"><img file="EP4603484A2_D0066.tif" /></chemistry>

0045In some embodiments of Formula II, Formula III, Formula IV and/or Formula V, one or more of X6, X7, X8, and X9 is not NH.

0046In another aspect, a method is provided for treating a bacterial infection comprising administering an effective amount of Compound A, Compound B, or Compound C <chemistry id="chem0067" num="0067"><img file="EP4603484A2_D0067.tif" /></chemistry><chemistry id="chem0068" num="0068"><img file="EP4603484A2_D0068.tif" /></chemistry><chemistry id="chem0069" num="0069"><img file="EP4603484A2_D0069.tif" /></chemistry><chemistry id="chem0070" num="0070"><img file="EP4603484A2_D0070.tif" /></chemistry> or a pharmaceutically acceptable salt thereof to a host in need thereof.

0047In certain embodiments a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof can be used to potentiate the effect of an antibiotic in the treatment of a bacterial infection.

0048In certain embodiments Compound A, Compound B, or Compound C or a pharmaceutically acceptable salt thereof can be used to potentiate the effect of an antibiotic in the treatment of a bacterial infection.

0049In certain embodiment, the bacterial infection is caused by a gram-positive bacterium.

0050In certain embodiment, the bacterial infection is caused by a gram-negative bacterium.

0051In certain embodiment, the bacterial infection is caused by a mycobacterium.

0052In another aspect, a method is provided for treating a gram-positive or a gram-negative bacterial infection comprising administering an effective amount of a compound of Formula VI: <chemistry id="chem0071" num="0071"><img file="EP4603484A2_D0071.tif" /></chemistry> or a pharmaceutically acceptable salt thereof wherein <ul id="ul0006" list-style="none" compact="compact"><li>R9 and R12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano; and</li><li>R10 and R11 are independently at each occurrence selected from the group consisting of hydroxyl, C1-C6alkanoyl, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, - C(O)R, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano.</li></ul>

0053In another aspect, a method is provided for treating a gram-positive or a gram-negative bacterial infection comprising administering an effective amount of Compound D or Compound E: <chemistry id="chem0072" num="0072"><img file="EP4603484A2_D0072.tif" /></chemistry><chemistry id="chem0073" num="0073"><img file="EP4603484A2_D0073.tif" /></chemistry> or a pharmaceutically acceptable salt thereof to a host in need thereof.

0054In some cases, the compound for use in treating a bacterial infection is not Compound D or Compound E.

0055In one aspect, the invention is a compound selected from Compound F - Compound L or a pharmaceutically acceptable salt thereof: <chemistry id="chem0074" num="0074"><img file="EP4603484A2_D0074.tif" /></chemistry><chemistry id="chem0075" num="0075"><img file="EP4603484A2_D0075.tif" /></chemistry><chemistry id="chem0076" num="0076"><img file="EP4603484A2_D0076.tif" /></chemistry><chemistry id="chem0077" num="0077"><img file="EP4603484A2_D0077.tif" /></chemistry><chemistry id="chem0078" num="0078"><img file="EP4603484A2_D0078.tif" /></chemistry><chemistry id="chem0079" num="0079"><img file="EP4603484A2_D0079.tif" /></chemistry><chemistry id="chem0080" num="0080"><img file="EP4603484A2_D0080.tif" /></chemistry>

0056A pharmaceutical composition is also provided comprising an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI or a compound selected from Compound A - Compound L or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier in combination with an effective amount of an additional antibiotic. In one embodiment, the pharmaceutical composition is suitable for topical administration, for example a cream or an ointment. The topical composition can include any carrier or carriers that do not adversely interact with the active agent and achieve the desired effect.

0057In another aspect, provided herein is a compound of Formula VII or a pharmaceutically acceptable salt thereof: <chemistry id="chem0081" num="0081"><img file="EP4603484A2_D0081.tif" /></chemistry> wherein: <ul id="ul0007" list-style="none" compact="compact"><li>m and n are independently selected from 1, 2, 3, or 4;</li><li>p is 0, 1, 2, or 3;</li><li>q and t are independently at each occurrence 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>L3 and L4 are each independently C(R3)2, O, or S;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;</li><li>R13 and R14 are independently at each occurrence selected from the group consisting of <chemistry id="chem0082" num="0082"><img file="EP4603484A2_D0082.tif" /></chemistry> and -C(R3)oNR4R5 wherein R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl and o is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>X11 and X12 are each independently selected from the group consisting of C(R3)2, O, NH, or S;</li><li>Y1 and Y2 are each independently selected from the group consisting of C(R3)2, O, NH, or S; and</li><li>Z is CR3 or N.</li></ul>

0058Optionally, R4 and R5 are hydrogen.

0059Optionally, X11 and X12 are the same. In some cases, X11 and X12 are selected from the group consisting of O, CH2, and S.

0060Optionally, Y1 and Y2 are the same. In some cases, Y1 and Y2 are selected from the group consisting of O and CH2.

0061Optionally, each R is independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and fluorine.

0062Optionally, the compound has the following structure: <chemistry id="chem0083" num="0083"><img file="EP4603484A2_D0083.tif" /></chemistry>

0063In another aspect, a method is provided for treatment of a bacterial infection comprising administering a compound of Formula VII or a pharmaceutically acceptable salt thereof. Also provided is a method of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection comprising administering a compound of Formula VII or a pharmaceutically acceptable salt thereof. In some cases, the bacterial infection is caused by gram-positive bacteria. In other cases, the bacterial infection is caused by gram-negative bacteria. Optionally, the bacterial infection is caused by a mycobacterium.

0064In another aspect, provided herein is a compound of Formula VIII or a pharmaceutically acceptable salt thereof: <chemistry id="chem0084" num="0084"><img file="EP4603484A2_D0084.tif" /></chemistry> wherein: <ul id="ul0008" list-style="none" compact="compact"><li>m and n are independently selected from 1, 2, 3, or 4;</li><li>p is 0, 1, 2, or 3;</li><li>q and t are independently at each occurrence 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>L3 and L4 are each independently C(R3)2, O, or S;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;</li><li>R13 and R14 are independently at each occurrence selected from the group consisting of <chemistry id="chem0085" num="0085"><img file="EP4603484A2_D0085.tif" /></chemistry> and -C(R3)oNR4R5 wherein R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl and o is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>X11 and X12 are each independently selected from the group consisting of C(R3)2, O, NH, or S;</li><li>Y1 and Y2 are each independently selected from the group consisting of C(R3)2, O, NH, or S; and</li><li>Z is CR3 or N.</li></ul>

0065Optionally, R4 and R5 are hydrogen.

0066Optionally, X11 and X12 are the same. In some cases, X11 and X12 are selected from the group consisting of O, CH2, and S.

0067Optionally, Y1 and Y2 are the same. In some cases, Y1 and Y2 are selected from the group consisting of O and CH2.

0068Optionally, each R is independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and fluorine.

0069Optionally, the compound has the following structure: <chemistry id="chem0086" num="0086"><img file="EP4603484A2_D0086.tif" /></chemistry>

0070In another aspect, a method is provided for treatment of a bacterial infection comprising administering a compound of Formula VIII or a pharmaceutically acceptable salt thereof. Also provided is a method of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection comprising administering a compound of Formula VIII or a pharmaceutically acceptable salt thereof. In some cases, the bacterial infection is caused by gram-positive bacteria. In other cases, the bacterial infection is caused by gram-negative bacteria. Optionally, the bacterial infection is caused by a mycobacterium.

0071In another aspect, provided herein is a pharmaceutical composition comprising a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

0072The present invention also provides a topical composition containing, either alone or in combination with an effective amount of an antibiotic, an effective amount of a compound selected from Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, or Formula VIII or a compound selected from Compound A - Compound L or a pharmaceutically acceptable salt thereof for the treatment of acne vulgaris. The compounds used in the topical compositions and methods provided herein have an anti-microbial effect that helps alleviate the symptoms of acne vulgaris and treat the underlying overgrowth of bacterial that cause acne, for example, the bacterium Propionibacterium acnes or Staphylococcus epidermidis.

0073The present invention also provides treatment options that may complement or replace those currently available in the treatment of this highly common dermatological condition.

0074For example, the topical carrier can be water-based or anhydrous. Water-based topical compositions are well known and described further below. Anhydrous pharmaceutically acceptable topical materials are also well known, and include silicon-based oils, aliphatic-based compositions, oleaginous materials, jellies, mineral oil, dimethicone, and other substantially anhydrous lipophilic carriers.

0075The active compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, or Formula VIII or a compound selected from Compound A - Compound L can be provided in the topical formulation in any amount that achieves the desired effect. In certain non-limiting examples, the weight percentage of the active compound in the topical formulation is from about 0.1% to about 50%, or from about 0.1% to about 40%, or about 1% to about 30%, or from about 2, 3, 4 or 5 % to about 20%, or between about 5% to about 10%.

0076Examples include at least about 0.5, 1, 2, 3, 4, 5, 10 or 15% by weight. In one embodiment, the topical formulation contains a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, or Formula VIII or a compound selected from Compound A - Compound L or a pharmaceutically acceptable salt thereof in combination with an additional active agent, for example benzoyl peroxide, a retinoid, azelaic acid, an antibiotic, or salicylic acid, as long as it does not adversely affect the active agent.

0077In one embodiment, at least one hydrogen within a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, or Formula VIII is replaced with a deuterium. In one aspect, the deuterium is at a location of metabolism. In one embodiment, at least one hydrogen within Compound A - Compound L is replaced with a deuterium. In one aspect, the deuterium is at a location of metabolism.

0078Thus, the present invention includes at least the following features: <ul id="ul0009" list-style="none" compact="compact"><li>(a) a compound of Formula I or a pharmaceutically salt thereof;</li><li>(b) a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof optionally in a pharmaceutically acceptable carrier;</li><li>(c) a method for the treatment of a bacterial infection comprising administering a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt to a host in need thereof;</li><li>(d) a method for the treatment of a bacterial infection comprising administering a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt in combination with an effective amount of an antibiotic to a host in need thereof;</li><li>(e) a method for potentiating the effect of an antibiotic in the treatment of a bacterial infection comprising administering the antibiotic in combination with a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof to a host in need thereof;</li><li>(f) the method of (c), (d), or (e) wherein the bacterial infection is caused by a gram-positive bacterial infection;</li><li>(g) the method of (c), (d), or (e) wherein the bacterial infection is caused by a gram-negative bacterial infection;</li><li>(h) the method of (c), (d), or (e) wherein the bacterial infection is caused by a mycobacterium;</li><li>(i) a method for the treatment of acne vulgaris comprising administering a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI or a pharmaceutically acceptable salt thereof, either alone or in combination with an antibiotic, to a host in need thereof;</li><li>(j) the method of (i) wherein the acne vulgaris is caused by the bacterium Propionibacterium acnes or Staphylococcus epidermidis;</li><li>(k) a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof for use to treat a bacterial infection in a host in need thereof;</li><li>(1) a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof in combination with an effective amount of an antibiotic for use to treat a bacterial infection in a host in need thereof;</li><li>(m)a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof for use in the potentiation of the effect of an antibiotic in the treatment of a bacterial infection;</li><li>(n) the compound of (k), (l) or (m) wherein the bacterial infection is caused by a gram-positive bacterial infection;</li><li>(o) the compound of (k), (1) or (m) wherein the bacterial infection is caused by a gram-negative bacterial infection;</li><li>(p) the compound of (k), (1) or (m) wherein the bacterial infection is caused by a mycobacterium;</li><li>(q) a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI or a pharmaceutically acceptable salt thereof for use to treat acne vulgaris in a host in need thereof;</li><li>(r) the compound of (q) wherein the acne vulgaris is caused by the bacterium Propionibacterium acnes or Staphylococcus epidermidis;</li><li>(s) the use of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a bacterial infection in a host in need thereof;</li><li>(t) the use of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof in combination with an effective amount of an antibiotic in the manufacture of a medicament for the treatment of a bacterial infection in a host in need thereof;</li><li>(u) the use of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the potentiation of the effect of an antibiotic in the treatment of a bacterial infection in a host in need thereof;</li><li>(v) the use of (s), (t), or (u) wherein the bacterial infection is caused by a gram-positive bacterial infection;</li><li>(w)the use of (s), (t), or (u) wherein the bacterial infection is caused by a gram-negative bacterial infection;</li><li>(x) the use of (s), (t), or (u) wherein the bacterial infection is caused by a mycobacterium;</li><li>(y) the use of a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of acne vulgaris in a host in need thereof;</li><li>(z) the use of (y) wherein the acne vulgaris is caused by the bacterium Propionibacterium acnes or Staphylococcus epidermidis;</li><li>(aa) a method for the treatment of a bacterial infection comprising administering a compound selected from Compound A, Compound B, Compound C, or Compound F - Compound L or a pharmaceutically acceptable salt to a host in need thereof;</li><li>(bb) a method for the treatment of a bacterial infection comprising administering a compound selected from Compound A, Compound B, Compound C, or Compound F - Compound L or a pharmaceutically acceptable salt in combination with an effective amount of an antibiotic to a host in need thereof;</li><li>(cc) a method for potentiating the effect of an antibiotic in the treatment of a bacterial infection comprising administering the antibiotic in combination with a compound selected from Compound A, Compound B, Compound C, or Compound F - Compound L or a pharmaceutically acceptable salt thereof to a host in need thereof;</li><li>(dd) the method of (aa), (bb), or (cc) wherein the bacterial infection is caused by a gram-positive bacterial infection;</li><li>(ee) the method of (aa), (bb), or (cc) wherein the bacterial infection is caused by a gram-negative bacterial infection; the method of (aa), (bb), or (cc) wherein the bacterial infection is caused by a mycobacterium;</li><li>(ff) a method for the treatment of acne vulgaris comprising administering a compound selected from Compound A, Compound B, Compound C, or Compound F - Compound L or a pharmaceutically acceptable salt thereof, either alone or in combination with an antibiotic, to a host in need thereof;</li><li>(gg) the method of (ff) wherein the acne vulgaris is caused by the bacterium Propionibacterium acnes or Staphylococcus epidermidis;</li><li>(hh) a method for the treatment of a gram-positive or a gram-negative bacterial infection comprising administering a compound of Formula VI or a pharmaceutically acceptable salt to a host in need thereof;</li><li>(ii) a method for the treatment of a gram-positive or a gram-negative bacterial infection comprising administering a compound of Formula VI or a pharmaceutically acceptable salt in combination with an effective amount of an antibiotic to a host in need thereof;</li><li>(jj) a method for potentiating the effect of an antibiotic in the treatment of a gram-positive or a gram-negative bacterial infection comprising administering the antibiotic in combination with a compound of Formula VI or a pharmaceutically acceptable salt thereof to a host in need thereof;</li><li>(kk) a method for the treatment of a gram-positive or a gram-negative bacterial infection comprising administering Compound D or Compound E or a pharmaceutically acceptable salt to a host in need thereof;</li><li>(ll) a method for the treatment of a gram-positive or a gram-negative bacterial infection comprising administering a compound selected from Compound D or Compound E or a pharmaceutically acceptable salt in combination with an effective amount of an antibiotic to a host in need thereof;</li><li>(mm)a method for potentiating the effect of an antibiotic in the treatment of a gram-positive or a gram-negative bacterial infection comprising administering the antibiotic in combination with a compound selected from Compound D or Compound E or a pharmaceutically acceptable salt thereof to a host in need thereof;</li><li>(nn) a pharmaceutical composition comprising an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier in combination with an effective amount of an antibiotic;</li><li>(oo) a topical formulation comprising an effective amount of a compound Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI or a pharmaceutically acceptable salt thereof in a topically acceptable carrier for the treatment of acne;</li><li>(pp) a pharmaceutical composition comprising an effective amount of a compound selected from Compound A, Compound B, Compound C, or Compound F - Compound L or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier in combination with an effective amount of an antibiotic;</li><li>(qq) a topical formulation comprising an effective amount of a compound selected from Compound A, Compound B, Compound C, or Compound F - Compound L or a pharmaceutically acceptable salt thereof in a topically acceptable carrier for the treatment of acne;</li><li>(rr) a compound of Formula VII or Formula VIII or a pharmaceutically salt thereof;</li><li>(ss)a pharmaceutical composition comprising a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt thereof optionally in a pharmaceutically acceptable carrier;</li><li>(tt) a method for the treatment of a bacterial infection comprising administering a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt to a host in need thereof;</li><li>(uu) a method for the treatment of a bacterial infection comprising administering a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt in combination with an effective amount of an antibiotic to a host in need thereof;</li><li>(vv) a method for potentiating the effect of an antibiotic in the treatment of a bacterial infection comprising administering the antibiotic in combination with a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt thereof to a host in need thereof;</li><li>(ww) the method of (tt), (uu), or (vv) wherein the bacterial infection is caused by a gram-positive bacterial infection;</li><li>(xx) the method of (tt), (uu), or (vv) wherein the bacterial infection is caused by a gram-negative bacterial infection;</li><li>(yy) the method of (tt), (uu), or (vv) wherein the bacterial infection is caused by a mycobacterium;</li><li>(zz) a process for the preparation of a therapeutic product that contains an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, or Formula VIII or a pharmaceutically acceptable salt thereof, either alone or in combination with an effective amount of an antibiotic.</li></ul>

0079The details of one or more embodiments are set forth in the drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the clauses.

DESCRIPTION OF DRAWINGS

0080<ul id="ul0010" list-style="none" compact="compact"><li><figref idref="f0001 f0002 f0003 f0004 f0005">Figure 1</figref> demonstrates that MD-124 sensitizes Gram-negative bacteria towards various existing antibiotics. Panel (A) is the structure of MD-124. Panel (B) shows that 5 µg/ml MD-124 sensitizes E. coli towards rifampicin (Rif). Values are means ± SD. n = 3. Panel (C) demonstrates that 5 µg/ml MD-124 itself showed no bacterial the growth inhibition effect. Values are means ± SD. n = 3. Panel (D) shows the results of a checkerboard assay of MD-124 (0 to 100 µg/ml) and rifampicin on E. coli. Panel (E) shows the results of a checkerboard assay of MD-124 (0 to 10 µg/ml) and rifampicin on E. coli. Panel (F) is a graph showing that MD-124 sensitizes various Gram-negative bacterial strains towards rifampicin (Rif). Sensitization fold = MIC of rifampicin only /MIC of rifampicin with MD-124. Panel (G) is a graph showing the bacterial sensitizations of E. coli towards rifampicin activity comparison between MD-124, pentamidine and PMBN. Panel (H) shows that 5 µg/ml MD-124 sensitizes E. coli toward a broad range of existing antibiotics. All results represent 3 replications.</li><li><figref idref="f0006 f0007">Figure 2</figref> shows the results of a resistance frequency study of MD-124. Panel (A) shows the resistance frequency of E. coli towards clindamycin (4, 6 and 7 times of the MIC) and clindamycin/MD-124 combination. Panel (B) shows the resistance frequency of E. coli towards trovafloxacin (2, 3 and 4 times of the MIC) and trovafloxacin/MD-124 combination. Panel (C) shows the resistance frequency of E. coli towards novobiocin (4, 5 and 6 times of the MIC) and novobiocin/MD-124 combination. The blue stars in Panels (A), (B), and (C) means no resistant colony was observed from 3 × 109 CFUs. Values are means ± SD. n = 3. ***: P < 0.001.</li><li><figref idref="f0008 f0009 f0010">Figure 3</figref> depicts results from a mechanistic study that revealed that MD-100 and MD-124 sensitize E.coli by disrupting the outer membrane and increasing antibiotics uptake. Panel (A) shows the proposed sensitization mechanism of MD-124 and MD-100. Panel (B) is a graph depicting that MD-124 showed compromised ability to sensitize a mutated, outer membrane "leaky" E. coli strain NR698 towards clarithromycin. Values are means ± SD. n = 3. Panel (C) shows that bacterial sensitizers can facilitate the E.coli lysis process by lysozyme. E.coli stock was incubated with 50 µg/ml lysozyme in the presence and absence of various bacterial sensitizers for 10 minutes at r.t and then the OD600 was recorded. Poly B and penta are short for polymyxin B and pentamidine, respectively. E.coli stock was also incubated with the same concentration of various bacterial sensitizers in the absence of lysozyme as control. Values are means ± SD. n = 3. ***: P < 0.001 compared with vehicle group. Panel (D) shows the correlation between outer membrane disruption ability and bacterial sensitization activity of the various bacterial sensitizer. Panel (E) shows the HPLC results of the O-methyl novobiocin concentration inside E.coli in the presence (a) and absence (b) of 25 µg/ml MD-100.</li><li><figref idref="f0011 f0012">Figure 4</figref> shows molecular mechanistic studies of bacterial sensitizers. Panel (A) shows that LPS can decrease the sensitization ability of MD-124 in a concentration dependent manner. E. coli was treated with 10 µM MD-124 (about 5 µg/ml) and rifampicin combination with varying concentration of LPS (from 0 to 40 µM) for 20 h at 37 °C, then the OD600 was measured and the sensitization fold were calculated as mentioned above. Panel (B) shows that Mg2+ can decrease the sensitization ability of MD-124 in a concentration dependent manner. E. coli was treated with 10 µM MD-124 (about 5 µg/ml) with vary concentration of Mg2+ (from 0 to 15 mM) for 20 hours at 37 °C, then the OD600 was measured and the sensitization fold under different conditions were calculated. Panel (C) depicts a Dansyl-PMBN displacement assay. To E.coli stock (OD600 = 0.3) in HEPES buffer (pH = 7.4) was added 10 µM Dansyl-PMBN and the fluorescent intensity was recorded as F1 (Ex = 340 nm; Em = 520 nm), then different concentration of bacterial sensitizers was added, and the fluorescent intensity was recorded as Fx. The fluorescent intensity of 10 µM Dansyl-PMBN in HEPES buffer was recorded as baseline F0. Fluorescent intensity/% = (F1-Fx)/(F1-F0). Values are means ± SD. n = 3; D) MD-124 sensitize mcr-1 over-expressing E. coli strains towards rifampicin. All results are triplicates.</li><li><figref idref="f0013 f0014 f0015">Figure 5</figref> shows that MD-124 sensitizes wild type A. baumannii, K. pneumoniae and drug-resistant Gram-negative strains towards existing antibiotics. Panels (A) and (B) are the results from checkerboard assays that showed MD-124 sensitized A. baumannii towards rifampicin and novobiocin. Panels (C) and (D) are the results from checkerboard assays that showed MD-124 sensitized K. pneumoniae towards rifampicin and clarithromycin. Panel (E) shows that MD-124 sensitized NDM-1 overexpression E. coli towards rifampicin. Panel (F) shows that MD-124 sensitized MCR-1 overexpression E. coli towards rifampicin. All experiments are at least duplicate results.</li><li><figref idref="f0016 f0017">Figure 6</figref> shows that MD-124 and antibiotic combinations achieved E. coli (wild-type and drug-resistant strain) growth inhibition in an ex vivo skin burn infection model. Panel (A) shows that MD-124 and novobiocin combination inhibited wild-type E. coli growth. Concentration (w/w) for polymyxin B (poly B), novobiocin (Novo) and MD-124 were 1‰, 4‰ and 1.5‰. The same novobiocin and MD-124 concentration was used in the combination group (Novo + MD-124). Panel (B) shows that MD-124 and clindamycin combination inhibited NDM-1 expressing E. coli growth. The concentrations (w/w) for polymyxin B (poly B), clindamycin (Clind) and MD-124 were 1‰, 3‰ and 1.5‰, respectively. The same clindamycin and MD-124 concentration was used in the combination group (Clind + MD-124). Values are means ± SEM. n = 5, ***P < 0.001 vs vehicle or antibiotic alone group. Panel (C) shows that the combination of MD-124 with various polymyxin B led to growth inhibition of mcr-1 positive E. coli in an ex vivo skin burn infection model. Concentration (w/w) for polymyxin B (poly B) and MD-124 were 3‰ and 1.5‰. The same concentration was used for polymyxin B and MD-124 in the combination groups (Poly B + MD-124). Values are means + SEM. n = 5, ***P < 0.001 vs antibiotics or the MD-124 alone group.</li><li><figref idref="f0018">Figure 7</figref> shows the results of a molecular mechanism study of bacterial sensitizers. Panel (A) shows that MD-100 failed to sensitize a mutated, outer membrane "leaky" E. coli strain NR698. Ery is short for erythromycin. 10 µg/ml MD-100 sensitized wild-type E. coli towards erythromycin for 32-fold (the comparison between the "Ery+10 µg/ml MD-100 line" and the "Ery only" line in Figure B, MIC of erythromycin is 50 µg/ml, and the MIC of erythromycin in the presence of 10 µg/ml MD-100 is 1.6 µg/ml ). E. coli NR698 was cultured with the antibiotic at various concentrations in the presence or absence of bacterial sensitizer for 24 h at 37 °C. Then bacterial growth density was determined by measuring OD600. Panel (B) shows the LPS and high concentration of Mg2+ decreased the sensitization ability of MD-100. E. coli was treated with 10 µg/ml MD-100 and erythromycin combination in the presence and absence of 40 µM LPS for 20 h at 37 °C. Then the growth density/% was calculated based on OD600. E. coli was treated with 10 µg/ml MD-100 and erythromycin combination in the presence and absence of 20 mM Mg2+ for 20 h at 37 °C, then the growth density/% was calculated based on OD600.</li><li><figref idref="f0019">Figure 8</figref> demonstrates that 5 µg/ml MD-124 sensitizes E. coli towards polymyxin B. E. coli was cultured with the polymyxin B at various concentrations in the presence or absence of 5 µg/ml MD-124 for 20 h at 37 °C. Then bacterial growth density was determined by measuring OD600.</li><li><figref idref="f0020">Figure 9</figref> shows the effect of phosphatidylcholine on MD-124 sensitization activity.</li><li><figref idref="f0021">Figure 10</figref> contains graphs showing that Membrane disruptor sensitize B. subtilis (Panel A) and MRSA (Panel B) towards Rifampicin. Bacteria was cultured with antibiotics at various concentrations in the presence or absence of bacteria sensitizer for 24 hours at 37 °C. Then bacterial growth density was determined by measuring OD600. ***: p <0.01.</li><li><figref idref="f0022">Figure 11</figref> contains graphs showing that MD-108 can change the composition between MRSA and E. coli (Panel A) or MRSA and B. subtilis (Panel B) when the bacteria strains are under the same antibiotic pressure.</li></ul>

DETAILED DESCRIPTION OF THE INVENTION

0081Described herein are compounds and methods for the treatment of bacterial infections as well as for the potentiation of the therapeutic effect of antibiotics in the treatment of bacterial infections. The methods include administering an effective amount of a compound described herein or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier. The bacterial infection may be caused by gram-positive bacteria, gram-negative bacteria, and/or antibiotic resistant bacteria. In one embodiment, the bacterial infection is caused by mycobacteria.

I. DEFINITIONS

0082Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention belongs.

0083The terms "a" and "an" do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. The term "or" means "and/or". Recitation of ranges of values merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of example, or exemplary language (e.g. "such as"), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise clauseed.

0084A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -(C=O)NH2 is attached through the carbon of the keto (C=O) group.

0085"Alkyl" is a branched or straight chain saturated aliphatic hydrocarbon group. In one non-limiting, preferred embodiment, the alkyl group generally contains from 1 to about 12 carbon atoms, from 1 to about 8 carbon atoms, from 1 to about 6 carbon atoms, or from 1 to about 4 carbon atoms. In certain embodiments, the alkyl is C1-C2, C1-C3, C1-C4, C1-C5, C1-C6, C1-C7, C1-C8, C1-C9, or C1-C10. In one embodiment, the alkyl group contains from about 1 to about 50 carbon atoms or from about 1 to about 36 carbon atoms. For example, the term C1-C6alkyl as used herein indicates a straight chain or branched alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these are described as an independent species. For example, the term C1-C4 alkyl as used herein indicates a straight or branched alkyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, tert-pentyl, sec-pentyl, 3-pentyl, active pentyl, neopentyl, n-hexyl, sec-hexyl, tert-hexyl, isohexyl, 2-methylpentance, 3-methylpentane, 2,2-dimethylbutane, and 2,3-dimethylbutane. In some embodiments, the alkyl group is optionally substituted as defined herein.

0086In one embodiment "alkyl" is a C1-C10alkyl, C1-C9alkyl, C1-C8alkyl, C1-C7alkyl, C1-C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, or C1-C2alkyl.

0087When a term is used that includes "alk" it should be understood that "cycloalkyl" or "carbocyclic" can be considered part of the definition, unless unambiguously excluded by the context. For example and without limitation, the terms alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkenloxy, haloalkyl, etc. can all be considered to include the cyclic forms of alkyl, unless unambiguously excluded by context.

0088For example, "cycloalkyl" is an alkyl group that forms or includes a ring. When composed of two or more rings, the rings may be joined together in a fused fashion. Non-limiting examples of typical cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

0089As used herein, "aryl" refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic system ("C6-C14aryl"). In some embodiments, an aryl group has 6 ring carbon atoms ("C6aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C10aryl"; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms ("C14aryl"; e.g., anthracyl). "Aryl" also includes ring systems wherein the aryl ring, as defined above, is fused with one or more cycloalkyl or heterocycloalkyl groups wherein the point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. The one or more fused cycloalkyl or heterocycloalkyl groups can be 4 to 7 or 5 to 7-membered cycloalkyl or heterocycloalkyl groups that optionally contain 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, phosphorous, sulfur, silicon, and boron. In one non-limiting embodiment, aryl groups are pendant. An example of a pendant ring is a phenyl group substituted with a phenyl group. In some embodiments, the aryl group is optionally substituted as defined herein.

0090In one embodiment "aryl" is a 6-carbon aromatic group (phenyl).

0091In one embodiment "aryl" is a 10-carbon aromatic group (naphthyl).

0092In one embodiment "aryl" is a 6-carbon aromatic group fused to a heterocycle wherein the point of attachment is the aryl ring. Non-limiting examples of "aryl" include indoline, tetrahydroquinoline, tetrahydroisoquinoline, and dihydrobenzofuran wherein the point of attachment for each group is on the aromatic ring.

0093For example <chemistry id="chem0087" num="0087"><img file="EP4603484A2_D0087.tif" /></chemistry> is an "aryl" group.

0094However, <chemistry id="chem0088" num="0088"><img file="EP4603484A2_D0088.tif" /></chemistry> is a "heterocycle" group.

0095In one embodiment "aryl" is a 6-carbon aromatic group fused to a cycloalkyl wherein the point of attachment is the aryl ring. Non-limiting examples of "aryl" include dihydro-indene and tetrahydronaphthalene wherein the point of attachment for each group is on the aromatic ring.

0096For example <chemistry id="chem0089" num="0089"><img file="EP4603484A2_D0089.tif" /></chemistry> is an "aryl" group.

0097However, <chemistry id="chem0090" num="0090"><img file="EP4603484A2_D0090.tif" /></chemistry> is a "cycloalkyl" group.

0098In one embodiment "aryl" is "substituted aryl".

0099In one embodiment "heteroaryl" is a 5-membered aromatic group containing 1, 2, 3, or 4 nitrogen atoms.

0100Non-limiting examples of 5 membered "heteroaryl" groups include pyrrole, furan, thiophene, pyrazole, imidazole, triazole, tetrazole, isoxazole, oxazole, oxadiazole, oxatriazole, isothiazole, thiazole, thiadiazole, and thiatriazole.

0101In one embodiment "heteroaryl" is a 6-membered aromatic group containing 1, 2, or 3 nitrogen atoms (i.e. pyridinyl, pyridazinyl, triazinyl, pyrimidinyl, and pyrazinyl).

0102In one embodiment "heteroaryl" is a 9-membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.

0103Non-limiting examples of "heteroaryl" groups that are bicyclic include indole, benzofuran, isoindole, indazole, benzimidazole, azaindole, azaindazole, purine, isobenzofuran, benzothiophene, benzoisoxazole, benzoisothiazole, benzooxazole, and benzothiazole.

0104In one embodiment "heteroaryl" is a 10-membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.

0105Non-limiting examples of "heteroaryl" groups that are bicyclic include quinoline, isoquinoline, quinoxaline, phthalazine, quinazoline, cinnoline, and naphthyridine.

0106In one embodiment "heteroaryl" is "substituted heteroaryl".

0107"Haloalkyl" is a branched or straight-chain alkyl groups substituted with 1 or more halo atoms described above, up to the maximum allowable number of halogen atoms. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. "Perhaloalkyl" means an alkyl group having all hydrogen atoms replaced with halogen atoms. Examples include but are not limited to, trifluoromethyl and pentafluoroethyl.

0108In one embodiment "haloalkyl" is a C1-C10haloalkyl, C1-C9haloalkyl, C1-C8haloalkyl, C1-C7haloalkyl, C1-C6haloalkyl, C1-C5haloalkyl, C1-C4haloalkyl, C1-C3haloalkyl, and C1-C2haloalkyl. "Alkoxy" is alkyl group as defined above covalently bounds through an oxygen bridge (-O-). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexyoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy. "Haloalkoxy" indicates a haloalkyl group as defined herein attached through an oxygen bridge (-O-).

0109As used herein, the term "active agent" refers to any type of drug, medicine, pharmaceutical, hormone, antibiotic, protein, gene, growth factor, bioactive material, etc., used for treating, controlling, or preventing diseases or medical conditions as described herein. The term "active agent" also includes the active compounds as described in the present application.

0110A "dosage form" means a unit of administration of an active agent. Examples of dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, implants, particles, spheres, creams, ointments, suppositories, inhalable forms, transdermal forms, buccal, sublingual, topical, gel, mucosal, and the like. A "dosage form" can also include an implant, for example an optical implant.

0111An "effective amount" as used herein means an amount which provides a therapeutic or prophylactic benefit.

0112"Parenteral" administration of a pharmaceutical composition includes, e.g., subcutaneous (s.c.), intravenous (i.v.), intramuscular (i.m.), intrasternal injection, or infusion techniques.

0113To "treat" a disease as the term is used herein means to reduce the frequency or severity of at least one sign or symptom of a disease or disorder experienced by a subject (i.e., palliative treatment) or to decrease a cause or effect of the disease or disorder (i.e. disease-modifying treatment).

0114As used herein, "pharmaceutical compositions" are compositions comprising at least one active agent and at least one other substance, such as a carrier. "Pharmaceutical combinations" are combinations of at least two active agents which may be combined in a single dosage form or provided together in separate dosage forms with instructions that the active agents are to be used together to treat any disorder described herein.

0115The term "carrier" applied to pharmaceutical compositions/combinations of the invention refers to a diluent, excipient, or vehicle with which an active compound is provided.

0116A "pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition/combination that is generally safe, non-toxic and neither biologically nor otherwise inappropriate for administration to a host, typically a human. In one embodiment, an excipient is used that is acceptable for veterinary use.

0117A "patient" or "host" or "subject" is a human or non-human animal in need of treatment or prevention of any of the disorders specifically described herein. Typically, the host is a human. A "host" may alternatively refer to for example, a mammal, primate (e.g. human), cow, sheep, goat, horse, dog, cat, rabbit, rat, mice, fish, bird, and the like.

0118A "therapeutically effective amount" of a pharmaceutical composition/combination of this invention means an amount effective, when administered to a host, to provide a therapeutic benefit such as an amelioration of symptoms or reduction or diminution of the disease itself.

0119The compounds in any of the Formulas described herein or Compound A - Compound L may be in the form of a racemate, enantiomer, mixture of enantiomers, diastereomer, mixture of diastereomers, tautomer, N-oxide, or other isomers, such as a rotamer, as if each is specifically described unless specifically excluded by context.

0120The present invention includes compounds of Formula I, Formula II, Formula III, Formula IV, or Formula V with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched. The present invention also includes compounds selected from Compound A - Compound L with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched. Isotopes are atoms having the same atomic number but different mass numbers, i.e., the same number of protons but a different number of neutrons.

0121Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine and iodine such as 2H, 3H, 11C, 13C, 14C, 15N, 17O, 18O,18F 31P, 32P, 35S, 36Cl, and 125I respectively. In one non-limiting embodiment, isotopically labelled compounds can be used in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

0122By way of general example and without limitation, isotopes of hydrogen, for example, deuterium (2H) and tritium (3H) may be used anywhere in described structures that achieves the desired result. Alternatively or in addition, isotopes of carbon, e.g., 13C and 14C, may be used.

0123Isotopic substitutions, for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium. In certain embodiments, the isotope is 90, 95 or 99% or more enriched in an isotope at any location of interest. In one non-limiting embodiment, deuterium is 90, 95 or 99% enriched at a desired location.

0124In one non-limiting embodiment, the substitution of one or more hydrogen atoms for a deuterium atoms can be provided in any of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI. In one non-limiting embodiment, the substitution of one or more hydrogen atoms for a deuterium atoms can be provided in a compound selected from Compound A - Compound L. In one non-limiting embodiment, the substitution of a hydrogen atom for a deuterium atom occurs within a group selected from any of R, R1, R2, R3, R4, and R5. For example, when any of the groups are, or contain for example through substitution, methyl, ethyl, or methoxy, the alkyl residue may be deuterated (in non-limiting embodiments, CDH2, CD2H, CD3, CH2CD3, CD2CD3, CHDCH2D, CH2CD3, CHDCHD2, OCDH2, OCD2H, or OCD3 etc.). In certain other embodiments, when two substituents are combined to form a cycle the unsubstituted carbons may be deuterated.

0125The compounds of the present invention may form a solvate with solvents. Therefore, in one non-limiting embodiment, the invention includes a solvated form of the compound. The term "solvate" refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules. Non-limiting examples of solvents are water, ethanol, dimethyl sulfoxide, acetone and other common organic solvents. Additional non-limiting examples of solvents are dimethyl acetamide and N-methyl-2-pyrrolidine. The term "hydrate" refers to a molecular complex comprising a compound of the invention and water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent may be isotopically substituted, e.g. D2O, d6-acetone, d6-DMSO. A solvate can be in a liquid or solid form.

0126As used herein, "pharmaceutically acceptable salt" is a derivative of the disclosed compound in which the parent compound is modified by making inorganic or organic, non-toxic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods.

0127Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reactive free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in a variety of solvents or solvent mixtures which are compatible with the compound. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practical. Salts of the present compounds further include solvates of the compound and the compound salts.

0128Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic organic acids. For example, conventional non-toxic acid salts include the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CH2)n-COOH where n is 0-4, and the like, or using a different acid that produces the same counterion. Lists of additional suitable salts may be found, e.g., in <nplcit id="ncit0016" npl-type="b"><text>Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985</text></nplcit>).

II. COMPOUNDS OF THE PRESENT INVENTION

0129In one aspect of the present invention, a compound of Formula I or a pharmaceutically acceptable salt is provided: <chemistry id="chem0091" num="0091"><img file="EP4603484A2_D0091.tif" /></chemistry> wherein: <ul id="ul0011" list-style="none" compact="compact"><li>m and o are independently selected from 0, 1, 2, or 3;</li><li>n is 0, 1, 2, 3, or 4;</li><li>X1 is O, S, or NR4;</li><li>X3 is independently at each occurrence selected from the group consisting of C(R3)2, O, S, and NR4;</li><li>X4 is independently at each occurrence selected from the group consisting of CR3 and N;</li><li>X5 is C(R3)2, O, or S;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R1 and R2 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0092" num="0092"><img file="EP4603484A2_D0092.tif" /></chemistry> and <chemistry id="chem0093" num="0093"><img file="EP4603484A2_D0093.tif" /></chemistry></li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine; and</li><li>R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, aryl, heteroaryl, heterocyclyl, -COOR, and -C(O)R.</li></ul>

0130In one embodiment, a compound is provided of Formula I or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to form a pharmaceutical composition.

0131In one embodiment of Formula I, m is 0. In one embodiment of Formula I, m is 1. In one embodiment of Formula I, m is 2. In one embodiment of Formula I, m is 3.

0132In one embodiment of Formula I, n is 0. In one embodiment of Formula I, n is 1. In one embodiment of Formula I, n is 2. In one embodiment of Formula I, n is 3. In one embodiment of Formula I, n is 4.

0133In one embodiment of Formula I, o is 0. In one embodiment of Formula I, o is 1. In one embodiment of Formula I, o is 2. In one embodiment of Formula I, o is 3. In one embodiment of Formula I, p is 0. In one embodiment of Formula I, p is 1. In one embodiment of Formula I, p is 2. In one embodiment of Formula I, X1 is O. In one embodiment of Formula I, X1 is NR4 and R4 is hydrogen. In one embodiment of Formula I, X1 is NR4 and R4 is C1-C6alkyl. In one embodiment of Formula I, X2 is O. In one embodiment of Formula I, X2 is S. In one embodiment of Formula I, X2 is NR4 and R4 is hydrogen. In one embodiment of Formula I, X2 is NR4 and R4 is C1-C6alkyl.

0134In one embodiment of Formula I, X3 is C(R3)2 and R3 is hydrogen. In one embodiment of Formula I, X3 is S. In one embodiment of Formula I, X3 is C(R3)2 and R3 is C1-C6alkyl. In one embodiment of Formula I, X3 is C(R3)2 and one R3 is hydrogen and the other is C1-C6alkyl. In one embodiment of Formula I, X3 is C(R3)2 and one R3 is fluorine, chlorine, bromine iodine or C1-C6haloalkyl. In one embodiment of Formula I, X3 is O. In one embodiment of Formula I, X3 is NR4 and R4 is hydrogen. In one embodiment of Formula I, X3 is NR4 and R4 is alkyl. In one embodiment of Formula I, X4 is N. In one embodiment of Formula I, X4 is CR3 and R3 is hydrogen. In one embodiment of Formula I, X4 is CR3 and R3 is C1-C6alkyl. In one embodiment of Formula I, X4 is C(R3)2 and R3 is fluorine, chlorine, bromine, iodine or C1-C6haloalkyl.

0135In one embodiment of Formula I, X5 is C(R3)2 and R3 is hydrogen. In one embodiment of Formula I, X3 is C(R3)2 and R3 is C1-C6alkyl. In one embodiment of Formula I, X5 is C(R3)2 and one R3 is hydrogen and the other is alkyl, hydroxyl, fluorine, chlorine, bromine iodine or C1-C6haloalkyl. In one embodiment of Formula I, X5 is O.

0136In one embodiment of Formula I, R is hydrogen, fluorine, chlorine, bromine, or iodine.

0137In one embodiment of Formula I, R1 is <chemistry id="chem0094" num="0094"><img file="EP4603484A2_D0094.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or C1-C6alkyl. In certain embodiments R1 is <chemistry id="chem0095" num="0095"><img file="EP4603484A2_D0095.tif" /></chemistry> wherein R4 and R3 are independently hydrogen or C1-C6alkyl.

0138In one embodiment of Formula I, R2 is <chemistry id="chem0096" num="0096"><img file="EP4603484A2_D0096.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or alkyl. In certain embodiments R2 is <chemistry id="chem0097" num="0097"><img file="EP4603484A2_D0097.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or C1-C6alkyl.

0139In one embodiment of Formula I, R1 and R2 are each <chemistry id="chem0098" num="0098"><img file="EP4603484A2_D0098.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or C1-C6alkyl. In one embodiment of Formula I, R1 and R2 are each <chemistry id="chem0099" num="0099"><img file="EP4603484A2_D0099.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or C1-C6alkyl.

0140In one embodiment of Formula I, <chemistry id="chem0100" num="0100"><img file="EP4603484A2_D0100.tif" /></chemistry> is selected from the group consisting of: <chemistry id="chem0101" num="0101"><img file="EP4603484A2_D0101.tif" /></chemistry><chemistry id="chem0102" num="0102"><img file="EP4603484A2_D0102.tif" /></chemistry><chemistry id="chem0103" num="0103"><img file="EP4603484A2_D0103.tif" /></chemistry>

0141In one embodiment of Formula I, <chemistry id="chem0104" num="0104"><img file="EP4603484A2_D0104.tif" /></chemistry> is selected from the group consisting of: <chemistry id="chem0105" num="0105"><img file="EP4603484A2_D0105.tif" /></chemistry><chemistry id="chem0106" num="0106"><img file="EP4603484A2_D0106.tif" /></chemistry>

0142In one embodiment of Formula I, <chemistry id="chem0107" num="0107"><img file="EP4603484A2_D0107.tif" /></chemistry> is selected from the group consisting of: <chemistry id="chem0108" num="0108"><img file="EP4603484A2_D0108.tif" /></chemistry><chemistry id="chem0109" num="0109"><img file="EP4603484A2_D0109.tif" /></chemistry><chemistry id="chem0110" num="0110"><img file="EP4603484A2_D0110.tif" /></chemistry><chemistry id="chem0111" num="0111"><img file="EP4603484A2_D0111.tif" /></chemistry><chemistry id="chem0112" num="0112"><img file="EP4603484A2_D0112.tif" /></chemistry><chemistry id="chem0113" num="0113"><img file="EP4603484A2_D0113.tif" /></chemistry><chemistry id="chem0114" num="0114"><img file="EP4603484A2_D0114.tif" /></chemistry><chemistry id="chem0115" num="0115"><img file="EP4603484A2_D0115.tif" /></chemistry><chemistry id="chem0116" num="0116"><img file="EP4603484A2_D0116.tif" /></chemistry>

0143In one embodiment of Formula I, <chemistry id="chem0117" num="0117"><img file="EP4603484A2_D0117.tif" /></chemistry> is selected from the group consisting of: <chemistry id="chem0118" num="0118"><img file="EP4603484A2_D0118.tif" /></chemistry><chemistry id="chem0119" num="0119"><img file="EP4603484A2_D0119.tif" /></chemistry>

0144In one embodiment of Formula I, <chemistry id="chem0120" num="0120"><img file="EP4603484A2_D0120.tif" /></chemistry> is selected from the group consisting of: <chemistry id="chem0121" num="0121"><img file="EP4603484A2_D0121.tif" /></chemistry><chemistry id="chem0122" num="0122"><img file="EP4603484A2_D0122.tif" /></chemistry> and <chemistry id="chem0123" num="0123"><img file="EP4603484A2_D0123.tif" /></chemistry>

0145In certain embodiments, the compound of Formula I is a compound of the formula: <chemistry id="chem0124" num="0124"><img file="EP4603484A2_D0124.tif" /></chemistry><chemistry id="chem0125" num="0125"><img file="EP4603484A2_D0125.tif" /></chemistry><chemistry id="chem0126" num="0126"><img file="EP4603484A2_D0126.tif" /></chemistry><chemistry id="chem0127" num="0127"><img file="EP4603484A2_D0127.tif" /></chemistry> or <chemistry id="chem0128" num="0128"><img file="EP4603484A2_D0128.tif" /></chemistry> In certain embodiments, the compound of Formula I is a compound of the formula: <chemistry id="chem0129" num="0129"><img file="EP4603484A2_D0129.tif" /></chemistry><chemistry id="chem0130" num="0130"><img file="EP4603484A2_D0130.tif" /></chemistry> or <chemistry id="chem0131" num="0131"><img file="EP4603484A2_D0131.tif" /></chemistry>

0146In certain embodiments, the compound of Formula I is a compound of the formula: <chemistry id="chem0132" num="0132"><img file="EP4603484A2_D0132.tif" /></chemistry><chemistry id="chem0133" num="0133"><img file="EP4603484A2_D0133.tif" /></chemistry><chemistry id="chem0134" num="0134"><img file="EP4603484A2_D0134.tif" /></chemistry><chemistry id="chem0135" num="0135"><img file="EP4603484A2_D0135.tif" /></chemistry><chemistry id="chem0136" num="0136"><img file="EP4603484A2_D0136.tif" /></chemistry>

0147Non-limiting examples of compounds of Formula I include: <chemistry id="chem0137" num="0137"><img file="EP4603484A2_D0137.tif" /></chemistry><chemistry id="chem0138" num="0138"><img file="EP4603484A2_D0138.tif" /></chemistry><chemistry id="chem0139" num="0139"><img file="EP4603484A2_D0139.tif" /></chemistry><chemistry id="chem0140" num="0140"><img file="EP4603484A2_D0140.tif" /></chemistry><chemistry id="chem0141" num="0141"><img file="EP4603484A2_D0141.tif" /></chemistry><chemistry id="chem0142" num="0142"><img file="EP4603484A2_D0142.tif" /></chemistry><chemistry id="chem0143" num="0143"><img file="EP4603484A2_D0143.tif" /></chemistry><chemistry id="chem0144" num="0144"><img file="EP4603484A2_D0144.tif" /></chemistry><chemistry id="chem0145" num="0145"><img file="EP4603484A2_D0145.tif" /></chemistry><chemistry id="chem0146" num="0146"><img file="EP4603484A2_D0146.tif" /></chemistry><chemistry id="chem0147" num="0147"><img file="EP4603484A2_D0147.tif" /></chemistry><chemistry id="chem0148" num="0148"><img file="EP4603484A2_D0148.tif" /></chemistry><chemistry id="chem0149" num="0149"><img file="EP4603484A2_D0149.tif" /></chemistry><chemistry id="chem0150" num="0150"><img file="EP4603484A2_D0150.tif" /></chemistry><chemistry id="chem0151" num="0151"><img file="EP4603484A2_D0151.tif" /></chemistry><chemistry id="chem0152" num="0152"><img file="EP4603484A2_D0152.tif" /></chemistry><chemistry id="chem0153" num="0153"><img file="EP4603484A2_D0153.tif" /></chemistry><chemistry id="chem0154" num="0154"><img file="EP4603484A2_D0154.tif" /></chemistry><chemistry id="chem0155" num="0155"><img file="EP4603484A2_D0155.tif" /></chemistry><chemistry id="chem0156" num="0156"><img file="EP4603484A2_D0156.tif" /></chemistry><chemistry id="chem0157" num="0157"><img file="EP4603484A2_D0157.tif" /></chemistry><chemistry id="chem0158" num="0158"><img file="EP4603484A2_D0158.tif" /></chemistry><chemistry id="chem0159" num="0159"><img file="EP4603484A2_D0159.tif" /></chemistry><chemistry id="chem0160" num="0160"><img file="EP4603484A2_D0160.tif" /></chemistry><chemistry id="chem0161" num="0161"><img file="EP4603484A2_D0161.tif" /></chemistry><chemistry id="chem0162" num="0162"><img file="EP4603484A2_D0162.tif" /></chemistry><chemistry id="chem0163" num="0163"><img file="EP4603484A2_D0163.tif" /></chemistry><chemistry id="chem0164" num="0164"><img file="EP4603484A2_D0164.tif" /></chemistry><chemistry id="chem0165" num="0165"><img file="EP4603484A2_D0165.tif" /></chemistry>

0148In another aspect, a method is provided for treating a bacterial infection comprising administering an effective amount of a compound of Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt thereof to a host in need thereof: <chemistry id="chem0166" num="0166"><img file="EP4603484A2_D0166.tif" /></chemistry><chemistry id="chem0167" num="0167"><img file="EP4603484A2_D0167.tif" /></chemistry> wherein <ul id="ul0012" list-style="none" compact="compact"><li>L1 is selected from <chemistry id="chem0168" num="0168"><img file="EP4603484A2_D0168.tif" /></chemistry></li><li>L2 is selected from <chemistry id="chem0169" num="0169"><img file="EP4603484A2_D0169.tif" /></chemistry></li><li>v and w are independently selected from 0, 1, 2, 3, and 4;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>X6, X7, X8, and X9 are independently selected from O, S, NH, or Se;</li><li>X10 is selected from Se, S, or NH;</li><li>R6 and R7 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0170" num="0170"><img file="EP4603484A2_D0170.tif" /></chemistry> and</li><li>R, R1, R2, R4, and R5 are as defined herein.</li></ul>

0149In some embodiments of Formula II, Formula III, Formula IV, and/or Formula V, X10 is not S.

0150In some embodiments of Formula II, Formula III, Formula IV, and/or Formula V, X10 is not NH.

0151In some embodiments of Formula II, Formula III, Formula IV and/or Formula V, L2 is not <chemistry id="chem0171" num="0171"><img file="EP4603484A2_D0171.tif" /></chemistry>

0152In some embodiments of Formula II, Formula III, Formula IV and/or Formula V, one or more of X6, X7, X8, and X9 is not NH.

0153In some embodiments of Formula II, the compound has a chemical structure selected from: <chemistry id="chem0172" num="0172"><img file="EP4603484A2_D0172.tif" /></chemistry><chemistry id="chem0173" num="0173"><img file="EP4603484A2_D0173.tif" /></chemistry><chemistry id="chem0174" num="0174"><img file="EP4603484A2_D0174.tif" /></chemistry><chemistry id="chem0175" num="0175"><img file="EP4603484A2_D0175.tif" /></chemistry>

0154Non-limiting examples of compounds of Formula II include: <chemistry id="chem0176" num="0176"><img file="EP4603484A2_D0176.tif" /></chemistry><chemistry id="chem0177" num="0177"><img file="EP4603484A2_D0177.tif" /></chemistry><chemistry id="chem0178" num="0178"><img file="EP4603484A2_D0178.tif" /></chemistry><chemistry id="chem0179" num="0179"><img file="EP4603484A2_D0179.tif" /></chemistry><chemistry id="chem0180" num="0180"><img file="EP4603484A2_D0180.tif" /></chemistry><chemistry id="chem0181" num="0181"><img file="EP4603484A2_D0181.tif" /></chemistry><chemistry id="chem0182" num="0182"><img file="EP4603484A2_D0182.tif" /></chemistry><chemistry id="chem0183" num="0183"><img file="EP4603484A2_D0183.tif" /></chemistry>

0155In some embodiments of Formula III, the compound has a chemical structure selected from: <chemistry id="chem0184" num="0184"><img file="EP4603484A2_D0184.tif" /></chemistry><chemistry id="chem0185" num="0185"><img file="EP4603484A2_D0185.tif" /></chemistry><chemistry id="chem0186" num="0186"><img file="EP4603484A2_D0186.tif" /></chemistry><chemistry id="chem0187" num="0187"><img file="EP4603484A2_D0187.tif" /></chemistry>

0156Non-limiting examples of compounds of Formula III include: <chemistry id="chem0188" num="0188"><img file="EP4603484A2_D0188.tif" /></chemistry><chemistry id="chem0189" num="0189"><img file="EP4603484A2_D0189.tif" /></chemistry><chemistry id="chem0190" num="0190"><img file="EP4603484A2_D0190.tif" /></chemistry><chemistry id="chem0191" num="0191"><img file="EP4603484A2_D0191.tif" /></chemistry>

0157In some embodiments of Formula IV, the compound has a chemical structure selected from: <chemistry id="chem0192" num="0192"><img file="EP4603484A2_D0192.tif" /></chemistry><chemistry id="chem0193" num="0193"><img file="EP4603484A2_D0193.tif" /></chemistry>

0158Non-limiting examples of compounds of Formula IV include: <chemistry id="chem0194" num="0194"><img file="EP4603484A2_D0194.tif" /></chemistry><chemistry id="chem0195" num="0195"><img file="EP4603484A2_D0195.tif" /></chemistry><chemistry id="chem0196" num="0196"><img file="EP4603484A2_D0196.tif" /></chemistry><chemistry id="chem0197" num="0197"><img file="EP4603484A2_D0197.tif" /></chemistry>

0159In some embodiments of Formula V, the compound has a chemical structure selected from: <chemistry id="chem0198" num="0198"><img file="EP4603484A2_D0198.tif" /></chemistry><chemistry id="chem0199" num="0199"><img file="EP4603484A2_D0199.tif" /></chemistry>

0160Non-limiting examples of compounds of Formula V include: <chemistry id="chem0200" num="0200"><img file="EP4603484A2_D0200.tif" /></chemistry><chemistry id="chem0201" num="0201"><img file="EP4603484A2_D0201.tif" /></chemistry><chemistry id="chem0202" num="0202"><img file="EP4603484A2_D0202.tif" /></chemistry><chemistry id="chem0203" num="0203"><img file="EP4603484A2_D0203.tif" /></chemistry><chemistry id="chem0204" num="0204"><img file="EP4603484A2_D0204.tif" /></chemistry><chemistry id="chem0205" num="0205"><img file="EP4603484A2_D0205.tif" /></chemistry><chemistry id="chem0206" num="0206"><img file="EP4603484A2_D0206.tif" /></chemistry><chemistry id="chem0207" num="0207"><img file="EP4603484A2_D0207.tif" /></chemistry><chemistry id="chem0208" num="0208"><img file="EP4603484A2_D0208.tif" /></chemistry><chemistry id="chem0209" num="0209"><img file="EP4603484A2_D0209.tif" /></chemistry><chemistry id="chem0210" num="0210"><img file="EP4603484A2_D0210.tif" /></chemistry><chemistry id="chem0211" num="0211"><img file="EP4603484A2_D0211.tif" /></chemistry>

0161In another aspect, a method is provided for treating a gram-positive or a gram-negative bacterial infection comprising administering an effective amount of a compound of Formula VI: <chemistry id="chem0212" num="0212"><img file="EP4603484A2_D0212.tif" /></chemistry> or a pharmaceutically acceptable salt thereof wherein <ul id="ul0013" list-style="none" compact="compact"><li>R9 and R12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano; and</li><li>R10 and R11 are independently at each occurrence selected from the group consisting of hydroxyl, C1-C6alkanoyl, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2-, - C(O)R, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano.</li></ul>

0162In one embodiment, the compound of Formula VI is a compound of the Formula: <chemistry id="chem0213" num="0213"><img file="EP4603484A2_D0213.tif" /></chemistry><chemistry id="chem0214" num="0214"><img file="EP4603484A2_D0214.tif" /></chemistry><chemistry id="chem0215" num="0215"><img file="EP4603484A2_D0215.tif" /></chemistry><chemistry id="chem0216" num="0216"><img file="EP4603484A2_D0216.tif" /></chemistry><chemistry id="chem0217" num="0217"><img file="EP4603484A2_D0217.tif" /></chemistry><chemistry id="chem0218" num="0218"><img file="EP4603484A2_D0218.tif" /></chemistry><chemistry id="chem0219" num="0219"><img file="EP4603484A2_D0219.tif" /></chemistry><chemistry id="chem0220" num="0220"><img file="EP4603484A2_D0220.tif" /></chemistry>

0163In one aspect, a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt is provided: <chemistry id="chem0221" num="0221"><img file="EP4603484A2_D0221.tif" /></chemistry><chemistry id="chem0222" num="0222"><img file="EP4603484A2_D0222.tif" /></chemistry> wherein: <ul id="ul0014" list-style="none" compact="compact"><li>m and n are independently selected from 1, 2, 3, or 4;</li><li>p is 0, 1, 2, or 3;</li><li>q and t are independently at each occurrence 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>L3 and L4 are each independently C(R3)2, O, or S;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;</li><li>R13 and R14 are independently selected from the group consisting of <chemistry id="chem0223" num="0223"><img file="EP4603484A2_D0223.tif" /></chemistry> and -C(R3)oNR4R5 wherein R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl and o is 0 to 10 (i.e., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10);</li><li>X11 and X12 are each independently selected from the group consisting of C(R3)2, O, NH, or S, wherein R3 is independently at each occurrence selected from a group as defined above;</li><li>Y1 and Y2 are each independently selected from the group consisting of C(R3)2, O, NH, or S, wherein R3 is independently at each occurrence selected from a group as defined above; and</li><li>Z is CR3 or N, wherein R3 is as defined above.</li></ul>

0164In some cases, a compound is provided of Formula VII or Formula VIII or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to form a pharmaceutical composition.

0165In some cases of Formula VII or Formula VIII, R13 is <chemistry id="chem0224" num="0224"><img file="EP4603484A2_D0224.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or C1-C6alkyl. In some cases of Formula VII or Formula VIII, R13 is <chemistry id="chem0225" num="0225"><img file="EP4603484A2_D0225.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or C1-C6alkyl.

0166In some examples of Formula VII or Formula VIII, R14 is <chemistry id="chem0226" num="0226"><img file="EP4603484A2_D0226.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or alkyl. In some examples of Formula VII or Formula VIII, R14 is <chemistry id="chem0227" num="0227"><img file="EP4603484A2_D0227.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or C1-C6alkyl.

0167In some examples of Formula VII or Formula VIII, R13 and R14 are each <chemistry id="chem0228" num="0228"><img file="EP4603484A2_D0228.tif" /></chemistry> wherein R4 and R5 are independently hydrogen or C1-C6alkyl. In some examples of Formula VII or Formula VIII, R13 and R14 are each <chemistry id="chem0229" num="0229"><img file="EP4603484A2_D0229.tif" /></chemistry> wherein R4 and Rs are independently hydrogen or C1-C6alkyl. In some cases, R4 and R5 are hydrogen.

0168Optionally, X11 and X12 are selected from the group consisting of O, CH2, and S. In some cases, X11 and X12 are the same (e.g., X11 and X12 are each O, X11 and X12 are each CH2, or X11 and X12 are each S).

0169Optionally, Y1 and Y2 are selected from the group consisting of O and CH2. In some cases, Y1 and Y2 are the same (e.g., Y1 and Y2 are each O or Y1 and Y2 are each CH2).

0170In some cases, each R is independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and fluorine is C1-C6alkyl, C1-C6alkoxy, or C1-C6haloalkyl.

0171In Formula VII, when t is 0, L3 is absent and a direct bond is present between X11 and the ring to which L3 is connected in the structure. Similarly, in Formula VII, when q is 0, L4 is absent and a direct bond is present between X12 and the ring to which L4 is connected in the structure. In some embodiments of Formula VII, both t and q are absent, resulting in a compound that has a chemical structure as shown below: <chemistry id="chem0230" num="0230"><img file="EP4603484A2_D0230.tif" /></chemistry> wherein m, n, p, R, R13, R14, X11, X12, Y1, Y2, and Z are as defined herein for Formula VII.

0172In Formula VIII, when t is 0, L3 is absent and a direct bond is present between X11 and the ring to which L3 is connected in the structure. Similarly, in Formula VIII, when q is 0, L4 is absent and a direct bond is present between X12 and the ring to which L4 is connected in the structure. In some embodiments of Formula VIII, both t and q are absent, resulting in a compound that has a chemical structure as shown below: <chemistry id="chem0231" num="0231"><img file="EP4603484A2_D0231.tif" /></chemistry> wherein m, n, p, R, R13, R14, XII, X12, Y1, Y2, and Z are as defined herein for Formula VIII.

0173In certain aspects, the compound of Formula VII is a compound of the following formula: <chemistry id="chem0232" num="0232"><img file="EP4603484A2_D0232.tif" /></chemistry><chemistry id="chem0233" num="0233"><img file="EP4603484A2_D0233.tif" /></chemistry><chemistry id="chem0234" num="0234"><img file="EP4603484A2_D0234.tif" /></chemistry><chemistry id="chem0235" num="0235"><img file="EP4603484A2_D0235.tif" /></chemistry><chemistry id="chem0236" num="0236"><img file="EP4603484A2_D0236.tif" /></chemistry><chemistry id="chem0237" num="0237"><img file="EP4603484A2_D0237.tif" /></chemistry><chemistry id="chem0238" num="0238"><img file="EP4603484A2_D0238.tif" /></chemistry><chemistry id="chem0239" num="0239"><img file="EP4603484A2_D0239.tif" /></chemistry><chemistry id="chem0240" num="0240"><img file="EP4603484A2_D0240.tif" /></chemistry><chemistry id="chem0241" num="0241"><img file="EP4603484A2_D0241.tif" /></chemistry><chemistry id="chem0242" num="0242"><img file="EP4603484A2_D0242.tif" /></chemistry><chemistry id="chem0243" num="0243"><img file="EP4603484A2_D0243.tif" /></chemistry><chemistry id="chem0244" num="0244"><img file="EP4603484A2_D0244.tif" /></chemistry><chemistry id="chem0245" num="0245"><img file="EP4603484A2_D0245.tif" /></chemistry><chemistry id="chem0246" num="0246"><img file="EP4603484A2_D0246.tif" /></chemistry><chemistry id="chem0247" num="0247"><img file="EP4603484A2_D0247.tif" /></chemistry><chemistry id="chem0248" num="0248"><img file="EP4603484A2_D0248.tif" /></chemistry><chemistry id="chem0249" num="0249"><img file="EP4603484A2_D0249.tif" /></chemistry><chemistry id="chem0250" num="0250"><img file="EP4603484A2_D0250.tif" /></chemistry><chemistry id="chem0251" num="0251"><img file="EP4603484A2_D0251.tif" /></chemistry><chemistry id="chem0252" num="0252"><img file="EP4603484A2_D0252.tif" /></chemistry><chemistry id="chem0253" num="0253"><img file="EP4603484A2_D0253.tif" /></chemistry><chemistry id="chem0254" num="0254"><img file="EP4603484A2_D0254.tif" /></chemistry><chemistry id="chem0255" num="0255"><img file="EP4603484A2_D0255.tif" /></chemistry><chemistry id="chem0256" num="0256"><img file="EP4603484A2_D0256.tif" /></chemistry>

0174In certain aspects, the compound of Formula VIII is a compound of the following formula: <chemistry id="chem0257" num="0257"><img file="EP4603484A2_D0257.tif" /></chemistry>

0175Additional compounds described herein include the following compounds. In some cases, the compounds are useful in the methods of treating bacterial infections as described herein. <chemistry id="chem0258" num="0258"><img file="EP4603484A2_D0258.tif" /></chemistry><chemistry id="chem0259" num="0259"><img file="EP4603484A2_D0259.tif" /></chemistry><chemistry id="chem0260" num="0260"><img file="EP4603484A2_D0260.tif" /></chemistry><chemistry id="chem0261" num="0261"><img file="EP4603484A2_D0261.tif" /></chemistry>

0176The compounds in any of the Formulas described herein may be in the form of a racemate, enantiomer, mixture of enantiomers, diastereomer, mixture of diastereomers, tautomer, N-oxide, or other isomer, such as a rotamer, as if each is specifically described unless specifically excluded by context. Compound A - Compound L may be in the form of a racemate, enantiomer, mixture of enantiomers, diastereomer, mixture of diastereomers, tautomer, N-oxide, or other isomer, such as a rotamer, as if each is specifically described unless specifically excluded by context.

0177The present invention includes compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, or Formula VIII with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e. enriched. The present invention also includes a compound selected from Compound A - Compound L with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e. enriched.

III. PHARMACEUTICAL COMPOSITIONS

0178An active compound as described herein can be administered to a host, for example, a human in need thereof in an effective amount as the neat chemical, but is more typically administered as a pharmaceutical composition that includes a pharmaceutically acceptable carrier suitable for the selected means of delivery. In one embodiment, the disclosure provides pharmaceutical compositions comprising an effective amount of compound or pharmaceutically acceptable salt thereof together with at least one pharmaceutically acceptable carrier for any of the uses described herein. The pharmaceutical composition may contain the compound or salt as the only active agent, or, in an alternative embodiment, the compound and at least one additional active agent.

0179Effective amount, when used to describe an amount of compound in a method, refers to the amount of a compound that achieves the desired pharmacological effect or other biological effect. For example, an effective amount can be a 10% reduction in a symptom or sign of a disease or condition as compared to a control. As used herein, control refers to the untreated condition (e.g., a subject or cell not treated with the compounds and compositions described herein). Thus, the reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels. It is understood that treatment does not necessarily refer to a cure or complete ablation of the disease, condition, or symptoms of the disease or condition.

0180An effective amount of the active compound as described herein, or the active compound described herein in combination or alternation with, or preceded by, concomitant with or followed by another active agent, can be used in an amount sufficient to (a) inhibit the progression of a bacterial infection; (b) cause a regression of a bacterial infection; (c) cause a cure of a bacterial infection; or (d) inhibit or prevent the development of a bacterial infection. The effective amount can be, for example, the concentrations of compounds at which a reduction in bacterial load is observed (e.g., a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any percent reduction in between 10% and 100% as compared to native or control levels).

0181A selected compound disclosed herein or used as described herein may be administered, for example, orally, topically, parenterally, by inhalation or spray, sublingually, via implant, including ocular implant, transdermally, via buccal administration, rectally, as an ophthalmic solution, injection, including ocular injection, intravenous, intra-aortal, intracranial, subdermal, intraperitoneal, subcutaneous, transnasal, sublingual, intrathecal, or rectal or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers.

0182For ocular delivery, the compound can be administered, as desired, for example, as a solution, suspension, or other formulation via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachorodial, subchorodial, chorodial, conjunctival, subconjunctival, episcleral, periocular, transscleral, retrobulbar, posterior juxtascleral, circumcorneal, or tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion or via an ocular device, injection, or topically administered formulation, for example a solution or suspension provided as an eye drop.

0183The exact amount of the active compound or pharmaceutical composition described herein to be delivered to the host, typically a human, in need thereof, may be determined at the discretion of the health care provider to achieve the desired clinical benefit.

0184In certain embodiments the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 1000 mg, from about 10 mg to about 750 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active compound and optionally from about 0.1 mg to about 2000 mg, from about 10 mg to about 750 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form.

0185Examples are dosage forms with at least about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 900, 1000, 1100, 1200, 1250, 1300, 1400, 1500, or 1600 mg of active compound, or pharmaceutically acceptable salt thereof or prodrug. In one embodiment, the dosage form has at least about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 400 mg, 500 mg, 600 mg, 1000 mg, 1200 mg, or 1600 mg of active compound, or pharmaceutically acceptable salt thereof. The amount of active compound in the dosage form is calculated without reference to the salt. The dosage form can be administered, for example, once a day (q.d.), twice a day (b.i.d.), three times a day (t.i.d.), four times a day (q.i.d.), once every other day (Q2d), once every third day (Q3d), as needed, or any dosage schedule that provides treatment of a disorder described herein.

0186The pharmaceutical composition may for example include a molar ratio of the active compound and an additional active agent that achieves the desired result. For example, the pharmaceutical composition may contain a molar ratio of about 0.5:1, about 1:1, about 2:1, about 3:1 or from about 1.5:1 to about 4:1 of an additional active agent in combination with the active compound (additional active agent: active compound), or pharmaceutically acceptable salt thereof, described herein. In one embodiment, the additional active agent is an antibiotic.

0187The pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as a cream, a gel, a gel cap, a pill, a capsule, a microparticle, a nanoparticle, an injection or infusion solution, a capsule, a tablet, a syrup, as an aerosol, a transdermal patch, a subcutaneous patch, a dry powder, an inhalation formulation, in a medical device, suppository, buccal, or sublingual formulation, parenteral formulation, or an ophthalmic solution or suspension. Some dosage forms, such as tablets and capsules, are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.

0188Pharmaceutical compositions, and methods of manufacturing such compositions, suitable for administration as contemplated herein are known in the art. Examples of known techniques include, for example, <patcit id="pcit0026" dnum="US4983593A"><text>US Patent Nos. 4,983,593</text></patcit>,<patcit id="pcit0027" dnum="US5013557A"><text> 5,013,557</text></patcit>, <patcit id="pcit0028" dnum="US5456923A"><text>5,456,923</text></patcit>, <patcit id="pcit0029" dnum="US5576025A"><text>5,576,025</text></patcit>, <patcit id="pcit0030" dnum="US5723269A"><text>5,723,269</text></patcit>, <patcit id="pcit0031" dnum="US5858411A"><text>5,858,411</text></patcit>, <patcit id="pcit0032" dnum="US6254889B"><text>6,254,889</text></patcit>, <patcit id="pcit0033" dnum="US6303148B"><text>6,303,148</text></patcit>, <patcit id="pcit0034" dnum="US6395302B"><text>6,395,302</text></patcit>, <patcit id="pcit0035" dnum="US6497903B"><text>6,497,903</text></patcit>, <patcit id="pcit0036" dnum="US7060296B"><text>7,060,296</text></patcit>,<patcit id="pcit0037" dnum="US7078057B"><text> 7,078,057</text></patcit>, <patcit id="pcit0038" dnum="US7404828B"><text>7,404,828</text></patcit>, <patcit id="pcit0039" dnum="US8202912B"><text>8,202,912</text></patcit>, <patcit id="pcit0040" dnum="US8257741B"><text>8,257,741</text></patcit>,<patcit id="pcit0041" dnum="US8263128B"><text> 8,263,128</text></patcit>, <patcit id="pcit0042" dnum="US8337899B"><text>8,337,899</text></patcit>,<patcit id="pcit0043" dnum="US8431159B"><text> 8,431,159</text></patcit>, <patcit id="pcit0044" dnum="US9028870B"><text>9,028,870</text></patcit>, <patcit id="pcit0045" dnum="US9060938B"><text>9,060,938</text></patcit>, <patcit id="pcit0046" dnum="US9211261B"><text>9,211,261</text></patcit>, <patcit id="pcit0047" dnum="US9265731B"><text>9,265,731</text></patcit>, <patcit id="pcit0048" dnum="US9358478B"><text>9,358,478</text></patcit>, and <patcit id="pcit0049" dnum="US9387252B"><text>9,387,252</text></patcit>, incorporated by reference herein.

0189The pharmaceutical compositions contemplated here can optionally include a carrier. Carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert, or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.

0190Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, fillers, flavorants, glidents, lubricants, pH modifiers, preservatives, stabilizers, surfactants, solubilizers, tableting agents, and wetting agents. Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin; talc, and vegetable oils.

0191Examples of other matrix materials, fillers, or diluents include lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch.

0192Examples of surface-active agents include sodium lauryl sulfate and polysorbate 80. Examples of drug complexing agents or solubilizers include the polyethylene glycols, caffeine, xanthene, gentisic acid and cylodextrins.

0193Examples of disintegrants include sodium starch gycolate, sodium alginate, carboxymethyl cellulose sodium, methyl cellulose, colloidal silicon dioxide, and croscarmellose sodium. Examples of binders include methyl cellulose, microcrystalline cellulose, starch, and gums such as guar gum, and tragacanth.

0194Examples of lubricants include magnesium stearate and calcium stearate. Examples of pH modifiers include acids such as citric acid, acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, phosphoric acid, and the like; bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like, and buffers generally comprising mixtures of acids and the salts of said acids. Optional other active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.

0195In certain embodiments, the pharmaceutical composition for administration further includes a compound or salt described herein and optionally comprises one or more of a phosphoglyceride; phosphatidylcholine; dipalmitoyl phosphatidylcholine (DPPC); dioleylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohol such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acid; fatty acid monoglyceride; fatty acid diglyceride; fatty acid amide; sorbitan trioleate (Span®85) glycocholate; sorbitan monolaurate (Span®20); polysorbate 20 (Tween®20); polysorbate 60 (Tween®60); polysorbate 65 (Tween®65); polysorbate 80 (Tween®80); polysorbate 85 (Tween®85); polyoxyethylene monostearate; surfactin; a poloxomer; a sorbitan fatty acid ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebroside; dicetylphosphate; dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl sterate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-phosphatidylethanolamine; poly(ethylene glycol)400-monostearate; phospholipid; synthetic and/or natural detergent having high surfactant properties; deoxycholate; cyclodextrin; chaotropic salt; ion pairing agent; glucose, fructose, galactose, ribose, lactose, sucrose, maltose, trehalose, cellbiose, mannose, xylose, arabinose, glucoronic acid, galactoronic acid, mannuronic acid, glucosamine, galatosamine, and neuramic acid; pullulan, cellulose, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), hydroxycellulose (HC), methylcellulose (MC), dextran, cyclodextran, glycogen, hydroxyethylstarch, carageenan, glycon, amylose, chitosan, N,O-carboxylmethylchitosan, algin and alginic acid, starch, chitin, inulin, konjac, glucommannan, pustulan, heparin, hyaluronic acid, curdlan, and xanthan, mannitol, sorbitol, xylitol, erythritol, maltitol, and lactitol, a pluronic polymer, polyethylene, polycarbonate (e.g. poly(1,3-dioxan-2one)), polyanhydride (e.g. poly(sebacic anhydride)), polypropylfumerate, polyamide (e.g. polycaprolactam), polyacetal, polyether, polyester (e.g., polylactide, polyglycolide, polylactide-co-glycolide, polycaprolactone, polyhydroxyacid (e.g. poly((β-hydroxyalkanoate))), poly(orthoester), polycyanoacrylate, polyvinyl alcohol, polyurethane, polyphosphazene, polyacrylate, polymethacrylate, polyurea, polystyrene, and polyamine, polylysine, polylysine-PEG copolymer, and poly(ethyleneimine), poly(ethylene imine)-PEG copolymer, glycerol monocaprylocaprate, propylene glycol, Vitamin E TPGS (also known as d-α-Tocopheryl polyethylene glycol 1000 succinate), gelatin, titanium dioxide, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), methyl cellulose (MC), block copolymers of ethylene oxide and propylene oxide (PEO/PPO), polyethyleneglycol (PEG), sodium carboxymethylcellulose (NaCMC), hydroxypropylmethyl cellulose acetate succinate (HPMCAS).

0196In some embodiments, the pharmaceutical preparation may include polymers for controlled delivery of the described compounds, including, but not limited to pluronic polymers, polyesters (e.g., polylactic acid, poly(lactic-co-glycolic acid), polycaprolactone, polyvalerolactone, poly(1,3-dioxan-2one)); polyanhydrides (e.g., poly(sebacic anhydride)); polyethers (e.g., polyethylene glycol); polyurethanes; polymethacrylates; polyacrylates; and polycyanoacrylates. In some embodiments, polymers may be modified with polyethylene glycol (PEG), with a carbohydrate, and/or with acyclic polyacetals derived from polysaccharides. See, e.g., <nplcit id="ncit0017" npl-type="s"><text>Papisov, 2001, ACS Symposium Series, 786:301</text></nplcit>, incorporated by reference herein.

0197The compounds of the present invention can be formulated as particles. In one embodiment the particles are or include microparticles. In an alternative embodiment the particles are or include nanoparticles.

0198Common techniques for preparing particles include, but are not limited to, solvent evaporation, solvent removal, spray drying, phase inversion, coacervation, and low temperature casting. Suitable methods of particle formulation are briefly described below. Pharmaceutically acceptable excipients, including pH modifying agents, disintegrants, preservatives, and antioxidants, can optionally be incorporated into the particles during particle formation.

0199In one embodiment, the particles are derived through a solvent evaporation method. In this method, a compound described herein (or polymer matrix and one or more compounds described herein) is dissolved in a volatile organic solvent, such as methylene chloride. The organic solution containing a compound described herein is then suspended in an aqueous solution that contains a surface active agent such as poly(vinyl alcohol). The resulting emulsion is stirred until most of the organic solvent evaporated, leaving solid nanoparticles or microparticles. The resulting nanoparticles or microparticles are washed with water and dried overnight in a lyophilizer. Nanoparticles with different sizes and morphologies can be obtained by this method.

0200Pharmaceutical compositions which contain labile polymers, such as certain polyanhydrides, may degrade during the fabrication process due to the presence of water. For these polymers, methods which are performed in completely or substantially anhydrous organic solvents can be used to make the particles.

0201Solvent removal can also be used to prepare particles from a compound that is hydrolytically unstable. In this method, the compound (or polymer matrix and one or more

0202In one embodiment an active compound as described herein is administered to a patient in need thereof as a spray dried dispersion (SDD). In another embodiment the present invention provides a spray dried dispersion (SDD) comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the SDD comprises a compound of the present invention and an additional active agent. In a further embodiment the SDD comprises a compound of the present invention, an additional active agent, and one or more pharmaceutically acceptable excipients.

0203In another embodiment any of the described spray dried dispersions can be coated to form a coated tablet. In an alternative embodiment the spray dried dispersion is formulated into a tablet but is uncoated. Particles can be formed from the active compound as described herein using a phase inversion method. In this method, the compound (or polymer matrix and one or more active compounds) is dissolved in a suitable solvent, and the solution is poured into a strong non-solvent for the compound to spontaneously produce, under favorable conditions, microparticles or nanoparticles. The method can be used to produce nanoparticles in a wide range of sizes, including, for example, from nanoparticles to microparticles, typically possessing a narrow particle size distribution.

0204In one embodiment, the polymeric particle is between about 0.1 nm to about 10000 nm, between about 1 nm to about 1000 nm, between about 10 nm and 1000 nm, between about 1 and 100 nm, between about 1 and 10 nm, between about 1 and 50 nm, between about 100 nm and 800 nm, between about 400 nm and 600 nm, or about 500 nm. In one embodiment, the micro-particles are no more than about 0.1 nm, 0.5 nm, 1.0 nm, 5.0 nm, 10 nm, 25 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 400 nm, 450 nm, 500 nm, 550 nm, 600 nm, 650 nm, 700 nm, 750 nm, 800 nm, 850 nm, 900 nm, 950 nm, 1000 nm, 1250 nm, 1500 nm, 1750 nm, or 2000 nm. In some embodiments, a compound described herein may be covalently coupled to a polymer used in the nanoparticle, for example a polystyrene particle, PLGA particle, PLA particle, or other nanoparticle.

0205The pharmaceutical compositions can be formulated for oral administration. These compositions can contain any amount of active compound that achieves the desired result, for example between 0.1 and 99 weight % (wt.%) of the compound and usually at least about 5 wt.% of the compound. Some embodiments contain at least about 10%, 15%, 20%, 25 wt.% to about 50 wt. % or from about 5 wt.% to about 75 wt.% of the compound.

0206Pharmaceutical compositions suitable for rectal administration are typically presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

0207Pharmaceutical compositions suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.

0208Pharmaceutical compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Pharmaceutical compositions suitable for transdermal administration may also be delivered by iontophoresis (see, for example, <nplcit id="ncit0018" npl-type="s"><text>Pharmaceutical Research 3 (6):318 (1986</text></nplcit>)) and typically take the form of an optionally buffered aqueous solution of the active compound. In one embodiment, microneedle patches or devices are provided for delivery of drugs across or into biological tissue, particularly the skin. The microneedle patches or devices permit drug delivery at clinically relevant rates across or into skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue.

0209Pharmaceutical compositions suitable for administration to the lungs can be delivered by a wide range of passive breath driven and active power driven single/-multiple dose dry powder inhalers (DPI). The devices most commonly used for respiratory delivery include nebulizers, metered-dose inhalers, and dry powder inhalers. Several types of nebulizers are available, including jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers. Selection of a suitable lung delivery device depends on parameters, such as nature of the drug and its formulation, the site of action, and pathophysiology of the lung.

0210Additional non-limiting examples of inhalation drug delivery devices and methods include, for example, <patcit id="pcit0050" dnum="US7383837B"><text>US 7,383,837</text></patcit> titled "Inhalation device" (SmithKline Beecham Corporation); <patcit id="pcit0051" dnum="WO2006033584A"><text>WO/2006/033584</text></patcit> titled "Powder inhaler" (Glaxo SmithKline Pharmaceuticals SA); <patcit id="pcit0052" dnum="WO2005044186A"><text>WO/2005/044186</text></patcit> titled "Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same" (Glaxo Group Ltd and SmithKline Beecham Corporation); <patcit id="pcit0053" dnum="US9095670B"><text>US9,095,670</text></patcit> titled "Inhalation device and method of dispensing medicament", <patcit id="pcit0054" dnum="US8205611B"><text>US 8,205,611</text></patcit> titled "Dry powder inhaler" (Astrazeneca AB); <patcit id="pcit0055" dnum="WO2013038170A"><text>WO/2013/038170</text></patcit> titled "Inhaler" (Astrazeneca AB and Astrazeneca UK Ltd.); <patcit id="pcit0056" dnum="US20140352690A"><text>US/2014/0352690</text></patcit> titled "Inhalation Device with Feedback System", <patcit id="pcit0057" dnum="US8910625B"><text>US 8,910,625</text></patcit> and <patcit id="pcit0058" dnum="US20150165137A"><text>US/2015/0165137</text></patcit> titled "Inhalation Device for Use in Aerosol Therapy" (Vectura GmbH); <patcit id="pcit0059" dnum="US6948496B"><text>US 6,948,496</text></patcit> titled "Inhalers", <patcit id="pcit0060" dnum="US20050152849A"><text>US/2005/0152849</text></patcit> titled "Powders comprising anti-adherent materials for use in dry powder inhalers", <patcit id="pcit0061" dnum="US6582678B"><text>US 6,582,678</text></patcit>, <patcit id="pcit0062" dnum="US8137657B"><text>US 8,137,657</text></patcit>, <patcit id="pcit0063" dnum="US20030202944A"><text>US/2003/0202944</text></patcit>, and <patcit id="pcit0064" dnum="US20100330188A"><text>US/2010/0330188</text></patcit> titled "Carrier particles for use in dry powder inhalers", <patcit id="pcit0065" dnum="US6221338B"><text>US 6,221,338</text></patcit> titled "Method of producing particles for use in dry powder inhalers", <patcit id="pcit0066" dnum="US6989155B"><text>US 6,989,155</text></patcit> titled "Powders", <patcit id="pcit0067" dnum="US20070043030A"><text>US/2007/0043030</text></patcit> titled "Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation", <patcit id="pcit0068" dnum="US7845349B"><text>US 7,845,349</text></patcit> titled "Inhaler", <patcit id="pcit0069" dnum="US20120114709A"><text>US/2012/0114709</text></patcit> and <patcit id="pcit0070" dnum="US8101160B"><text>US 8,101,160</text></patcit> titled "Formulations for Use in Inhaler Devices", <patcit id="pcit0071" dnum="US20130287854A"><text>US/2013/0287854</text></patcit> titled "Compositions and Uses", <patcit id="pcit0072" dnum="US20140037737A"><text>US/2014/0037737</text></patcit> and <patcit id="pcit0073" dnum="US8580306B"><text>US 8,580,306</text></patcit> titled "Particles for Use in a Pharmaceutical Composition", <patcit id="pcit0074" dnum="US20150174343A"><text>US/2015/0174343</text></patcit> titled "Mixing Channel for an Inhalation Device", <patcit id="pcit0075" dnum="US7744855B"><text>US 7,744,855</text></patcit> and <patcit id="pcit0076" dnum="US20100285142A"><text>US/2010/0285142</text></patcit> titled "Method of making particles for use in a pharmaceutical composition", <patcit id="pcit0077" dnum="US7541022B"><text>US 7,541,022</text></patcit>, <patcit id="pcit0078" dnum="US20090269412A"><text>US/2009/0269412</text></patcit>, and <patcit id="pcit0079" dnum="US20150050350A"><text>US/2015/0050350</text></patcit> titled "Pharmaceutical formulations for dry powder inhalers" (Vectura Limited).

IV. METHODS OF TREATMENT

0211In one embodiment, an effective amount of a compound of Formula I through Formula V or a pharmaceutically acceptable salt or composition thereof or a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt or composition thereof is used to treat or to prevent a medical disorder which is caused by the presence of a bacterium, for example a bacterial infection. Optionally, the compound is MD-124 as described herein. In one embodiment, an effective amount of a compound selected from Compound A, Compound B, or Compound F - Compound L or a pharmaceutically acceptable salt or composition thereof is used to treat or to prevent a medical disorder which is mediated by the presence of a bacterium, for example a bacterial infection. In one embodiment, the compounds of the present invention may be used to treat a disorder, typically an infection, caused by a pathogenic bacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound of Formula I through Formula V or a pharmaceutically acceptable salt or composition thereof or a compound of Formula VIII or a pharmaceutically acceptable salt or composition thereof to a subject, typically a human, to treat an infection caused by a pathogenic bacterium.

0212The compounds described herein are particularly effective in combination with antibiotics due to their potentiation of the antimicrobial effect of the antibiotic. In one embodiment, an active compound or its salt or composition as described herein may be used in combination or alternation with an antibiotic to potentiate the antibacterial effect of the antibiotic. Commonly used antibiotics include clindamycin, erythromycin, metronidazole, sulfacetamide, and tetracyclines such as doxycycline and minocycline. Other representative topical antibiotics include bacitracin, polymycin b, neomycin, retapamulin, mupirocin, pramoxine, gentamicin, mafenide, and ozenoxacin. In one embodiment, an active compound or its salt is formulated in combination with an antibiotic in a topical formulation as described herein.

0213In one embodiment, the compounds of the present invention may be used to treat a disorder, typically an infection, caused by a gram-positive bacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition thereof to treat an infection caused by a gram-positive bacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound selected from Compound A - Compound L or a pharmaceutically acceptable salt or composition thereof to treat an infection caused by a gram-positive bacterium.

0214Non-limiting examples of gram-positive bacteria which may be treated using the compounds of the present invention either alone or in combination with another therapeutic include: Actinomyces species including Actinomyces israelii, Actinomyces naeslundii, Actinomyces viscosus, Actinomyces odontolyticus, and Actinomyces pyogenes; Bacillus species including Bacillus anthracis, Bacillus cereus, and Bacillus subtilis; Clostridium species including Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium sordellii, and Clostridium tetani; Corynebacterium species including Corynebacterium diphtheriae, Corynebacterium jeikeium, Corynebacterium minutissimum, Corynebacterium mucifaciens, Corynebacterium pseudotuberculosis, Corynebacterium striatum, Corynebacterium tenuis, and Corynebacterium ulcerans; Enterococcus species including Enterococcus casseliflavus, Enterococcus faecalis, Enterococcus faecium, Enterococcus raffinosus, and Enterococcus hirae; Leuconostoc species including Leuconostoc pseudomesenteroides; Micrococcus species such as Microccocus luteus; Nocardia species including Nocardia asteroides; Propionibacterium species including Propionibacterium acnes; Staphylococcus species including Staphylococcus aureus, Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphyloccocus pasteuri, and Staphyloccocus saprophyticus; and Streptococcus species including Streptococcus agalactiae, Streptococcus anginosus, Streptococcus bovis, Streptococcus dysgalactiae, Streptococcus mitis, Streptococcus mutans, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus sanguinis, Streptococcus suis, and Streptococcus viridans.

0215In one embodiment, the compounds of the present invention may be used to treat a disorder, typically an infection, caused by a gram-negative bacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition thereof to treat an infection caused by a gram-negative bacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound selected from Compound A - Compound L or a pharmaceutically acceptable salt or composition thereof to treat an infection caused by a gram-negative bacterium.

0216Non-limiting examples of gram-negative bacteria which may be treated using the compounds of the present invention either alone or in combination with another therapeutic include: Acinetobacter species including Acinetobacter baumannii and Acinetobacter iwoffii; Aeromonas species including Aeromonas veronii biovar sobria (previously Aeromonas sobria), Aeromonas caviae, and Aeromonas hydrophila; Alcaligenes/Achromobacter species including Alcaligenes faecalis and Alcaligenes xylosoxidans; Bacteroides species including Bacteroides fragilis; Bartonella species including Bartonella bacilliformis, Bartonella clarridgeiae, Bartonella elizabethae, Bartonella henselae, Bartonella koehlerae, Bartonalla naantalienis, Bartonella quintana, Bartonella rochalimae, Bartonella vinsonii, and Bartonella washoensis; Bordetella species including Bordetella bronchispetica, Bordetella pertussis, and Bordetella parapertussis; Borrelia species including Borrelia afzelii, Borrelia burgdorferi, Borrelia crocidurae, Borrelia duttoni, Borrelia garinii, Borrelia hermsii, Borrelia hispanica, Borellia miyamotoi, Borrelia parkeri, Borrelia persica, Borrelia recurrentis, Borrelia turicatae, and Borrelia venezuelensis; Brevundimonas species including Brevundimonas diminuta and Brevundimonas vesicularis; Brucella species including Brucella abortus, Brucella canis, Brucella melitensis, and Brucella suis; Burkholderia species including Burkholderia cepacia, Burkholderia mallei, and Burkholderia pseudomallei; Campylobacter species including Campylobacter jejuni, Campylobacter coli, Campylobacter upsaliensis, Campylobacter lari, and Campylobacter coli; Chlamydia/Chlamidophila species including Chlamydophila pneumoniae, Chlamydophila psittaci, Chlamidophila pecorum, and Chlamydia trachomatis; Citrobacter species including Citrobacter amalonaticus, Citrobacter freundii, Citrobacter koseri, and Citrobacter diversus; Coxiella burnetti; Ehrlichia species including Ehrlichia canis and Ehrlichia chaffeensis; Enterobacter species including Enterobacter aerogenes and Enterobacter cloacae; Escherichia species including Escherichia coli; Francisella species including Francisella novicida, Francisella philomiragia, and Francisella tularensis; Haemophilus species including Haemophilus influenzae and Haemophilus ducreyi; Helicobacter species including Helicobacter pylori; Klebsiella species including Klebsiella granulomatis, Klebsiella oxytoca, and Klebsiella pneumoniae; Leclercia adecarboxylata; Legionella species including Legionella pneumophila; Leptospira species including Leptospira interrogans, Leptospira noguchii, Leptospira santarosai, and Leptospira weilii; Listeria species including Listeria monocytogenes; Moraxella species including Moraxella catarrhalis, Moraxella lacunata, and Moraxella bovis; Morganella species including Morganella morganii; Mycoplasma species including Mycoplasma amphoriforme, Mycoplasma buccale, Mycoplasma faucium, Mycoplasma fermentans, Mycoplasma genitalium, Mycoplasma hominis, Mycoplasma lipophilum, Mycoplasma orale, Mycoplasma penetrans, Mycoplasma pirum, Mycoplasma pneumoniae, Mycoplasma primatum, Mycoplasma salivarium, and Mycoplasma spermatophilum; Neisseria species including Neisseria meningitidis and Neisseria gonorrhoeae; Orientia species including Orientia tsutsugamushi and Orientia chuto; Pantoea species including Pantoea agglomerans; Paracoccus species including Paracoccus yeei; Prevotella species including Prevotella intermedia and Prevotella melaninogenica; Proteus species including Proteus mirabilis, Proteus penneri, and Proteus vulgaris; Providencia species including Providencia rettgeri and Providencia stuartii; Pseudomonas species including Pseudomonas aeruginoas, Pseudomonas oryzihabitans, Pseudomonas plecoglossidica, and Pseudomonas stutzeri; Ralstonia species including Ralstonia pickettii and Ralstonia insidiosa; Rickettsia species including Rickettsia africae, Rickettsia akari, Rickettsia australis, Rickettsia conorii, Rickettsia felis, Rickettsia japonica, Rickettsia prowazekii, Rickettsia rickettsia, Rickettsia sibirica, and Rickettsia typhi; Roseomonas species including Roseomonas gilardii; Salmonella species including Salmonella bongori, Salmonella enterica, Salmonella paratyphi, Salmonella typhi, and Salmonella typhimurium; Serratia species including Serratia marcescens, Serratia liquefaciens, Serratia rubidaea, and Serratia odoriferae; Shigella species including Shigella dysenteriae and Shigella sonnei; Sphingomonas species including Sphingomonas mucosissima and Sphingomonas paucimobilus; Stenotrophomas species including Stenotrophomas maltophilia; Treponema species including Treponema carateum, Treponema paraluiscuniculi, and Treponema pallidum; Ureaplasma species including Ureaplasma urealyticum; Vibrio species including Vibrio cholera, Vibrio parahaemolyticus, and Vibrio vulnificus; and Yersinia species including Yersinia enterocolitica, Yersinia pestis, and Yersinia pseudotuberculosis.

0217In one embodiment, the compounds of the present invention may be used to treat a disorder, typically an infection, caused by a mycobacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound of Formula I through Formula V or a pharmaceutically acceptable salt or composition thereof to treat an infection caused by a mycobacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt or composition thereof to treat an infection caused by a mycobacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound selected from Compound A, Compound B, or Compound F - Compound L or a pharmaceutically acceptable salt or composition thereof to treat an infection caused by a mycobacterium.

0218Non-limiting examples of mycobacteria which may be treated using the compounds of the present invention either alone or in combination with another therapeutic include Mycobacterium abcessus, Mycobacterium africanum, Mycobacterium agri, Mycobacterium aichiense, Mycobacterium alvei, Mycobacterium arabiense, Mycobacterium aromaticivorans, Mycobacterium arosiense, Mycobacterium arupense, Mycobacterium aquaticum, Mycobacterium asiaticum, Mycobacterium aubagnese, Mycobacterium aurum, Mycobacterium austroafricanum, Mycobacterium avium, Mycobacterium avium paratuberculosis, Mycobacterium avium silvaticum, Mycobacterium avium hominussuis, Mycobacterium bacteremicum, Mycobacterium barrassiae, Mycobacterium boenickei, Mycobacterium bohemicum, Mycobacterium bolletii, Mycobacterium botniense, Mycobacterium bovis, Mycobacterium branderi, Mycobacterium brisbanense, Mycobacterium brumae, Mycobacterium canariasense, Mycobacterium canettii, Mycobacterium caprae, Mycobacterium chimaera, Mycobacterium chelonae, Mycobacterium chitae, Mycobacterium chubuense, Mycobacterium colombiense, Mycobacterium conceptionense, Mycobacterium confluentis, Mycobacterium conspicuum, Mycobacterium cookii, Mycobacterium cosmeticum, Mycobacterium diernhoferi, Mycobacterium doricum, Mycobacterium duvalii, Mycobacterium elephantis, Mycobacterium fallax, Mycobacterium farcinogenes, Mycobacterium flavescens, Mycobacterium florentinum, Mycobacterium fortuitum, Mycobacterium frederikbergense, Mycobacterium gadium, Mycobacterium gastri, Mycobacterium genavense, Mycobacterium gilvum, Mycobacterium gordonae, Mycobacterium haemophilum, Mycobacterium hassiacum, Mycobacterium heidelbergense, Mycobacterium heckshornense; Mycobacterium hiberniae, Mycobacterium hodleri, Mycobacterium holsaticum, Mycobacterium houstonense, Mycobacterium icosiumassilensis, Mycobacterium immunogenum, Mycobacterium indicus pranii, Mycobacterium intacellulare, Mycobacterium intracellulare, Mycobacterium interjectum, Mycobacterium intermedium, Mycobacterium iranicum, Mycobacterium kansasii, Mycobacterium komossense, Mycobacterium kubicae, Mycobacterium lentiflavum, Mycobacterium leprae, Mycobacterium lepraemurium, Mycobacterium lepromatosis, Mycobacterium liflandii, Mycobacterium llatzerense, Mycobacterium madagascariense, Mycobacterium mageritense, Mycobacterium malmoense, Mycobacterium marinum, Mycobacterium massiliense, Mycobacterium massilipolynesiensis, Mycobacterium microti, Mycobacterium monacense, Mycobacterium montfiorense, Mycobacterium morokaense, Mycobacterium mucogenicum, Mycobacterium mungi, Mycobacterium murale, Mycobacterium nebraskense, Mycobacterium neoaurum, Mycobacterium neworleansense, Mycobacterium nonchromogenicum, Mycobacterium obuense, Mycobacterium orygis, Mycobacterium palustre, Mycobacterium parascofulaceum, Mycobacterium parafortuitum, Mycobacterium perigrinum, Mycobacterium phlei, Mycobacterium phocaicum, Mycobacterium pinnipedii, Mycobacterium porcinum, Mycobacterium pseudoshottsii, Mycobacterium psychotolerans, Mycobacterium pulveris, Mycobacterium pyrenivorans, Mycobacterium saskatchewanense, Mycobacterium sediminis, Mycobacterium senegalense, Mycobacterium septicum, Mycobacterium shimoidei, Mycobacterium shottsii, Mycobacterium simiae, Mycobacterium smegmatis, Mycobacterium sphagni, Mycobacterium stephanolepidis, Mycobacterium suricattae, Mycobacterium szulgai, Mycobacterium talmoniae, Mycobacterium terrae, Mycobacterium thermoresistibile, Mycobacterium triplex, Mycobacterium triviale, Mycobacterium tuberculosis, Mycobacterium tusciae, Mycobacterium ulcerans, Mycobacterium vaccae, Mycobacterium vanbaalenii, Mycobacterium xenopi, and Mycobacterium yongonense.

0219In one embodiment, an effective amount of an active compound or pharmaceutically acceptable salt thereof or composition as described herein is used to treat or to prevent a medical disorder which is mediated by the presence of an antibiotic-resistant bacterium. In one embodiment, the compounds of the present invention may be used to treat a disorder, typically an infection, caused by a pathogenic antibiotic-resistant bacterium.

0220In one embodiment, a method is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable salt thereof or composition thereof described herein to a subject, typically a human, to treat an infection caused by a pathogenic antibiotic-resistant bacterium.

0221Non-limiting examples of gram-positive antibiotic-resistant bacteria include: antibiotic-resistant Clostridium difficile, drug-resistant Streptococcus pneumoniae, clindamycin-resistant Group B Streptococcus, erythromycin-resistant Group A Streptococcus, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), and vancomycin-resistant Enterococcus (VRE).

0222Non-limiting examples of gram-negative antibiotic-resistant bacteria include: antibiotic-resistant Burkholderia cepacia, carbapenem-resistant Enterobacteriaceae (CRE) gut bacteria, drug-resistant Campylobacter, drug-resistant non-typhoidal Salmonella, drug-resistant Shigella, multi-drug-resistant Acinetobacter, multi-drug-resistant Escherichia coli, multi-drug-resistant Klebsiella pneumoniae, multi-drug-resistant Neisseria Gonorrhoeae, and multidrug-resistant Pseudomonas aeruginosa.

0223In one embodiment, an effective amount of a compound of Formula I through Formula V or a pharmaceutically acceptable salt or composition thereof is used to treat or to prevent a medical disorder which is mediated by the presence of an antibiotic-resistant mycobacterium. Optionally, an effective amount of a compound of Formula VII or Formula VIII or a pharmaceutically acceptable salt or composition thereof is used to treat or to prevent a medical disorder which is mediated by the presence of an antibiotic-resistant mycobacterium. In one embodiment, an effective amount of a compound selected from Compound A - Compound L or a pharmaceutically acceptable salt or composition thereof is used to treat or to prevent a medical disorder which is mediated by the presence of an antibiotic-resistant mycobacterium. In one embodiment, the compounds of the present invention may be used to treat a disorder, typically an infection, caused by a pathogenic antibiotic-resistant mycobacterium. In one embodiment, a method is provided comprising administering an effective amount of a compound as described herein or a pharmaceutically acceptable salt thereof or composition thereof described herein to a subject, typically a human, to treat an infection caused by a pathogenic antibiotic-resistant mycobacterium. In one embodiment, the antibiotic-resistant mycobacterium is multi-drug-resistant Mycobacterium tuberculosis (MDR-TB).

0224Non-limiting examples of disorders mediated by a bacterium that may be treated by the compounds of the present invention, either alone or in combination with another therapeutic, include actinomycosis, anaplasmosis, anthrax, bacillary angiomatosis, actinomycetoma, bacterial pneumonia, bacterial vaginosis, bacterial endocarditis, bartonellosis, botulism, boutenneuse fever, brucellosis, bejel, brucellosis spondylitis, bubonic plague, Buruli ulcer, Bairnsdale ulcer, bacillary dysentery, campylobacteriosis, Carrion's disease, cat-scratch disease, cellulitis, chancroid, chlamydia, chlamydia conjunctivitis, clostridial myonecrosis, cholera, Clostridium difficile colitis, diphtheria, Daintree ulcer, donavanosis, dysentery, erhlichiosis, epidemic typhus, fried rice syndrome, five-day fever, floppy baby syndrome, Far East scarlet-like fever, gas gangrene, glanders, gonorrhea, granuloma inguinale, human necrobacillosis, hemolytic-uremic syndrome, human ewingii ehrlichiosis, human monocytic ehrlichiosis, human granulocytic anaplasmosis, infant botulism, Izumi fever, Kawasaki disease, Kumusi ulder, lymphogranuloma venereum, Lemierre's syndrome, Legionellosis, leprosy, leptospirosis, listeriosis, Lyme disease, lymphogranuloma venereum, Malta fever, Mediterranean fever, myonecrosis, mycoburuli ulcer, mucocutaneous lymph node syndrome, meliodosis, meningococcal disease, murine typhus, Mycoplasma pneumonia, mycetoma, neonatal conjunctivitis, nocardiosis, Oroya fever, ophthalmia neonatorum, ornithosis, Pontiac fever, peliosis hepatis, pneumonic plague, postanginal shock including sepsis, pasteurellosis, pelvic inflammatory disease, pertussis, plague, pneumococcal infection, pneumonia, psittacosis, parrot fever, pseudotuberculosis, Q fever, quintan fever, rabbit fever, relapsing fever, rickettsialpox, Rocky Mountain spotted fever, rat-bite fever, Reiter syndrome, rheumatic fever, salmonellosis, scarlet fever, sepsis, septicemic plague, Searls ulcer, shigellosis, soft chancre, syphilis, streptobacillary fever, scrub typhus, Taiwan acute respiratory agent, Trench fever, trachoma, tuberculosis, tularemia, typhoid fever, typhus, tetanus, toxic shock syndrome, undulant fever, ulcus molle, Vibrio parahaemolyticus enteritis, Whitmore's disease, walking pneumonia, Waterhouse-Friderichsen syndrome, yaws, and yersiniosis.

0225In one embodiment, the compounds of the present invention may be used to treat an inflammatory disorder caused by the presence of a bacterial infection. Non-limiting examples of such inflammatory disorders include adenoiditis, appendicitis, arteritis, ascending cholangitis, balanitis, blepharitis, bronchitis, bursitis, cellulitis, cerebral vasculitis, cervicitis, chemosis, cholecystitis, chondritis, choroioamnionitis, colitis, conjunctivitis, constrictive pericarditis, cryptitis, dacryoadenitis, dermatitis, duodenal lymphocytosis, encephalitis, endocarditis, endometritis, endotheliitis, enteritis, enterocolitis, eosinophilis fasciitis, epididymitis, esophagitis, folliculitis, gastritis, gingivitis, glomerulonephritis, glossitis, hepatitis, infectious arthritis, ileitis, intertrigo, keratitis, keratoconjunctivitis, labyrithitis, lymphadenitis, mastitis, mastoiditis, myocarditis, myopericarditis, myositis, necrotizing fasciitis, nephritis, omaphalitis, oophoritis, ophthalmitis, orchitis, osteitis, osteomyelitis, pancreatitis, paraproctitis, parotitis, pericarditis, perichondritis, perifolliculitis, periodontitis, peritonitis, pharyngitis, phlebitis, pleurisy, pneumonitis, pulmonitis, proctitis, prostatitis, pulpitis, pyelonephritis, pyomyositis, retinal vasculitis, rheumatic fever, rhinitis, scleritis, salpingitis, sialadenitis, sinusitis, stomatitis, synovitis, septicemia, tenosynovitis, thyroiditis, tonsillitis, tularemia, urethritis, uveitis, vaginitis, vasculitis, and vulvitus.

V. COMBINATION THERAPY

0226In one embodiment, an active compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition thereof may be provided in combination or alternation with or preceded by, concomitant with or followed by, an effective amount of at least one additional active agent, for example, for treatment of a disorder listed herein. Non-limiting examples of additional active agents for such combination therapy are provided below.

0227In the described below and herein generally, whenever any of the terms referring to an active compound or pharmaceutically acceptable salt thereof or composition as described herein are used, it should be understood that pharmaceutically acceptable salt, prodrugs, or compositions are considered included, unless otherwise stated or inconsistent with the text.

0228In one embodiment, an active compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition thereof as described herein may be used in combination or alternation with an antibiotic.

0229In one embodiment, a compound selected from Compound A - Compound L or a pharmaceutically acceptable salt or composition thereof as described herein may be used in combination or alternation with an antibiotic.

0230In one embodiment, the antibiotic is an aminoglycoside. In one embodiment, the antibiotic is selected from amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, streptomycin, and spectinomycin.

0231In one embodiment, the antibiotic is an ansamycin. In one embodiment, the antibiotic is selected from geldanamycin, herbimycin, and rifaximin.

0232In one embodiment, the antibiotic is a carbapenem. In one embodiment, the antibiotic is selected from ertapenem, doripenem, imipenem, panipenem, biapenem, tebipenem, and meropenem.

0233In one embodiment, the antibiotic is a cephalosporin. In one embodiment, the antibiotic is selected from cefacetrile, cefadroxil, cephalexin, cefaloglycin, cefalonium, cefaloridine, cefalotin, cefapirin, cefatrizine, cefazaflur, cefazedone, cefazolin, cefradrine, cefroxadine, and ceftezole. In one embodiment, the antibiotic is selected from cefaclor, cefonicid, cefprozil, cefuroxime, cefuzonam, cefmetazole, cefotetan, cefoxitin, loracarbef, cefbuperazone, cefminox, cefoxitin, and cefotiam. In one embodiment, the antibiotic is selected from cefcapene, cefdaloxime, cefdinir, cefditoren, cefetamet, cefixime, cefmenoxime, cefodizime, cefotaxime, cefovecin, cefpimizole, cefpodoxime, cefteram, ceftamere, ceftibuten, ceftiofur, ceftiolene, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, and latamoxef. In one embodiment, the antibiotic is selected from cefclidine, cefepime, cefluprenam, cefoselis, cefozopran, cefpirome, cefquinome, and flomoxef. In one embodiment, the antibiotic is selected from ceftobiprole, ceftaroline, and ceftolozane.

0234In one embodiment, the antibiotic is a glycopeptide. In one embodiment, the antibiotic is selected from teicoplanin, vancomycin, telavancin, dalbavancin, ramoplanin, decaplanin, and oritavancin.

0235In one embodiment, the antibiotic is a lincosamide. In one embodiment, the antibiotic is selected from lincomycin, clindamycin, and pirlimycin. In one embodiment, the antibiotic is daptomycin.

0236In one embodiment, the antibiotic is a macrolide. In one embodiment, the antibiotic is selected from azithromycin, clarithromycin, erythromycin, fidaxomicin, telithromycin, carbomycin A, josamycin, kitasamycin, midecamycin, oleandomycin, solithromycin, spiramycin, troleandomycin, tylosin, and roxithromycin.

0237In one embodiment, the antibiotic is a ketolide. In one embodiment, the antibiotic is selected from telithromycin, cethromycin, and solithromycin.

0238In one embodiment, the antibiotic is a monobactam.

0239In one embodiment, the antibiotic is selected from aztreonam. In one embodiment, the antibiotic is a nitrofuran. In one embodiment, the antibiotic is selected from diruazone, furazolidone, nifurfoline, nifuroxazide, nifurquinazol, nifurtoinol, nifurzide, nitrofural, and nitrofurantoin.

0240In one embodiment, the antibiotic is an oxazolidinone. In one embodiment, the antibiotic is selected from linezolid, posizolid, tedizolid, radezolid, torezolid, and cycloserine.

0241In one embodiment, the antibiotic is a penicillin. In one embodiment, the antibiotic is selected from penicillin G, penicillin K, penicillin N, penicillin O, and penicillin V. In one embodiment, the antibiotic is selected from meticillin, nafcillin, oxacillin, cloxacillin, dicloxacillin, and flucoxacillin. In one embodiment, the antibiotic is selected from ampicillin, amoxicillin, pivampicillin, hetacillin, bacampicillin, metampicillin, talampicillin, and epicillin. In one embodiment, the antibiotic is selected from carbenicilin, ticarcillin, and temocillin. In one embodiment, the antibiotic is selected from mezlocillin and piperacillin. In one embodiment, the antibiotic is selected from clavulanic acid, sulbactam, and tazobactam.

0242In one embodiment, the antibiotic is a polypeptide antibiotic. In one embodiment, the antibiotic is selected from bacitracin, colistin, and polymyxin B.

0243In one embodiment, the antibiotic is a quinolone or fluoroquinolone antibiotic. In one embodiment, the antibiotic is selected from flumequine, oxolinic acid, rosoxacin, cinoxacin, nalidixic acid, and piromidic acid. In one embodiment, the antibiotic is selected from ciprofloxacin, fleroxacin, lomefloxacin, nadifloxacin, norfloxacin, ofloxacin, pefloxacin, rufloxacin, and enoxacin. In one embodiment, the antibiotic is selected from balofloxacin, grepafloxacin, levofloxacin, pazufloxacin, sparfloxacin, temafloxacin, and tosufloxacin. In one embodiment, the antibiotic is selected from clinafloxacin, gatifloxacin, moxifloxacin, sitafloxacin, prulifloxacin, besifloxacin, gemifloxacin, trovafloxacin, delafloxacin, and ozenoxacin.

0244In one embodiment, the antibiotic is a sulfonamide. In one embodiment, the antibiotic is selected from sulfacetamide, sulfadiazine, sulfadimidine, sulfafurazole, sulfisomidine, sulfadoxine, sulfamethoxazole, sulfamoxole, sulfanitran, sulfadimethoxine, sulfamethoxypyridazine, sulfametoxydiazine, sulfadoxine, sulfametopyrazine, terephtyl, mafenide, sulfanilamide, sulfasalazine, sulfisoxazole, and sulfonamicochrysoidine.

0245In one embodiment, the antibiotic is a tetracycline. In one embodiment, the antibiotic is selected from tetracycline, chlortetracycline, oxytetracycline, demeclocycline, lymecycline, meclocycline, metacycline, minocycline, and rolitetracycline. In one embodiment, the antibiotic is selected from clofazimine, dapsone, capreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifampicin, rifabutin, rifapentine, and streptomycin. In another embodiment, the antibiotic is selected from arsphenamide, chloramphenicol, fosfomycin, fusidic acid, metronidazole, mupirocin, platensimycin, quinupristin, dalfopristin, thiamphenicol, tigecycline, and trimethoprim.

VI. TOPICAL FORMULATIONS FOR THE TREATMENT OF ACNE VULGARIS

0246Acne vulgaris is a skin disease caused in part by excessive outgrowth of Propionibacterium acnes bacteria and inflammation induced in response to the P. acnes bacteria. Acne, a common skin disease, occurs when hair follicles become clogged with dead skin cells and oil from the skin. Acne develops due to blockages that occur through increased sebum production influenced by androgens, excessive deposition of keratin in the hair follicle leading to comedo formation. The earliest pathological change involves the formation of a microcomedone due to the accumulation of skin cells in the hair follicle, which mix with oily sebum to block the follicle, a process further exacerbated by the presence of the P. acnes biofilm. If the microcomedone is superficial, melanin within the plug oxidizes upon exposure to air, forming a blackhead or open comedo. If the microcomedone is deeper within the hair follicle, a whitehead or closed comedo forms.

0247Propionibacterium acnes (reclassified as Cutibacterium acnes in 2016) is a Gram-positive bacterium (rod) linked to acne that belongs to the Cutibacterium Genus and the Propionibacteriaceae Family. Typically, slow growing, it is aerotolerant anaerobe, meaning that it can tolerate the presence of oxygen, but does not utilize oxygen for its growth. While the bacteria is involved in the maintenance of healthy skin, it can also cause many common skin disorders such as acne vulgaris. The bacteria predominately live deep within follicles and pores, where it uses sebum, cellular debris, and metabolic byproducts from surrounding skin tissue as a source of energy and nutrients. Elevated production of sebum or blockage of follicles can cause the bacteria to grow and this rapid growth can trigger inflammation that can led to the symptoms of common skin disorders, such as folliculitis and acne vulgaris. While less common, Staphylococcus epidermidis can also cause acne. It is a Gram-positive bacterium belonging to the Staphylococcus Genus and the Staphylococcaceae Family that is part of the normal human flora and typically skin flora or mucosal flora. It is a facultative anaerobic bacterium and can therefore grow with or without oxygen. It is usually not pathogenic, but in patients with comprised immune systems, the bacteria can cause an infection. Staphylococcus epidermidis has ability to form biofilms on plastic and its infections are generally related to catheters or surgical implants. The presence of P. acnes induces skin inflammation due to the bacteria's ability to bind to toll-like receptors (TLRs), especially TLR2 and TLR4 and by altering the fatty composition of the oily sebum by oxidizing squalene. The subsequent inflammatory cascades lead to the formation of inflammatory acne lesions such as papules, pustules, or nodules. If the inflammatory reaction is very severe, the follicle will break into the dermis and subcutaneous tissue as a deep nodule, leading to local tissue destruction and scarring.

0248Traditionally, acne is classified as either non-inflammatory (open/closed comedones) or inflammatory (papules, pustules, or nodules). Mounting evidence indicates that inflammation exists throughout the entire duration of the acne lesion lifecycle, establishing the critical role of inflammation in the pathology of acne. In the earliest stages of acne lesion development, CD3+ T cell, CD4+ T cell, and macrophage populations are elevated, while the levels of the pro-inflammatory cytokine interleukin-1 are also upregulated. Initiation of inflammatory events have been documented even before clinical detection of acne lesions.

0249An active compound described herein can be administered to a human in need thereof as a neat chemical or as a topical formulation that includes an effective amount of a compound described herein, or its pharmaceutically acceptable salt, for a human in need of treatment of acne vulgaris. Thus, in one embodiment, the disclosure provides topical formulations comprising an effective amount of a compound described herein, or its pharmaceutically acceptable salt, together with at least one topically acceptable carrier for any of the uses described herein. The topical formulation may contain a compound or salt as the only active ingredient, or, in an alternative embodiment, the compound and at least one additional active agent.

0250An effective amount of a compound as described herein, or a compound described herein in combination or alternation with, or preceded by, concomitant with or followed by another active agent, can be used in an amount sufficient to (a) inhibit the progression of acne vulgaris; (b) cause a regression of acne vulgaris; (c) cause a cure of acne vulgaris; or inhibit or prevent the development of acne vulgaris. Accordingly, an effective amount of a compound or pharmaceutically acceptable salt thereof or composition described herein will provide a sufficient amount of the agent when administered to human to provide a desired benefit.

0251Topical formulations are classified into three major categories: solid forms (such as dusting powders); liquid forms (such as lotions and liniments); and semi-liquid forms (such as ointments, pastes, creams, and gels). Additives or excipients are used as inactive ingredients in topical formulations for structuring. The main use of topical formulation additives is to control the extent of absorption of the active compound, maintaining the viscosity, improving the stability and organoleptic properties, and increasing the bulk of the formulation. The main goal of topical formulations is to confine the desired effect to the skin or within the skin. Such formulations are preferred because they are protective, emollient, and deliver the active agent to exert local activity when applied to the skin or mucous membranes.

0252In one embodiment, the topical formulation is a solid formulation such as a dusting powder. A dusting powder is a finely divided insoluble powder containing ingredients used on skin especially for allaying irritation or absorbing moisture, discouraging bacterial growth and providing lubricant properties. Easy powder flow ability and spreadability are important parameters that are considered in the manufacture and evaluation of a dusting powder formulation. The dusting powder should adhere to the skin, provide good coverage and skin adsorption, should be free of irritant properties, and should protect the skin from drying and irritation. Representative examples of excipients that can be used in dusting powder formulations include, but are not limited to, talc, starch (such as corn starch, wheat starch, or potato starch), kaolin, zinc stearate, zinc oxide, aluminum chlorohydrate, aluminum zirconium chlorhydrex, micronized wax, and chlorhexidine (as the acetate, gluconate, or hydrochloride salt).

0253In one embodiment, the topical formulation is a cream formulation. Creams are semisolid emulsion formulation for application to the skin or mucous membranes. Creams may be formulated as water in oil (w/o) emulsions or as oil in water (o/w) emulsions. Water in oil emulsion creams are less greasy and provide good spreadability compared to ointments. Oil in water emulsion creams, often called vanishing creams, readily rub into the skin and are easily removed by water.

0254Water in oil emulsion formulations typically consist of a hydrophilic component, e.g. water or other hydrophilic diluent, and a hydrophobic component, e.g. a lipid, oil, or oily material. The hydrophilic component is typically dispersed, i.e. exists as small particles and droplets, within the hydrophobic component. Water in oil emulsions typically comprise from about 1% to about 98% of the dispersed hydrophilic phase and from about 1% to about 50% of the hydrophobic phase. Additives commonly used in water in oil emulsion formulations include wool fat (containing sterols, cholesterol, oxycholesterol, triterpene, or aliphatic alcohols), waxes, bivalent soaps, sorbitan esters, borax, and oleic acid. In some embodiments, the water in oil emulsion refers to a water in silicone emulsion.

0255Oil in water emulsion formulations typically consist of a hydrophilic component, e.g. water or other hydrophilic diluent, and a hydrophobic component, e.g. a lipid, oil, or oily material. The hydrophobic component is typically dispersed, i.e. exists as small particles and droplets, within the hydrophilic component. Water in oil emulsions typically comprise from about 1% to about 98% of the hydrophilic phase and from about 1% to about 50% of the dispersed hydrophobic phase. Additives commonly used in oil in water emulsion formulations include polysorbates (such as Tween 80, Tween 21, and Tween 40), methylcellulose, acacia, tragacanth, triethanolamine oleate, arachis oil, and cetostearyl alcohol.

0256In one embodiment, the topical formulation is an ointment formulation. Ointments are greasy semisolid preparations of a dissolved or dispersed active compound. Ointment bases often influence topical drug bioavailability due to their occlusive properties of the stratum corneum, which enhances the flux of drug across the skin and affects drug dissolution or partitioning within and from the ointment to the skin. Ointments usually are moisturizing and are good for dry skin, as well as having a low risk of sensitization or irritation due to having few ingredients beyond the base oil or fat. The vehicle for an ointment formulation, known as an ointment base, may be an oleaginous base, an absorption base, or a water-soluble base.

0257Oleaginous bases are composed entirely of lipophilic materials. They are anhydrous, insoluble in water, and not easily removable with water. Oleaginous bases are inexpensive, non-reactive, nonirritating, are good emollients, have protective and occlusive properties, and are not water washable. Representative examples of oleaginous bases include hydrocarbons (such as petrolatum, paraffin wax, liquid paraffin, microcrystalline wax, plastibase, or Ceresi), vegetable oils and animal fat (such as coconut oil, bees wax, olive oil, lanolin, peanut oil, spermacetic wax, sesame oil, or almond oil), hydrogenated and sulfated oils (such as hydrogenated castor oil, hydrogenated cotton seed oil, hydrogenated soya bean oil, hydrogenated corn oil, or hydrogenated sulfated castor oils), alcohols/acids/esters (such as cetyl alcohol, stearic acid, stearyl alcohol, oleic acid, olelyl alcohol, palmitic acid, lauryl alcohol, lauraic acid, myristyl alcohol, ethyl oleate, isopropyl myristicate, or ethylene glycol), and silicones (such as dimethylpropylsiloxanes, methyl phenyl polysiloxanes, and steryl esters of dimethyl polysiloxanes).

0258Absorption bases are known to take up several times their own weights in water but not permit absorption of medicament form the base. The advantages of absorption bases are their protective, occlusive, and emollient properties, their ability to absorb liquids, and that they do not wash off easily, so they hold the incorporated compound with sufficient contact with the skin. Representative examples of absorption bases include hydrophilic petrolatum and anhydrous lanolin.

0259Water-soluble bases, also known as greaseless ointment bases, consists of water-soluble ingredients such as polyethylene glycol polymer (carbowax). Polyethylene glycol is water soluble, nonvolatile, and inert. Other water-soluble bases include glyceryl monostearate, cellulose derivatives, sodium alginate, bentonite, and carbopol 934.

0260In one embodiment, the topical formulation is a gel formulation. Gels are transparent or translucent semisolid preparations of one or more active ingredients in suitable hydrophilic or hydrophobic bases. Gels may be clear or opaque, and polar hydroalcoholic or nonpolar. Gels are prepared by either a fusion process or a special procedure necessitated by the gelling agents, humectants, and preservatives. Gelling agents exhibit pseudoplastic properties that give the formulation a thixotropic consistency. Gelling agents are typically used in concentrations of 0.5-10% to allow for easy addition of the active drug before the gel is formed. Representative examples of agents used in gel formulations include tragacanth, fenugreek mucilage, methyl cellulose, hydroxy ethyl cellulose, hydroxy propyl cellulose, hydroxy propyl methyl cellulose, carboxy methylcellulose, carbopol, pectin, poloxamers, alginates (such as sodium, potassium, or ammonium alginates), gelatin, starch, polyvinyl alcohol, povidone, propylene glycol, and ethyldiamine tetraacetic acid.

0261In one embodiment, the topical formulation is a paste formulation. Pastes are stiff preparations containing a high proportion of a finely powdered solid such as starch, zinc oxide, calcium carbonate, or talc. Pastes are often less greasy than ointment formulations.

0262In one embodiment, the topical formulation is a lotion formulation. Lotions are low-to medium-viscosity preparations intended for application to unbroken skin. Lotions are applied to external skin with bare hands, a clean cloth, cotton wool or gauze. Lotions provide cooling effects to the skin by the evaporation of solvents formulated therein. Typical additives in lotion formulations include bentonite, sodium carboxymethylcellulose, alcohols, and glycerin.

0263In one embodiment, the topical formulation is a liniment formulation. Liniments are liquid or semiliquid preparations meant for application to the skin with friction or rubbing. They act as a rubefacient, soother, or stimulant. Typical vehicles for liniment formulations are alcohol, oil, or soap based. Typical additives in a liniment formulation include castor oil, cotton seed oil, peanut oil, sesame oil, and oleic acid.

0264A wide variety of optional components/ingredients may be included in the topical formulations including, but not limited to, absorbents, abrasives, anticaking agents, antifoaming agents, antimicrobial agents, binders, biological actives, buffering agents, bulking agents, chemical additives, cosmetic biocides, denaturants, cosmetic astringents, drug astringents, external analgesics, film formers, humectants, opacifying agents, fragrances, pigments, colorings, essential oils, skin sensates, emollients, skin soothing agents, skin healing agents, pH adjusters, plasticizers, preservatives, preservative enhancers, propellants, reducing agents, additional skin-conditioning agents, skin penetration enhancing agents, skin protectants, solvents, suspending agents, emulsifiers, thickening agents, solubilizing agents, sunscreens, sunblocks, ultraviolet light absorbers or scattering agents, sunless tanning agents, antioxidants and/or radical scavengers, chelating agents, oil/sebum control agents, sweat control agents, sequestrants, anti-inflammatory agents, anti-androgens, depilation agents, desquamation agents/exfoliants, organic hydroxy acids, vitamins and derivatives thereof, and natural extracts.

0265An effective amount of a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition thereof can also be used to treat or prevent acne vulgaris in a human, due to any bacteria that causes such acne, including P. acnes and S. epidermis.

0266An effective amount of a compound selected from Compound A - Compound L or a pharmaceutically acceptable salt or composition thereof can also be used to treat or prevent acne vulgaris in a human, due to any bacteria that causes such acne, including P. acnes and S. epidermis. In one embodiment, a method is provided comprising administering to a human an effective amount of a compound described herein or its pharmaceutically acceptable salt thereof or composition either alone or in combination with an effective amount of an additional active agent, for example an antibiotic or anti-inflammatory agent, to treat acne vulgaris.

0267Acne vulgaris severity may be classified as mild, moderate, or severe. Mild acne is classically defined by the presence of clogged skin follicle (known as comedones) limited to the face with occasional inflammatory lesions. Moderate acne occurs when a higher number of inflammatory papules and pustules occur on the face, with some being found on the trunk of the body. Severe acne occurs when nodules are the characteristic facial lesions and involvement of the trunk is extensive.

0268The present method includes identifying a target portion of skin affected with acne vulgaris and in need of treatment and applying a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition thereof to the target portion of skin. In some instances, the target portion of skin may not appear to be suffering from acne vulgaris, i.e. the compound Formula I through Formula VIII or a pharmaceutically acceptable salt or composition as described herein may be used as a preventative therapy for acne vulgaris. The compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition as described herein, may be applied to the target skin portion and, if desired, to the surrounding skin at least once a day, twice a day, or on a more frequent daily basis during the treatment period. Typically, the compound described herein or pharmaceutically acceptable salt thereof or composition is applied in the morning and/or in the evening before bed.

0269The treatment period is ideally sufficient time for the active compound to reduce or eliminate the appearance of acne vulgaris on the target portion of skin. The treatment period may last for at least 1 week, about two weeks, about 4 weeks, about 8 weeks, or about 12 weeks. The treatment period may extend over multiple months (about 3-12 months) or multiple years. The step of applying a compound described herein or a pharmaceutically acceptable salt or composition may be accomplished by localized application, i.e. by applying to the targeted area while minimizing delivery to skin surfaces where treatment is not desired, or by applying more generally or broadly to one or more skin surfaces. Propionibacterium acnes (reclassified as Cutibacterium acnes in 2016) is a Gram-positive bacterium (rod) linked to acne that belongs to the Cutibacterium Genus and the Propionibacteriaceae Family. Typically, slow growing, it is aerotolerant anaerobe, meaning that it can tolerate the presence of oxygen, but does not utilize oxygen for its growth. While the bacteria is involved in the maintenance of healthy skin, it can also cause many common skin disorders such as acne vulgaris. The bacteria predominately live deep within follicles and pores, where it uses sebum, cellular debris, and metabolic byproducts from surrounding skin tissue as a source of energy and nutrients. Elevated production of sebum or blockage of follicles can cause the bacteria to grow and this rapid growth can trigger inflammation that can led to the symptoms of common skin disorders, such as folliculitis and acne vulgaris.

0270Staphylococcus epidermidis is a Gram-positive bacterium belonging to the Staphylococcus Genus and the Staphylococcaceae Family that is part of the normal human flora and typically skin flora or mucosal flora. It is a facultative anaerobic bacterium and can therefore grow with or without oxygen. It is usually not pathogenic, but in patients with comprised immune systems, the bacteria can cause an infection. Staphylococcus epidermidis has ability to form biofilms on plastic and its infections are generally related to catheters or surgical implants.

0271In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition thereof may be used in combination or alternation with benzoyl peroxide. In the skin follicle, benzoyl peroxide kills P. acnes by oxidizing its proteins through the formation of oxygen free radicals and benzoic acid. These radicals are believed to interfere with the bacterium's metabolism and ability to make proteins. Additionally, benzoyl peroxide is mildly effective at breaking down comedones and inhibiting inflammation. In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt is formulated in combination with benzoyl peroxide in a topical formulation as described herein.

0272In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition as described herein may be used in combination or alternation with a retinoid. Retinoids are medications which reduce inflammation, normalize the follicle cell life cycle, and reduce sebum production. They are structurally related to vitamin A. The retinoids appear to influence the cell life cycle in the follicle lining; this helps prevent the accumulation of skin cells within the hair follicle that can create a blockage. Frequently used topical retinoids include adapalene, isotretinoin, retinol, tazarotene, and tretinoin. In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt thereof is formulated in combination with a retinoid in a topical formulation as described herein.

0273In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition as described herein may be used in combination or alternation with an antibiotic. Antibiotics are frequently applied to the skin or taken orally to treat acne and are thought to work due to their antimicrobial activity against P. acnes and their ability to reduce inflammation. Commonly used antibiotics include clindamycin, erythromycin, metronidazole, sulfacetamide, and tetracyclines such as doxycycline and minocycline. Other representative topical antibiotics include bacitracin, polymycin b, neomycin, retapamulin, mupirocin, pramoxine, gentamicin, mafenide, and ozenoxacin. The antibiotics described herein can be applied to the skin, taken orally, or administered in any other suitable way as determined by one of skill in the art. The compounds described herein are particularly effective in combination with antibiotics due to their potentiation of the antimicrobial effect of the antibiotic. In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt thereof, is formulated in combination with an antibiotic in a topical formulation as described herein.

0274In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt or composition as described herein may be used in combination or alternation with azelaic acid. Azelaic acid is thought to be an effective acne treatment due to its ability to reduce skin cell accumulation in the follicle, along with its antibacterial and anti-inflammatory properties. In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt thereof is formulated in combination with an antibiotic in a topical formulation as described herein.

0275In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt thereof or composition as described herein may be used in combination or alternation with salicyclic acid. Salicyclic acid is a topically applied beta-hydroxy acid that has keratolytic properties in addition to stopping bacterial reproduction. In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt thereof is formulated in combination with salicyclic acid in a topical formulation as described herein.

0276In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt thereof or composition as described herein may be used in combination or alternation with niacinamide. Niacinamide can improve acne by decreasing inflammation, suppressing sebum production, and promoting wound healing. In one embodiment, a compound of Formula I through Formula VIII or a pharmaceutically acceptable salt thereof is formulated in combination with salicyclic acid in a topical formulation as described herein.

VII. GENERAL SYNTHESIS

0277The compounds described herein can be prepared by methods known to those skilled in the art. In one non-limiting example, the disclosed compounds can be made using the routes provided below.

0278Compounds of the present invention with stereocenters may be drawn without stereochemistry for convenience. One skilled in the art will recognize that pure enantiomers and diastereomers can be prepared by methods known in the art. Example of methods to obtain optically active materials include at least the following. <ol id="ol0001" compact="compact"><li>i. physical separation of crystals -a technique whereby macroscopic crystals of the individual enantiomers are manually separated. This technique can be used if crystals of the separate enantiomers exist, i.e., the material is a conglomerate, and the crystals are visually distinct;</li><li>ii. simultaneous crystallization - a technique whereby the individual enantiomers are separately crystallized from a solution of the racemate, possible only if the enantiomer is a conglomerate in the solid state;</li><li>iii. enzymatic resolutions - a technique whereby partial or complete separation of a racemate by virtue of differing rates of reaction for the enantiomers with an enzyme;</li><li>iv. enzymatic asymmetric synthesis - a synthetic technique whereby at least one step in the synthesis uses an enzymatic reaction to obtain an enantiomerically pure or enriched synthetic precursor of the desired enantiomer;</li><li>v. chemical asymmetric synthesis - a synthetic technique whereby the desired enantiomer is synthesized from an achiral precursor under conditions that produce asymmetry (i.e. chirality) in the product, which may be achieved by chiral catalysts or chiral auxiliaries;</li><li>vi. diastereomer separations - a technique whereby a racemic compound is reaction with an enantiomerically pure reagent (the chiral auxiliary) that converts the individual enantiomers to diastereomers. The resulting diastereomers are then separated by chromatography or crystallization by virtue of their now more distinct structural differences the chiral auxiliary later removed to obtain the desired enantiomer;</li><li>vii. first- and second-order asymmetric transformations - a technique whereby diastereomers from the racemate quickly equilibrate to yield a preponderance in solution of the diastereomer from the desired enantiomer of where preferential crystallization of the diastereomer from the desired enantiomer perturbs the equilibrium such that eventually in principle all the material is converted to the crystalline diastereomer from the desired enantiomers. The desired enantiomer is then released from the diastereomer;</li><li>viii. kinetic resolutions - this technique refers to the achievement of partial or complete resolution of a racemate (or of a further resolution of a partially resolved compound) by virtue of unequal reaction rates of the enantiomers with a chiral, non-racemic reagent or catalyst under kinetic conditions;</li><li>ix. enantiospecific synthesis from non-racemic precursors - a synthetic technique whereby the desired enantiomer is obtained from non-chiral starting materials and where the stereochemical integrity is not or is only minimally compromised over the course of the synthesis;</li><li>x. chiral liquid chromatography - a technique whereby the enantiomers of a racemate are separated in a liquid mobile phase by virtue of their differing interactions with a stationary phase (including vial chiral HPLC). The stationary phase can be made of chiral material or the mobile phase can contain an additional chiral material to provoke the differing interactions;</li><li>xi. chiral gas chromatography - a technique whereby the racemate is volatilized and enantiomers are separated by virtue of their differing interactions in the gaseous mobile phase with a column containing a fixed non-racemic chiral adsorbent phase;</li><li>xii. extraction with chiral solvents - a technique whereby the enantiomers are separated by virtue of preferential dissolution of one enantiomer into a particular chiral solvent;</li><li>xiii. transport across chiral membranes - a technique whereby a racemate is place in contact with a thin 5 membrane barrier. The barrier typically separates two miscible fluids, one containing the racemate, and a driving force such as concentration or pressure differential causes preferential transport across the membrane barrier. Separation occurs as a result of the non-racemic chiral nature of the membrane that allows only one enantiomer of the racemate to pass through; and</li><li>xiv. simulated moving bed chromatography is used in one embodiment. A wide variety of chiral stationary phases are commercially available.</li></ol>

VIII. EXAMPLES

Example 1. Synthesis of Representative Examples of the Present Invention

0279The synthesis of representative compounds of the present invention are described in <nplcit id="ncit0019" npl-type="s"><text>Arafa et. Al., "Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozal agents", European Journal of Medicinal Chemistry, 2008, 43, 2901-2908</text></nplcit> (Compound A); <nplcit id="ncit0020" npl-type="s"><text>Wang et al. "Evaluation of the Influence of Compound Structure on Stacked-Dimer Formation in the DNA Minor Groove" Biochemistry, 2001, 40, 2511</text></nplcit> (Compound B); <patcit id="pcit0080" dnum="WO2002055025A"><text>WO2002/055025</text></patcit>, Scheme 1 and page 22, paragraph 120 (Compound D); <nplcit id="ncit0021" npl-type="s"><text>Giordani et al. "Green Fluorescent Diamidine as Diagnostic Probes for Trypanosomes" Antimicrobial Agents and Chemotherapy 2014, 58:1793</text></nplcit> (Compound M, Compound N, Compound P, Compound Q); <nplcit id="ncit0022" npl-type="s"><text>Ismail MA, Boykin DW, and Stephens CE, "An efficient synthesis of 2,5'-diarylbichalcophenes", Tetrahedron Letters, 2006, 47, pg. 795-797</text></nplcit> (Compound O); <patcit id="pcit0081" dnum="WO2009051796A"><text>WO2009/051796</text></patcit>, Example 1, Scheme 1 on page 40 and 41 (Compound R); <nplcit id="ncit0023" npl-type="s"><text>Gonzalez et. al., "Synthesis and antiparasitic evaluation of bis-2,5-[4-guanidinophenyl]thiophenes", European Journal of Medicinal Chemistry, 2007, 42, 552-557</text></nplcit> (Compound C); <patcit id="pcit0082" dnum="EP1726589A"><text>EP1726589</text></patcit>, Example 3, Scheme 4 on page 27, and paragraph 142 (Compound T).

Synthesis of Compound U

0280<chemistry id="chem0262" num="0262"><img file="EP4603484A2_D0262.tif" /></chemistry><ul id="ul0015" list-style="none" compact="compact"><li>a) 3,4-diaminobenzonitrile 4-cyanobenzeneboronic acid, Pd(PPh3)4, reflux, overnight;</li><li>b) 3,4-diaminobenzonitrile, sodium bisulfite, DMF, reflux, overnight; c) hydroxylamine hydrochloride, potassium t-butoxide, DMSO, rt, overnight; d) glacial acetic acid, acetic anhydride, 2h;</li><li>e) H2, Pd/C.</li></ul>

5-(4-Cyanophenyl)indole-3-carbaldehyde (U-1)

0281To a solution of 5-bromoindole-3-carbaldehyde (1.12 g, 5.0 mmol) and Pd(PPh3)4 (0.30 g, 0.26 mmol) in 20 mL of toluene under a nitrogen atmosphere was added 10 mL of 2M aqueous NaHCO3 and 0.74 g (5.0 mmol) of 4-cyanobenzeneboronic acid in 5 mL of methanol. The mixture was vigorously stirred and heated under reflux overnight. The mixture was cooled and extracted with dichloromethane. The organic layer was dried and concentrated to dryness under reduced pressure to afford 1.0 g (81%) of product, mp 248-250 °C. 1H-NMR(DMSO-d6)δ 10.98 (d, 1H, J = 2), 8.40 (d, 1H, J = 2), 7.87 (dd, 4H, J = 8 and J = 2), 7.62 (s, 1H); 13C-NMR (DMSO-d6) δ 185.2, 145.7, 139.4, 137.2, 132.8, 132.7, 127.6, 124.9, 122.9, 119.4, 119.0, 118.4, 113.2, 109.3. Anal. calcd. C16H10N2O: C, 78.03; H, 4.09. Found: C, 77.73; H, 4.17.

3-(5-Cyanobenzimidazol-2-yl)-5-(4-cyanophenyl)indole (U-2)

0282A solution of 5-(4-cyanophenyl)indole-3-carbaldehyde (0.80 g, 3.25 mmol), 3,4-diaminobenzonitrile (0.44 g, 3.3 mmol) and sodium bisulfite (0.40 g, 3.9 mmol) in 5 mL DMF was heated under reflux overnight. After cooling, the mixture was poured onto chipped ice. The solid was collected by filtration and washed with aqueous sodium bicarbonate (2.5%) and water to yield 1.0 g (85%) of an off white solid, mp 311-313 °C. 1H-NMR(DMSO-d6) δ 8.82 (s, 1H), 8.28(s, 1H), 7.93(s, 4H), 7.61 (m, 4H); 13C-NMR(DMSO-d6) δ 152.3, 146.3, 136.8, 132.9, 131.4, 128.7, 125.7, 125.2, 122.0, 120.4, 119.1, 113.0, 109.1, 106.3, 103.0; HRMS (FAB) calcd. mass for C23H13N5 (M + H): 360.383; observed mass, 360.125.

3-(5-Hydroxyamidinobenzimidazol-2-yl)-5-(4-hydroxyamidinophenyl)indole (U-3)

0283To a solution of hydroxylamine hydrochloride (0.72 g, 10. 3 mmol) in 5 mL of DMSO, potassium t-butoxide (1.16 g, 10.3 mmol) was added in portions under nitrogen. After stirring the mixture for 30 minutes, 0.37 g (1.01 mmol) of 3-(5-cyanobenzimidazol-2-yl)-5-(4-cyanophenyl)indole was added and the mixture was stirred at room temperature overnight. The mixture was poured into ice water and filtered to yield the expected 3-(5-hydroxyamidinobenzimidazol-2-yl)-5-(4-hydroxyamidinophenyl)indole as a white solid, 0.43 g (98%); mp 370 °C (decomp.); 1H-NMR (DMSO-d6) δ 9.71(s, 1H), 9.60 (s, 1H), 8.79 (s, 1H), 8.23 (d, 1H, J = 2.7), 7.84 (d, 2H, J = 8.4), 7.76 (d, 2H, J = 8.4), 7.60 (m, 5H), 5.98 (s, 2H), 5.91 (s, 4H); 13C-NMR (DMSO-d6) δ 172.1, 152.3, 150.8, 150.4, 142.3, 136.3, 132.5, 131.5, 127.4 , 126.6, 126.4, 126.0, 125.7, 121.7, 119.5, 119.4, 112.6, 106.9. Anal. calcd. for C23H19N7O2·2.3H2O: C, 59.17; H, 5.09. Found: C, 59.11; H, 4.99.

3-(5-Acetoxyamidinobenzimidazol-2-yl)-5-(4-acetoxyamidinophenyl)indole

0284The above amidoxime (0.35 g, 2.0 mmol) was dissolved in glacial acetic acid (5 mL) and acetic anhydride (0.5 mL, 6.5 mmol) was added. The mixture was allowed to stir for 2 hours and the solvent was evaporated. The product was used in the next step without further characterization.

3-(5-Amidinobenzimidazol-2-yl)-5-(4-amidinophenyl)indole acetate salt (Compound U)

0285Crude 3-(5-acetoxyamidinobenzimidazol-2-yl)-5-(4-acetoxyamidinophenyl)indole was submitted to catalytic hydrogenation in the presence of Pd/C to afford 0.25 g (43% yield) of Compound L, mp >228 °C. 1H-NMR (DMSO-d6) δ 8.86(s, 1H), 8.37(s, 1H), 8.12(s, 1H), 7.93(m, 4H), 7.62(m, 4H), 5.99(br, 1H), 1.82(s, 11H);13C-NMR(DMSO-d6) δ175.5, 166.7, 165.9, 152.5, 146.5, 136.9, 131.5, 128.8, 128.4, 127.1, 127.0, 125.9, 121.9, 121.4, 120.9, 119.9, 112.9, 106.6, 24.0; HRMS (FAB) calcd. mass for C23H19N6 (M + H): 394.450; observed mass, 394.178. Anal. calcd. for C23H19N6.3.5CH3COOH·3.0H2O: C, 54.78, H, 5.97; N, 14.90. Found: C, 54.83, H, 5.79; N, 14.81.

General Methods for the Synthesis of Diamidine Compounds

0286Diamidine compounds were synthesized from dinitrile compounds, either through method B or method C. Substituted amidine or cyclized amidine compounds (MD-102, MD-112, MD-113 and MD-129) were synthesized from dinitrile compounds through method D. <chemistry id="chem0263" num="0263"><img file="EP4603484A2_D0263.tif" /></chemistry>

General procedures for the preparation of dinitriles (Method A)

0287A mixture of 1,3-bis (bromomethyl)-benzene/substituted benzene (5 mmol), 4-hydroxybenzonitrile or 4-hydroxy substituted benzonitrile (10 mmol) and anhydrous K2CO3 (2.07 g, 15 mmol) in 10 mL DMF was heated at 45 °C for 4 hours. Then the reaction mixture was diluted with ice water (70 mL) and stirred for 30 minutes. The white precipitate was filtered, washed with water, and dried in air. Then the white solid was dissolved in organic solvent (75 mL) (DCM, methanol or THF). The organic phase was dried over anhydrous MgSO4. MgSO4 was then filtered and the supernatant was concentrated with rotavapor to afford crude product. The crude product was then triturated with hexane, filtered and dried in vacuum to yield white solid in 80-90% yield.

General procedures for diamidines as dihydrochloride salt (Method B)

0288To a cold and stirred suspension of dinitrile (1 mmol) in 15 mL dry THF was added 6.0 mL (6 mmol) of LiN(TMS)2 (1M in THF). The reaction was stirred for 24 hours at room temperature. Then the mixture was cooled and acidified with saturated ethanolic-HCl to form a white solid. The mixture was stirred for 2 hours, after which all solvents were removed under vacuum to afford a crude product. The crude product was then diluted with ether and the mixture was filtered to obtain a white solid. The white solid was then diluted with 10 mL ice water and basified with 2M NaOH to afford a white precipitate. The white precipitate was then filtered, washed with water and dried in air. The solid was suspended in anhydrous ethanol (15 mL) and 5 mL saturated ethanolic HCl for 6 hours. Then ethanol was distilled off and the product was triturated with dry ether and filtered. The solid was dried in vacuum at 80 °C for 12 hours to yield (65-75%) diamidine dihydrochloride as white solid.

General procedures for diamidines as dihydrochloride salt (Method C)

0289Dinitrile (1 mmol) was added to anhydrous ethanol (EtOH) saturated with hydrogen chloride (20 mL) at 0 °C in a dry flask. The reaction mixture was then sealed, slowly warmed to ambient temperature, and stirred for 7 days. Ethanol was removed using rotary evaporator. Anhydrous diethyl ether (20 mL) was added to the reaction mixture and the precipitated imidate ester dihydrochloride was filtered off and dried under high vacuum. Ammonia gas (using a cylinder) was passed through imidate ester in EtOH (10 mL) and stirred for a day. The reaction mixture was concentrated in vacuum. Then anhydrous ether was added, and the product was filtered and dried under vacuum. The diamidine was converted to its dihydrochloride salt by stirring the diamidine with saturated ethanolic HCl (2 mL) for 2-3hours. The solvent was removed, and the solid was dried in vacuum at 80 °C for 12 hours to yield final product (65-75%).

General procedure for the preparation of substituted diamidine or cyclized diamidine as dihydrochloride salts (Method D)

0290The nitrile compound was added to anhydrous EtOH saturated with hydrogen chloride at 0 °C in a dry flask. The reaction mixture was then sealed, slowly warmed to ambient temperature, and stirred until the nitrile compound was no longer detectable by TLC. The reaction mixture was diluted with anhydrous ether. The precipitated imidate ester dihydrochloride was filtered off under nitrogen and dried under high vacuum. The imidate was then reacted immediately with 2.5 equivalents of the appropriate amine in EtOH for 24hours. The reaction mixture was concentrated in vacuum. Then ether was added, and the product was filtered. The solid was suspended in 10 mL ice-water and basified with 2M NaOH. The resulting white precipitate was filtered, washed with water, and air dried. The free base was converted to its dihydrochloride salt using saturated ethanolic HCl as white solid, which was dried in vacuum at 80 °C for 12 hours to yield final product (65-75%).

Synthesis of MD-100

0291<chemistry id="chem0264" num="0264"><img file="EP4603484A2_D0264.tif" /></chemistry>

0292Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))dibenzonitrile (10). Reaction of 1,3-bis (bromomethyl)-5-methylbenzene (8, 1.38 g, 5 mmol) and 4-hydroxybenzonitrile (9, 1.19 g, 10 mmol) in the presence of anhydrous K2CO3 (2.07 g, 15 mmol) in 10 mL DMF yielded 1, 3-bis (4-cyano-phenoxy methyl)-5-methyl-benzene as white solid (10, 1.58 g, 90%) using method A. 1H NMR (CDCl3): δ 7.59 (d, J= 8.8 Hz, 4H), 7.26 (s, 1H), 7.22 (s, 2H), 7.02 (d, J = 8.8 Hz, 4H), 5.09 (s, 4H), 2.40 (s, 3H). 13C NMR (CDCl3): δ 161.9, 139.3, 136.4, 134.1, 128.3, 123.7, 119.2, 115.6, 104.3, 70.1, 21.4. HRMS calcd for C23H18N2O2Na [M+Na]+ : 377.1266, found: 377.1269.

0293Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))dibenzimidamide dihydrochloride (MD-100). 10 (0.354 g, 1 mmol) was converted to MD-100 as brown solid following method B (MD-100, 0.33 g, 71%). 1H NMR (DMSO-d6): δ 9.24 (s, 4H), 8.90 (s, 4H), 7.82 (d, J= 8.8 Hz, 4H), 7.34 (s, 1H), 7.25 (s, 2H), 7.20 (d, J= 8.8 Hz, 4H), 5.18 (s, 4H), 2.32 (s, 3H). 13C NMR (DMSO-d6): δ 165.0, 162.9, 138.6, 136.9, 130.5, 128.5, 124.6, 120.0, 115.5, 69.9, 21.2. HRMS calcd for C23H25N4O2 [M+H] +: 389.1972, found: 389.1976.

1,4-Bis [(4-amidino)-phenoxy methyl]benzene dihydrochloride (MD-101)

0294Reaction of 1,4-bis (bromomethyl)lbenzene (1.32 g, 5 mmol) and 4-hydroxybenzonitrile (1.19 g, 10 mmol) yielded 1, 4-bis (4-cyano-phenoxy methyl) benzene as white solid (1.74 g, 78%), using method A; 1H NMR (CDCl3): 7.59 (d, 4H, J = 8.9 Hz), 7.45 (s, 4H), 7.02 (d, J= 8.9 Hz, 4H), 5.13 (s, 4H); 13C NMR (CDCl3): 161.82, 136.01, 134.07, 127.86, 119.10, 115.57, 104.45, 69.88; MS: HRMS-ESI-POS.: calc. for C22H17N2O2m/z 341.1285 (M++1), found m/z 341.1283. Dinitrile (0.340 g, 1 mmol) was converted to 1, 4-bis (4-amidino (phenoxy methyl))benzene dihydrochloride as pale yellow solid following Method B (0.33 g, 76%). 1H NMR (DMSO-d6): 9.25 (s, 4H), 9.02 (s, 4H), 7.85 (d, J= 8.9 Hz, 4H), 7.51 (s, 4H), 7.23 (d, J= 9.0 Hz, 4H), 5.26 (s, 4H); 13C NMR (DMSO-d6): 165.16, 163.12, 136.67, 130.67, 128.49, 120.12, 115.64, 69.79; MS: HRMS-ESI-POS.: calc. for C22H24N4O2m/z 188.0944(M/2++2), found m/z 188.0936.

Synthesis of MD-102

0295<chemistry id="chem0265" num="0265"><img file="EP4603484A2_D0265.tif" /></chemistry>

0296Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(N-isopropylbenzimidamide) dihydrochloride (MD-102). Dinitrile (10, 0.35 g, 1 mmol) was converted to MD-102 by the reaction with isopropyl amine (0.15 g, 2.5 mmol) in ethanol (10 mL) at room temperature for 24 hours as a pale yellow solid using general method D (MD-102, 0.27 g, 50%). 1H NMR (DMSO-d6): δ 9.43 (d, J= 8.0 Hz, 2H), 9.33 (s, 2H), 8.99 (s, 2H), 7.73 (d, J= 8.8 Hz, 4H), 7.36 (s, 1H), 7.27 (s, 2H) , 7.21 (d, J = 8.8 Hz, 4H), 5.20 (s, 4H), 4.09-4.04 (m, 2H), 2.34 (s, 3H), 1.26 (d, J= 6.4 Hz, 12H). 13C NMR (DMSO-d6): δ 162.1, 161.2, 138.1, 136.7, 130.3, 128.1, 124.3, 121.2, 114.9, 69.5, 54.9, 44.9, 21.3, 21.0. HRMS calcd for C29H38N4O2 [M+2H]2+/2: 237.1492, found 237.1482.

Synthesis of MD-103

0297<chemistry id="chem0266" num="0266"><img file="EP4603484A2_D0266.tif" /></chemistry>

0298Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(3-methoxybenzonitrile) (12). Reaction of 1,3-bis (bromomethyl)-5-methylbenzene (8, 1.4 g, 5 mmol) and 4-hydroxy- 2-methoxybenzonitrile (11, 1.37 g, 10 mmol) in the presence of anhydrous K2CO3 (2.07 g, 15 mmol) in 10 mL DMF yielded 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(3-methoxybenzonitrile) as white solid (12, 1.57 g, 76%) following method A. 1H NMR (DMSO-d6): δ 7.41-7.39 (m, 4H), 7.30 (s, 1H), 7.24 (s, 2H), 7.18 (d, J= 8.8 Hz, 2H), 5.15 (s, 4H), 3.80 (s, 6H), 2.33 (s, 3H). 13C NMR (DMSO-d6): δ 151.8, 149.2, 138.0, 136.5, 128.5, 126.3, 124.6, 119.2, 114.7, 113.4, 102.9, 69.9, 56.0, 21.0. HRMS calcd for C25H23N2O4[M+H]+: 415.1652, found 415.1643.

0299Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(3-methoxybenzimidamide) dihydrochloride (MD-103). Dinitrile (12, 0.41 g, 1 mmol) was converted to yield 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(3-methoxybenzimidamide) dihydrochloride as brown solid following method B (MD-103, 0.39 g, 76%). 1H NMR (DMSO-d6): δ 9.27 (s, 4H), 8.97 (s, 4H), 7.49 - 7.48 (m, 4H), 7.33 (s, 1H), 7.26 - 7.24 (m, 4H), 5.18 (s, 4H), 3.86 (s, 6H), 2.34 (s, 3H). 13C NMR (DMSO-d6): δ 164.7, 152.3, 148.81, 138.1, 136.7, 128.5, 124.7, 121.9, 119.5, 112.8, 111.6, 70.0, 56.1, 21.0. HRMS calcd for C25H30N4O4 [M+2H]2+/2: 225.1128, found 225.1119.

1, 4-Bis [((4-amidino)-2-methoxy)-phenoxy methyl]2-fluorobenzene dihydrochloride (MD-104)

0300Dinitrile (0.41 g, 1 mmol) was converted to 1, 4-Bis [((4-amidino)-2-methoxy)-phenoxy methyl]2-fluorobenzene dihydrochloride as a brown solid following Method B (0.37 g, 72%). 1H_NMR (DMSO-d6): 9.32 (s, 4H), 9.04 (s, 4H), 7.61(t, 2H, J = 7.2Hz),7.53 (m, 4H), 7.39-7.28 (m,4H), 5.27 (s, 4H), 3.863 (s, 6H);13C NMR (DMSO-d6): 165.30, 159.29 (d, JC-F = 250 Hz), 152.58, 149.19, 131.86 (d, JC-F = 2.9 Hz), 125.03 (d, JC-F = 3.6 Hz), 123.88 (d, JC-F = 14.7 Hz), 122.23, 120.32, 113.18, 111.99, 64.79 (d, JC-F = 3.2 Hz), 56.40; MS: HRMS-ESI-POS.: calc. for C24H27FN4O4m/z 237.1003 (M/2++2), found m/z 237.0995.

Synthesis of MD-105

0301<chemistry id="chem0267" num="0267"><img file="EP4603484A2_D0267.tif" /></chemistry>(i) LiAlH4,THF, 0°C - rt, overnight (ii) PBr3, CH2Cl2, 0°C - r.t., 4h.

0302Synthesis of diol (5-(tert-butyl)-1,3-phenylene)dimethanol (14). 5-tert-butylisophthalic acid (13, 4 g, 18 mmol) in THF (100 mL) was added dropwise under ice-bath condition to a solution of lithium aluminium hydride (1.5 g, 38mmol) in THF (100 mL). The reaction was stirred for 1 hour at 0 °C, after which the reaction was heated at 60 °C for 24 hours. The reaction was monitored by TLC. Upon completion, the reaction mixture was cooled to 0 °C and quenched with methanol and water. The quenched reaction was filtered through celite and washed with EtOAc (100 mL). The combined organic solvent was removed under reduced pressure and was extracted with EtOAc (3 × 100 mL), dried over MgSO4 and concentrated to give the required diol (5-(tert-butyl)-1,3-phenylene)dimethanol (14, 3.2 g, 94%). 1H NMR (CDCl3): δ 7.32 (s, 2H), 7.19 (s, 1H), 4.69 (s, 4H), 1.33 (s, 6H). 13C NMR (CDCl3): δ 152.2, 141.1, 123.6, 123.1, 65.7, 34.9, 31.5. HRMS calcd for C12H17O[M- H2O] +: 177.1274, found 177.1274. Synthesis of 1, 3-bis (4-cyano-phenoxy methyl)- 5-(tert-butyl)benzene (16). PBr3 (2.5 mL, 26 mmol) was added dropwise to a solution of diol (5-(tert-butyl)-1,3-phenylene)dimethanol (14, 2.3 g, 11.8mmol) in DCM at 0°C. The reaction mixture was stirred at room temperature for 4 hours and then quenched with ice water. The solution was extracted with CH2Cl2 (3 × 100 mL), dried over MgSO4 and concentrated to give the required dibromo compound (1,3-bis(bromomethyl)-5-(tert-butyl)benzene) as a white solid (15, 3.4 g, 90%). Reaction of 1,3-bis(bromomethyl)-5-(tert-butyl)benzene (15, 1.6 g, 5 mmol) and 4-hydroxybenzonitrile (9, 1.19 g, 10 mmol) yielded dinitrile compound as white solid (16, 1.54 g, 78%) using method A. 1H NMR (DMSO-d6): δ 7.79 -7.78 (m, 4H), 7.48 (s, 2H), 7.36 (s, 1H), 7.20 - 7.18 (m, 4H), 5.20 (s, 4H), 1.29 (s, 9H). 13C NMR (CDCl3): δ 161.8, 151.3, 136.1, 134.2, 124.8, 119.1, 115.9, 103.0, 69.9, 34.5, 31.1. HRMS calcd for C26H25N2O2[M+H]+: 397.1911, found 397.1912.

0303Synthesis of 4,4'-(((5-(tert-butyl)-1,3-phenylene)bis(methylene))bis(oxy))dibenzimidamide dihydrochloride(MD-105). 1, 3-bis (4-cyano-phenoxy methyl)- 5-(tert-butyl)benzene (16, 0.370 g, 1 mmol) was converted to yielded 4,4'-(((5-(tert-butyl)-1,3-phenylene)bis(methylene))bis(oxy))dibenzimidamide dihydrochloride as brown solid following method B (MD-105, 0.35 g, 70%). 1H NMR (DMSO-d6): δ 9.42 (s, 4H), 9.21 (s, 4H), 7.94 (d, J= 8.4 Hz, 4H), 7.49 (s, 2H), 7.39 (s, 1H), 7.23 (d, J= 8.4 Hz, 4H), 5.23 (s, 4H), 1.28 (s, 9H). 13C NMR (DMSO-d6): δ 165.7, 163.5, 152.5, 137.0, 131.0, 125.6, 120.3, 116.1, 70.7, 35.2, 31.8. HRMS calcd for C26H31N4O2[M+H]+: 431.2442, found 431.2425.

Synthesis of MD-106

0304<chemistry id="chem0268" num="0268"><img file="EP4603484A2_D0268.tif" /></chemistry>(i) LiAlH4,THF, 0°C - rt, 16 h.

0305Synthesis of ((((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(4,1-phenylene))dimethanamine dihydrochloride(MD-106). A solution of 1, 3-bis (4-cyano-phenoxy methyl)-5-methyl-benzene (10, 1.0 g, 2.8 mmol) in THF (20 mL) was added dropwise to a suspension of LiAlH4 (0.32 g, 7.4 mmol) in THF under argon gas at 0 °C and the mixture was stirred at room temperature for 16 hours. The reaction was quenched with the addition of H2O (5 mL) at 0 °C followed by addition of 16% NaOH solution (2 mL). The mixture was stirred at room temperature for around 2 hours after which it was filtered through celite. The solution was then concentrated in vacuo to obtain the free diamine. The product residue was then dissolved in ethanol followed by addition of HCl in ethanol (2 mL) for salt formation. The reaction mixture was evaporated in vacuo followed by ether precipitation to obtain the product as a green solid. (MD-106, 1.0 g, 87%).1H NMR (DMSO-d6): δ 8.45 (s, 6H), 7.43 (d, J= 8.4 Hz, 4H), 7.32 (s, 1H), 7.22 (s, 2H), 7.03 (d, J= 8.4 Hz, 4H), 5.09 (s, 4H), 2.32 (s, 3H). 13C NMR (DMSO-d6): δ 158.4, 137.9, 137.2, 130.5, 127.8, 126.2, 124.3, 114.8, 69.2, 41.6, 21.0. HRMS calcd for C23H27N2O2 [M+H]+: 363.2079, found 363.2067.

Synthesis of MD-107

0306<chemistry id="chem0269" num="0269"><img file="EP4603484A2_D0269.tif" /></chemistry>

0307Synthesis of 4,4',4"-((benzene-1,3,5-triyltris(methylene))tris(oxy))tribenzonitrile (18). Reaction of 1,3,5-tris (bromomethyl)benzene (17, 1.54 g, 4.3 mmol) and 4-hydroxybenzonitrile (9, 1.64 g, 14 mmol) the presence of anhydrous K2CO3 (2.35 g, 17 mmol) in 10 mL DMF yielded 4,4',4"-((benzene-1,3,5-triyltris(methylene))tris(oxy))tribenzonitrile as a white solid (18, 1.69 g, 84%), using method A. 1H NMR (DMSO-d6): δ 7.77 (d, J = 9.2 Hz, 6H), 7.53 (s, 3H), 7.18 (d, J = 9.2 Hz, 6H), 5.24 (s, 6H). 13C NMR (DMSO-d6): δ 161.7, 137.0, 134.2, 126.9, 119.1, 115.9, 103.2, 69.3. HRMS calcd for C30H21N3O3Na [M+Na] +: 494.1481, found 494.1481.

0308Synthesis of 4,4',4"-((benzene-1,3,5-triyltris(methylene))tris(oxy))tribenzimidamide trihydrochloride (MD-107). Trinitrile (18, 0.56 g, 1.2 mmol) was converted to 4,4',4"-((benzene-1,3,5-triyltris(methylene))tris(oxy))tribenzimidamide trihydrochloride (MD-107) as brown solid using method B (MD-107, 0.58 g, 78%). 1H NMR (DMSO-d6): δ 9.45 (s, 6H), 9.25 (s, 6H), 7.95 (d, J = 8.4 Hz), 7.56 (s, 3H), 7.22 (d, J = 8.4 Hz, 6H), 5.27 (s, 6H). 13C NMR (DMSO-d6): δ 164.7, 162.6, 137.1, 130.3, 126.9, 119.6, 115.1, 69.4. HRMS calcd for C30H32N6O3 [M+2H]2+/2: 262.1262, found 262.1258.

Synthesis of MD-108

0309<chemistry id="chem0270" num="0270"><img file="EP4603484A2_D0270.tif" /></chemistry><ul id="ul0016" list-style="none" compact="compact"><li>(i) 3 mol% Pd(PPh3)4, 6 mol% sodium ascorbate, 1 mol% CuSO4, 1:1 Et3N; DMSO (ii) H2,</li><li>Pd/C, MeOH, overnight.</li></ul>

0310Synthesis of 4,4'-((5-methyl-1,3-phenylene)bis(ethyne-2,1-diyl))dibenzonitrile(21). 3,5-dibromotoluene (19, 0.98 g, 3.9 mmol) was dissolved with 1:1 DMF-Et3N (6 mL). To this solution, 3 mole% Pd(PPh3)4 and 4-ethynylbenzonitrile (1 g, 7.8 mmol) were added and the mixture was stirred for 5 minutes. Further, 6 mol% sodium ascorbate solution, 1 mol% CuSO4 solution in DMF were added to the reaction mixture and stirred for 4 h at 80 °C. The reaction mixture was extracted with ethyl acetate followed by ammonium chloride and brine wash. The combined organic layer was dried over anhydrous Na2SO4 and then concentrated in vacuo. The product was purified using column chromatography and obtained using 5:1 hexane: ethyl acetate system as a white solid (21, 0.67 g, 50%).1 1H NMR (CDCl3): δ 7.66 - 7.59 (m, 8H), 7.55 (s, 1H), 7.38 (s, 2H), 2.38 (s, 3H). 13C NMR (CDCl3): δ 38.9, 133.1, 132.3, 132.2, 128.1, 122.8, 118.6, 111.9, 92.9, 88.3, 21.2. HRMS-calcd for C25H14N2Na[M+Na] +: 365.1055 found 365.1068.

0311Synthesis of 4,4'-((5-methyl-1,3-phenylene)bis(ethane-2,1-diyl))dibenzonitrile(22). To 10% Pd/C in THF (30 mL) under argon gas was added 4,4'-((5-methyl-1,3-phenylene)bis(ethyne-2,1-diyl))dibenzonitrile (21, 0.5 g, 1.46 mmol). The argon gas was exchanged for H2 gas and the reaction mixture was stirred overnight. The reaction mixture was quenched with CH2Cl2 and filtered through celite. Extraction was carried out with CH2Cl2 followed by washing with H2O. The combined organic layer was dried over anhydrous Na2SO4 and then concentrated under vacuum to give the product as a pale-yellow solid (22, 0.45 g, 87.6%). 1H NMR (CDCl3): δ 7.56 (d, J = 8.4 Hz, 4H), 7.24 (d, J = 8.4 Hz, 4H,), 6.81 (s, 2H), 6.67 (s, 1H), 2.95 - 2.90 (m, 4H), 2.85 - 2.81 (m, 4H), 2.29 (s, 3H). 13C NMR (CDCl3): δ 147.5, 141.0, 138.4, 132.3, 129.4, 127.3, 125.8, 119.2, 110.0, 38.1, 37.3, 21.5. HRMS calcd for C25H23N2 [M+H] +: 351.1856 found 351.1846.

0312Synthesis of 4,4'-((5-methyl-1,3-phenylene)bis(ethane-2,1-diyl))dibenzimidamide dihydrochloride(MD-108). Dinitrile compound (21, 0.35 g, 1 mmol) was converted to 4,4'-((5-methyl-1,3-phenylene)bis(ethane-2,1-diyl))dibenzimidamide dihydrochloride (MD-108) as a white solid following method B (MD-108, 0.32 g, 70%). 1H NMR (DMSO-d6): δ 9.34 (s, 4H), 9.12 (s, 4H), 7.78 (d, J= 8.4 Hz, 4H), 7.49 (d, J= 8.4 Hz, , 4H), 6.94 (s, 1H), 6.90 (s, 2H), 2.98 - 2.94 (m, 4H), 2.85 - 2.81 (m, 4H), 2.24 (s, 3H).13C NMR (DMSO-d6): δ 165.5, 148.4, 141.0, 137.3, 129.1, 128.2, 126.9, 125.6, 125.5, 36.9, 36.6, 21.1. HRMS calcd for C25H30N4 [M+2H]2+/2: 193.1230, found 193.1222.

Synthesis of MD-109

0313<chemistry id="chem0271" num="0271"><img file="EP4603484A2_D0271.tif" /></chemistry>i) K2CO3, DMF, rt, overnight.

0314Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(oxy))bis(methylene))dibenzonitrile(25). A mixture of orcinol (23, 0.5 g, 4.1 mmol), 4-cyanobenzyl bromide (24, 1.65 g, 8.4 mmol) and anhydrous K2CO3 (1.66 g, 12 mmol) in 10 mL DMF was stirred at room temperature overnight. Then the reaction mixture was diluted with ice water (70 mL) and stirred for 30 minutes. The yellow precipitate was filtered, washed with water, and dried in air. Then the yellow solid was dissolved in a dichloromethane (100 mL), dried over anhydrous MgSO4, filtered and concentrated with rotavapor. The crude product was triturated with hexane and the precipitate was filtered, which was then dried in vacuo to yield 4,4'-(((5-methyl-1,3-phenylene)bis(oxy))bis(methylene))dibenzonitrile as a yellow solid (25, 0.97 g, 66.5%). 1H NMR (CDCl3): δ 7.68 (d, J= 8.4 Hz, 4H), 7.53 (d, J= 8.4 Hz, 4H), 6.43 (d, J = 2.0 Hz, 2H), 6.39 (t, J = 2.0 Hz, 1H), 5.08 (s, 4H), 2.30 (s, 3H). 13C NMR (CDCl3): δ 159.5, 142.5, 140.9, 132.5, 127.7, 118.8, 111.9, 108.7, 99.5, 69.0, 22.0. HRMS calcd for C23H18N2O2Na [M+Na]+: 377.1266, found 377.1283.

0315Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(oxy))bis(methylene))dibenzimidamide dihydrochloride(MD-109). Dinitrile (25, 0.33 g, 0.93 mmol) was converted to 4,4'-(((5-methyl-1,3-phenylene)bis(oxy))bis(methylene))dibenzimidamide dihydrochloride as white solid following method C (MD-109, 0.3 g, 75%). 1H NMR (DMSO-d6): δ 9.45 (s, 4H), 9.25 (s, 4H), 7.86 (d, J = 7.6 Hz, 4H), 7.64 (d, J = 8.0 Hz, 4H), 6.50 (s, 1H), 6.48 (s, 2H), 5.20 (s, 4H), 2.23 (s, 3H). 13C NMR (DMSO-d6): δ 165.5, 159.1, 143.4, 140.0, 128.4, 127.6, 127.3, 108.3, 99.3, 68.3, 21.5. HRMS calcd for C23H25N4O2 [M+H]+: 389.1978, found 389.1960.

1, 3-Bis{(4-isopropylamidino)-phenoxy methyl}-2-fluorobenzene dihydrochloride (MD-110)

0316<chemistry id="chem0272" num="0272"><img file="EP4603484A2_D0272.tif" /></chemistry>

0317Reaction of 1,3-bis (bromomethyl)-2-fluorobenzene (1.4 g, 5 mmol) and 4-hydroxybenzonitrile (1.19 g, 10 mmol) yielded 1, 3-bis (4-cyano-phenoxy methyl)-2-fluorobenzene as white solid (2.53 g, 70%), following method A; mp 173-5 °C; 1H NMR (DMSO-d6): 7.78 (d, 4H, J = 8.4Hz), 7.59 (t, 2H, J = 7.2Hz), 7.29 (t, 1H, J = 7.2Hz), 7.23 (d, 4H, J = 8.4Hz), 5.3 (s, 4H); 13C NMR (DMSO-d6): 161.4, 158.4 (d, JC-F = 248Hz), 134.0, 130.7 (d, JC-F = 4.1Hz), 124.2 (d, JC-F = 4.1Hz),123.1 (d, JC-F = 13.5Hz), 118.7, 115.6, 103.3,63.8 (d, JC-F = 3.3Hz); MS: HRMS-ESI-POS.: calc. for C22H15FN2O2Na m/z 381.1015 (M++Na), found m/z 381.1005. <chemistry id="chem0273" num="0273"><img file="EP4603484A2_D0273.tif" /></chemistry>

0318Dinitrile (0.35 g, 0.97 mmol) was converted to 1, 3-bis {4-isopropylamidino (phenoxy methyl)-2-fluorobenzene dihydrochloride as white solid following Method D (0.38 g, 73%) with isopropylamine (0.17g, 2.92mmol); mp. 269-70 °C; 1H NMR (DMSO-d6): 9.48 (d, 2H, J = 8.0 Hz,), 9.37 (s, 2H), 9.06 (s, 2H), 7.76 (d, 4H, J= 8.7 Hz), 7.62 (t, 2H, J = 7.2 Hz), 7.30 (t, 1H, J = 7.6 Hz), 7.25 (d, 4H, J = 8.7 Hz), 5.30 (s, 4H), 4.10 (dd, 2H, J = 13.6, 6.6 Hz), 1.27 (d, 12H, J = 6.3 Hz) ;13C NMR (DMSO-d6): 162.31, 161.55, 159.23(d, JC-F = 249.7 Hz), 131.66 (d, JC-F = 3.4 Hz), 130.85, 125.01 (d, JC-F = 3.6 Hz), 123.93 (d, JC-F = 14.6 Hz), 121.86, 115.28, 64.45 (d, JC-F = 3.5 Hz), 45.42, 21.76; MS: HRMS-ESI-POS.: calc. for C28H34FN4O2 m/z 477.2660 (M++1), found m/z 477.2643; analysis calc. for C28H34FN4O2.2HCl.1.19H2O): C, 58.79; H, 6.76; N, 9.79; Found: C, 58.49; H, 6.05; N, 9.85.

1, 3-Bis {(4-isopropylamidino-2-fluoro)-phenoxy methyl}-2-fluorobenzene dihydrochloride (MD-111)

0319<chemistry id="chem0274" num="0274"><img file="EP4603484A2_D0274.tif" /></chemistry>

0320Reaction of 1,3-bis(bromomethyl)-2-fluorobenzene (1.4 g, 5 mmol) and 2-fluoro-4-hydroxybenzonitrile (1.37 g, 10 mmol) following Method A yielded 1, 3-bis (2-fluoro-4-cyano-phenoxymethyl)-2-fluorobenzene as white solid (2.8g, 71%); mp 185-7 °C; 1H NMR (DMSO-d6): 7.88 (d, 2H, J = 8.4 Hz), 7.72 (d, 8.4 Hz), 7.64 (t, 2H, J = 7.6 Hz), 7.54 (t, 2H, J = 7.6 Hz), 7.33 (t, 1H, J = 7.6 Hz), 7.23 (d, 4H, J = 8.4 Hz), 5.37 (s, 4H); 13C NMR (DMSO-d6): 158.50 (d, JC-F =250 Hz), 151.0 (d, JC-F =248 Hz), 150.1 (d, JC-F =11.0Hz), 131.1 (d, JC-F = 4.4 Hz), 130.1 (d, JC-F =3.75Hz), 124.4 (d, JC-F = 4.28Hz), 122.7 (d, JC-F =15.4Hz), 119.6 (d, JC-F = 21.4 Hz), 117.6 (d, JC-F = 3.4 Hz),115.91 (d, JC-F = 2.25 Hz), 103.3 (d, JC-F = 8.73 Hz), 64.84 (d, JC-F = 4.21 Hz); MS: HRMS-ESI-POS.: calc. for C22H13F3N2O2Na m/z 417.0827 (M++Na), found m/z 417.0832. <chemistry id="chem0275" num="0275"><img file="EP4603484A2_D0275.tif" /></chemistry>

0321Dinitrile (0.32g, 0.81 mmol) was converted to 1, 3-bis (4-isopropylamidino-2-fluoro-phenoxy methyl)-2-fluorobenzene dihydrochloride as white solid following (Method D) (0.28 g, 70%) using isopropylamine (0.14g, 2.43mmol); mp. 193-5°C; 1H NMR (DMSO-d6): 9.50 (s, 2H), 9.21 (s, 2H), 7.77 (dd, 2H, J = 11.9, 2.2 Hz), 7.69 - 7.62 (m, 4H), 7.57 (t, 2H, J = 8.6 Hz), 7.33 (t, 1H, J = 7.6 Hz), 5.39 (s, 4H), 4.10 (dt, 2H, J = 13.0, 6.5 Hz), 1.27 (d, 12H, J = 6.4 Hz);13C NMR (DMSO-d6): 160.01, 158.90 (d, JC-F = 250.6 Hz), 151.95, 149.85, 149.63 (d, JC-F = 24.1 Hz), 131.56 (d, JC-F = 2.5 Hz), 125.91 (d, JC-F = 2.9 Hz), 124.68 (d, JC-F = 3.8 Hz), 123.08 (d, JC-F = 14.5 Hz), 121.60 (d, JC-F = 7.2 Hz), 116.63 (d, JC-F = 20.9 Hz), 114.91, 64.89 (d, JC-F = 3.7 Hz), 45.13, 21.25, MS: HRMS-ESI-POS.: calc. for C28H32F3N4O2m/z 513.2472 (M++1), found m/z 513.2450; analysis calc. for C22H19F3N4O2.2HCl.1.25H2O; C, 55.31; H, 5.88; N, 9.21; Found: C, 55.39; H, 5.85; N, 8.95.

Synthesis of MD-112

0322<chemistry id="chem0276" num="0276"><img file="EP4603484A2_D0276.tif" /></chemistry>

0323Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(oxy))bis(methylene))bis(N-propylbenzimidamide) dihydrochloride(MD-112). Dinitrile (10, 0.35 g, 0.98 mmol) was converted to 4,4'-(((5-methyl-1,3-phenylene)bis(oxy))bis(methylene))bis(N-propylbenzimidamide) dihydrochloride (MD-112) by the reaction with n-propylamine (0.14 g, 2.45 mmol) in ethanol (10 mL) at 49 °C for 24 h as white solid following method D (0.37 g, 70%). 1H NMR (DMSO-d6): δ 9.90 (s, 2H), 9.53 (s, 2H), 9.18 (s, 2H), 7.79 (d, J = 8.4 Hz, 4H), 7.63 (d, J = 8.4 Hz, 4H), 6.50 - 6.48 (m, 3H), 5.19 (s, 4H), 3.41 - 3.36 (m, 2H), 2.23 (s, 3H), 1.68-1.63 (m, 4H), 0.95 (t, J= 7.2 Hz, 6H). 13C NMR (DMSO-d6): δ 162.5, 159.1, 142.7, 140.2, 128.5, 128.3, 127.6, 108.3, 99.7, 68.3, 44.2, 21.5, 20.9, 11.2. HRMS- calcd for C29H37N4O2 [M+H] +: 473.2917, found 473.2940.

Synthesis of MD-113

0324<chemistry id="chem0277" num="0277"><img file="EP4603484A2_D0277.tif" /></chemistry>

0325Synthesis of 2,2'-((((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(4,1-phenylene))bis(1,4,5,6-tetrahydropyrimidine) dihydrochloride (MD-113). Dinitrile (10, 0.4 g, 1.12 mmol) was converted to 2,2'-((((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(4,1-phenylene))bis(1,4,5,6-tetrahydropyrimidine) dihydrochloride (MD-113) by the reaction with 1,3-diaminopropane (0.25 g, 3.4 mmol) in ethanol (10 mL) at 140 °C as white solid following method D (MD-113, 0.48 g, 75%). 1H NMR (DMSO-d6): δ 10.23 (s, 4H), 7.82 (d, J = 8.0 Hz, 4H), 7.63 (d, J =8.0 Hz, 4H), 6.51 (s, 1H), 6.48 (s, 2H), 5.19 (s, 4H), 3.48 - 3.37 (m, 8H), 2.23 (s, 3H), 1.98-1.95 (m, 4H). 13C NMR (DMSO-d6): δ 159.1, 158.5, 142.6, 139.9, 128.0, 127.6, 127.6, 108.3, 99.2, 68.3, 38.7, 21.4, 17.7. HRMS calcd for C29H33N4O2 [M+H]+: 469.2604, found 469.2617.

1, 3-Bis {[4-amidino-2-methoxy)-phenoxy methyl]} - 5-(tert-butyl)benzene dihydrochloride (MD-114)

0326<chemistry id="chem0278" num="0278"><img file="EP4603484A2_D0278.tif" /></chemistry>

0327Reaction of 1,3-bis(bromomethyl)-5-(tert-butyl)benzene (1.2g, 3.75mmol) and 2-methoxy-4-hydroxybenzonitrile (1.2g, 7.5mmol) yielded yielded 1, 3-bis (2-methoxy-4-cyano-phenoxy methyl)- 5-(tert-butyl)benzene as white solid (1.35g, 79%) following Method A. 1H NMR (CDCl3): 7.41 (s, 2H), 7.31 (s, 1H), 7.23 (dd, J=8.3, 1.5 Hz, 2H), 7.11 (d, J= 1.4 Hz, 2H), 6.93 (d, J=8.4 Hz, 2H), 5.19 (s, 4H), 3.90 (s, 6H), 1.32 (s, 9H); 13C NMR (CDCl3): 152.36, 152.05, 149.70, 136.07, 126.26, 124.48, 123.58, 119.18, 114.46, 113.45, 104.31, 71.17, 56.21, 34.81, 31.29; MS: HRMS-ESI-POS.: calc. for C28H28N2O4Na m/z 479.1947 (M++Na), found m/z 479.1942. <chemistry id="chem0279" num="0279"><img file="EP4603484A2_D0279.tif" /></chemistry>

0328Dinitrile (0.35g, 0.76mmol) was converted to yielded 1, 3-bis (2-methoxy-4-cyano-phenoxy methyl)- 5-(tert-butyl)benzene dihydrochloride as white solid following Method B (0.30g, 72%);1H NMR (DMSO-d6): 9.33 (s,4H), 9.04 (s, 4H), 7.55-7.46 (m, 6H), 7.35 (s, 1H), 7.28 (d, J=9.2 Hz, 2H), 5.21 (s, 4H), 3.86 (s, 6H), 1.29 (s, 9H); 13C NMR (DMSO-d6): 165.11, 152.79. 151.78, 149.26, 136.74, 125.39, 122.29, 119.97, 113.35, 111.94, 70.80, 56.45, 34.91, 31.55; MS: HRMS-ESI-POS.: calc. for C28H35N4O4m/z 479.1947 (M++1) 491.2658, found m/z 491.2645.

Synthesis of BW-MD-115

0329<chemistry id="chem0280" num="0280"><img file="EP4603484A2_D0280.tif" /></chemistry>

0330Synthesis of 4,4'-(((5-(tert-butyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(3-fluorobenzonitrile)(27). Reaction of 1,3-bis(bromomethyl)-5-(tert-butyl)benzene (15, 1.5g, 4.7mmol) and 2-fluoro-4-hydroxybenzonitrile (26, 1.3 g, 9.4 mmol) yielded 4,4'-(((5-(tert-butyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(3-fluorobenzonitrile) as white solid (27, 1.52 g, 75%) using method A. 1H NMR (DMSO-d6): δ 7.85 (dd, J = 11.2, 1.6 Hz, 2H), 7.68-7.66 (m, 2H), 7.50 (s, 2H), 7.44 (t, J= 8.8 Hz, 2H), 7.36 (s, 1H), 5.29 (s, 4H), 1.29 (s, 9H). 13C NMR (DMSO-d6): δ 153.4, 151.8 (d, JC-F = 186 Hz), 151.0, 135.6, 129.7 (d, JC-F = 4 Hz), 125.0, 123.9, 120.0 (d, JC-F = 21 Hz), 118.0 (d, JC-F = 3 Hz), 115.4 (d, JC-F = 3 Hz), 104.6 (d, JC-F = 9 Hz), 71.5, 35.0, 31.4. HRMS calcd for C26H22F2N2O2Na [M+Na]+: 455.1547, found 455.1541.

0331Synthesis of 4,4'-(((5-(tert-butyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(3-fluorobenzimidamide) dihydrochloride(MD-115). Dinitrile (27, 0.35 g, 0.8 mmol) was converted to 4,4'-(((5-(tert-butyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(3-fluorobenzimidamide) dihydrochloride (MD-115) as brown solid following method B (0.30 g, 70.1%). 1H NMR (DMSO-d6): δ 9.49 (s, 4H), 9.26 (s, 4H), 7.90 (dd, J = 12.4, 2.4 Hz, 2H), 7.81-7.79 (m, 2H), 7.52-7.50 (m, 4H), 7.39 (s, 1H), 5.31 (s, 4H), 1.28 (s, 9H). 13C NMR (DMSO-d6): δ 164.0, 152.3, 151.0 (d, JC-F = 11 Hz), 150.8 (d, JC-F = 177 Hz), 136.0, 126.0 (d, JC-F = 3 Hz), 125.2, 124.9, 120.0 (d, JC-F = 7 Hz), 116.3 (d, JC-F = 20 Hz), 115.3, 70.9, 34.6, 31.2. HRMS calcd for C26H29F2N4O2 [M+H]+: 467.2272, found 467.2271.

Synthesis of MD-116

0332<chemistry id="chem0281" num="0281"><img file="EP4603484A2_D0281.tif" /></chemistry>

0333Synthesis of 3,3'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))dibenzonitrile(29). Reaction of 1,3-bis (bromomethyl)-5-methylbenzene (8, 2.13 g, 7.7 mmol) and 3-cyanophenol (28, 2.05 g, 17 mmol) yielded 3,3'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))dibenzonitrile as white solid (29, 2.6 g, 91%) using method A. 1H NMR(CDCl3): δ 7.38-7.36 (m, 2H), 7.27-7.25 (m, 3H), 7.22-7.19 (m, 6H), 5.06 (s, 4H), 2.41 (s, 3H). 13C NMR (CDCl3): δ 158.8, 139.3, 136.6, 130.6, 128.3, 125.0, 123.6, 120.2, 118.8, 117.9, 113.4, 70.2, 21.5. HRMS calcd for C23H18N2O2Na[M+Na]+: 377.1266, found 377.1250.

0334Synthesis of 3,3'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))dibenzimidamide dihydrochloride(MD-116). Dinitrile (29, 0.32 g, 0.9 mmol) was converted to 3,3'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))dibenzimidamide dihydrochloride (MD-116) as white solid using method B (0.32 g, 76%). 1H NMR (DMSO-d6): δ 9.40 (s, 4H), 9.07 (s, 4H), 7.53 (t, J= 8.0 Hz, 2H), 7.47 (s, 2H), 7.41-7.34 (m, 5H), 7.26 (s, 2H), 5.16 (s, 4H), 2.33 (s, 3H). 13C NMR (DMSO-d6): δ 165.6, 158.7, 138.5, 137.0, 130.8, 129.5, 128.5, 124.6, 120.7, 120.5, 114.5, 69.9, 21.2. HRMS calcd for C23H25N4O2 [M+H] + : 389.1978, found 389.1980.

Synthesis of MD-117

0335<chemistry id="chem0282" num="0282"><img file="EP4603484A2_D0282.tif" /></chemistry>

0336Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(sulfanediyl))dibenzonitrile(31). Reaction of 1,3-bis (bromomethyl)-5-methylbenzene (8, 0.93 g, 3.3 mmol) and 4-mercaptobenzonitrile (30, 1.0 g, 7.3 mmol) yielded 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(sulfanediyl))dibenzonitrile as white solid (1.12 g, 85%), using method A. 1H NMR (CDCl3): δ 7.50 (d, J= 8.4 Hz, 4H), 7.28 (d, J= 8.4 Hz, 4H), 7.14 (s, 1H), 7.08 (s, 2H), 4.13 (s, 4H), 2.32 (s, 3H). 13C NMR (DMSO-d6): δ 144.3, 139.0, 136.2, 132.1, 128.9, 127.1, 126.1, 118.7, 108.4, 36.7, 21.2. HRMS calcd for C23H19N2S2 [M+H] +: 387.0984, found 387.1003.

0337Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(sulfanediyl)) dibenzimidamide dihydrochloride(MD-117). Dinitrile (31, 0.30 g, 0.74 mmol) was converted to 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(sulfanediyl))dibenzimidamide dihydrochloride (MD-117) as green solid following method C (MD-117, 0.19 g, 50%). 1H NMR (DMSO-d6): δ 9.30 (s, 4H), 9.03 (s, 4H), 7.74 (d, J = 8.4 Hz, 4H), 7.51 (d, J = 8.4 Hz, 4H), 7.31 (s, 1H), 7.16 (s, 2H) , 4.33 (s, 4H), 2.26 (s, 3H). 13C NMR (DMSO-d6): δ 164.9, 144.8, 138.1, 136.8, 128.6, 128.5, 126.5, 126.3, 124.1, 35.0, 20.9. HRMS calcd for C23H25N4S2 [M+H]+: 421.1521, found 421.1532.

1, 3-Bis {(4-(2-imidazolino))-thiophenoxy methyl}-5-methylbenzene dihydrochloride (MD-118)

0338<chemistry id="chem0283" num="0283"><img file="EP4603484A2_D0283.tif" /></chemistry>

0339Dinitrile (0.386 g, 1 mmol) was converted to 1, 3-Bis {(4-(2-imidazolino))-thiophenoxy methyl}-5-methylbenzene dihydrochloride as a brown solid following Method D (0.39 g, 72%) by refluxing imidate ester with 1,2 diaminoethane. 1H NMR (DMSO-d6): 10.73(s, 4H), 7.96 (d, 4H, J = 8.6 Hz), 7.54 (d, 4H, J = 8.6Hz), 7.32 (s, 1H), 7.16 (s, 2H), 4.36 (s, 4H), 3.98 (s, 8H), 2.26 (s, 3H); 13C NMR (DMSO-d6): 164.00, 145.86, 138.05, 136.70, 129.01, 128.61, 126.32, 118.23, 44.19, 34.77, 20.88; MS:HRMS-ESI-POS.: calc. for C27H29N4S2m/z 473.1834(M++1), found m/z 473.1842.

1, 3-Bis {(4-amidino)-phenoxy methyl}-6-methylbenzene dihydrochloride (BW-MD-119)

0340<chemistry id="chem0284" num="0284"><img file="EP4603484A2_D0284.tif" /></chemistry>

03413-bromo-4 methylbenzoic acid (5g, 23.25mmol) was added to 50 ml dry THF in a three neck round bottom flask under Ar gas atmosphere. The temperature of this reaction mixture was cooled to 0°C and a solution of 3.0 M methyl magnesium bromide (8.5ml, 25.57mmol) was added to it and stirred for 2hrs. The temperature was further lowered to -65°C and 1.6M n-butyl lithium solution (29 mL, 46.5mmol) in hexane was added to it with constant stirring. After 4 h of reaction time, dry ice was added to the reaction mixture, sealed and stirred overnight. On completion of reaction, mixture was acidified and then filtered. This residue was taken with catalytic amounts of conc. H2SO4 in methanol and refluxed overnight to form the methyl ester. The reaction mixture was cooled to room temperature on completion, 10 ml water was added to it and extracted with ethyl acetate (3 X 50 mL). The organic layer was dried with anhydrous Na2SO4 and concentrated in vacuo to yield Dimethyl 4-methylisophthalate as white solid (3.92g, 81%). 1H NMR (CDCl3): 8.57 (d, J= 1.7 Hz, 1H), 8.04 (dd, J = 8.0, 1.8 Hz, 1H), 7.33 (d, , J = 8.0 Hz 1H), 3.92 (d, J= 3.2 Hz, 6H), 2.66 (s, 3H); 13C NMR (CDCl3): 167.34, 166.50, 145.73, 132.79, 132.12, 132.04, 129.90, 128.11, 52.36, 52.20, 22.03; MS: HRMS-ESI-POS.: calc. for C11H12O4m/z 231.0633 (M++Na), found m/z 231.0642. <chemistry id="chem0285" num="0285"><img file="EP4603484A2_D0285.tif" /></chemistry>

0342Dimethyl 4-methylisophthalate (1g, 4.8mmol) in THF (20 ml) was added dropwise under icebath condition in a solution of lithium aluminium hydride (0.73g, 19.2mmol) in THF (30ml). The reaction was stirred for 1 h at 0 °C following which the reaction was stirred overnight at room temperature. The reaction was monitored by TLC. On completion, the reaction mixture was cooled to 0 °C and quenched with methanol and water. The quenched reaction was filtered through Celite and washed with EtOAc (50 mL). The solvent was removed under reduced pressure and was extracted with EtOAc (3 × 50 mL), dried over MgSO4 and concentrated to give the required diol (4-methyl-1,3-phenylene)dimethanol (0.62g, 85%) as a white solid. %). 1H NMR (CDCl3): 7.32 (s, 1H), 7.14 (d, J = 1.8 Hz, 2H), 4.60 (d, J = 14.4 Hz, 4H), 2.29 (s, 3H); 13C NMR (CDCl3): 139.13, 138.71, 135.34, 130.50, 126.45, 126.24, 65.14, 63.21, 18.45; MS: HRMS-ESI-POS.: calc. for C9H12O2m/z 175.0735 (M++Na), found m/z 175.0730. <chemistry id="chem0286" num="0286"><img file="EP4603484A2_D0286.tif" /></chemistry>

0343PBr3 (0.7mL, 7.38 mmol) was added dropwise to a solution of diol (0.511g, 3.35 mmol)in DCM maintained at 0°C. The reaction mixture was stirred at room temperature for 4 h and then quenched with ice water. The solution was extracted with CH2Cl2 (3 × 25 mL), dried over MgSO4 and concentrated to give the required dibromo compound as a white solid (0.93g, 90%).1H NMR (CDCl3): 7.34(d, J = 1.6 Hz, 1H), 7.28-7.24 (m, 1H), 7.17(d, J = 7.8 Hz, 1H), 4.48(d, J = 12.6 Hz, 4H), 2.41 (s, 3H); 13C NMR (CDCl3): 137.81, 136.37, 136.10, 131.47, 130.64, 129.66, 33.10, 31.82, 18.70; <chemistry id="chem0287" num="0287"><img file="EP4603484A2_D0287.tif" /></chemistry>

0344Reaction of 2,4-bis(bromomethyl)-1-methylbenzene (0.9 g, 3.2 mmol) and 4-hydroxybenzonitrile (0.84 g, 7 mmol) yielded 1, 3-bis (4-cyano-phenoxy methyl)-6-methylbenzene as white solid (0.81 g, 72%), using method A; 1H NMR (CDCl3): 7.59(dd, J= 11.2, 8.9 Hz, 4H), 7.44 (s, 1H), 7.36-7.27 (m, 2H), 7.08-6.96 (m, 4H), 5.09(d, J= 1.6 Hz, 4H), 2.38 (s, 3H); 13C NMR (CDCl3): 162.05, 162.01, 137.10, 134.28, 134.21, 134.15, 133.81, 131.18, 128.02, 127.87, 119.24, 115.68, 115.59, 104.59, 104.44, 70.08, 68.74, 18.83; MS: HRMS-ESI-POS.: calc. for C23H18N2O2m/z 377.1266 (M++Na), found m/z 377.1256. <chemistry id="chem0288" num="0288"><img file="EP4603484A2_D0288.tif" /></chemistry>

0345Dinitrile (0.35 g, 1 mmol) was converted to 1, 3-bis {4-amidino (phenoxy methyl)-6-methylbenzene dihydrochloride as brown solid following Method B (0.32 g, 70%); 1H NMR (DMSO-d6):9.33 (d, J = 9.8 Hz, 4H), 9.14 (d, J = 6.6 Hz, 4H), 7.90 (dd, J = 12.8, 8.9 Hz, 4H), 7.55 (s, 1H), 7.41-7.35 (m, 1H), 7.31-7.18 (m, 5H), ), 5.23 (d, J = 7.0 Hz, 4H), 2.34 (s, 3H); 13C NMR (DMSO-d6): 164.73, 162.73, 162.61, 136.74, 134.52, 133.87, 130.45, 130.24, 130.20, 128.21, 127.95, 119.70, 119.59, 115.15, 115.08, 69.45, 68.36, 18.29; MS: HRMS-ESI-POS.: calc. for C23H24N4O2m/z 389.1978 (M++1), found m/z 389.1971.

Synthesis of MD-120

0346<chemistry id="chem0289" num="0289"><img file="EP4603484A2_D0289.tif" /></chemistry>

0347Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(3-fluorobenzonitrile) (32). Reaction of 1,3-bis (bromomethyl)-5-methylbenzene (8, 0.99 g, 3.6 mmol) and 3-fluoro-4-hydroxybenzonitrile (26, 1.1 g, 7.9 mmol) yielded 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(3-fluorobenzonitrile) as white solid (32, 1.12 g, 80%), using method A. 1H NMR (CDCl3): δ 7.40 - 7.37 (m, 4H), 7.28 (s, 1H), 7.23 (s, 2H), 7.04 (t, J = 8.4 Hz, 2H), 5.17 (s, 4H), 2.40 (s, 3H). 13C NMR (CDCl3): δ 152.2 (d, JC-F = 242 Hz), 150.9 (d, JC-F = 4 Hz), 139.5, 135.9, 129.7 (d, JC-F = 4 Hz), 128.5, 123.6, 120.0 (d, JC-F = 21 Hz), 118.0 (d, JC-F = 2 Hz), 115.3 (d, JC-F = 2 Hz), 104.6 (d, JC-F = 8 Hz), 71.1, 21.5. HRMS calcd for C23H16F2N2O2Na [M+Na] +: 413.1078, found 413.1087.

0348Synthesis of 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(3-fluorobenzimidamide) dihydrochloride(MD-120). Dinitrile (32, 0.35 g, 0.9 mmol) was converted to 4,4'-(((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(3-fluorobenzimidamide) dihydrochloride as white solid following method B (MD-120, 0.32 g, 72%). 1H NMR (DMSO-d6): δ 9.42 (s, 4H), 9.24 (s, 4H), 7.90 (dd, J= 12.0, 2.0 Hz, 2H), 7.78-7.76 (m, 2H), 7.49 (t, J = 8.8 Hz, 2H), 7.38 (s, 1H), 7.29 (s, 2H), 5.30 (s, 4H), 2.35 (s, 3H). 13C NMR (DMSO-d6): δ 163.8, 150.9 (d, JC-F = 244 Hz), 150.6 (d, JC-F = 10 Hz), 138.3, 136.2, 128.5, 125.8 (d, JC-F = 3 Hz), 124.5, 119.8 (d, JC-F = 7 Hz), 116.1 (d, JC-F = 21 Hz), 151.0, 70.3, 20.9. HRMS calcd for C23H23F2N4O2 [M+H]+: 425.1789, found 425.1777.

Synthesis of MD-123

0349<chemistry id="chem0290" num="0290"><img file="EP4603484A2_D0290.tif" /></chemistry>

0350Synthesis of 4,4'-(((5-butyl-1,3-phenylene)bis(oxy))bis(methylene))dibenzonitrile (34). A mixture of olivetol (33, 1.4 g, 8.2 mmol), 4-cyanobenzyl bromide (24, 3.53 g, 18 mmol) and anhydrous K2CO3 (3.4 g, 24.6 mmol) in 100 mL DMF was stirred at room temperature overnight. Then the reaction mixture was diluted with ice water (50 mL) and extracted with ethyl acetate (3 x 100 mL) followed by water and brine wash. The combined organic layer is dried over anhydrous Na2SO4, filtered, concentrated in vacuum to yield 4,4'-(((5-butyl-1,3-phenylene)bis(oxy))bis(methylene))dibenzonitrile (34) as an orange solid (34, 3.2 g, 95.0%). 1H NMR (CDCl3): δ 7.67 (d, J = 8.4 Hz, 4H), 7.53 (d, J = 8.4 Hz, 4H), 6.44 (d, J = 2.0 Hz, 2H), 6.40 (t, J = 2.0 Hz, 1H), 5.09 (s, 4H), 2.56 - 2.52 (m, 2H), 1.60 - 1.57 (m, 2H), 1.33 - 1.27 (m, 4H), 0.89 (t, J = 7.2 Hz, 3H). 13C NMR (CDCl3): δ 59.4, 146.0, 142.5, 132.5, 127.7, 118.8, 111.8, 108.0, 99.5, 69.0, 36.3, 31.5, 31.0, 22.6, 14.1. HRMS calcd for C27H26N2O2Na [M+Na]+: 433.1892, found 433.1873.

0351Synthesis of 4,4'-((5-pentyl-1,3-phenylene)bis(ethane-2,1-diyl))dibenzimidamide dihydrochloride(MD-123). Dinitrile (34, 0.32 g, 0.78 mmol) was converted to 4,4'-((5-pentyl-1,3-phenylene)bis(ethane-2,1-diyl))dibenzimidamide dihydrochloride (MD-123) as white solid following method C (MD-123, 0.32 g, 80%). 1H NMR (DMSO-d6): δ 9.47 (s, 4H), 9.28 (s, 4H), 7.87 (d, J = 8.4 Hz, 4H), 7.65 (d, J = 8.4 Hz, 4H), 6.51 (t, J = 2.0 Hz, 1H), 6.48 (d, J = 2.0 Hz, 2H), 5.20 (s, 4H) , 2.50 - 2.46 (m, 2H), 1.55 - 1.52 (m. 2H), 1.29 - 1.20 (m, 4H), 0.84 (t, J = 6.8 Hz, 3H). 13C NMR (DMSO-d6): δ 165.4, 159.1, 145.0, 143.4, 128.3, 127.7, 127.3, 107.6, 99.6, 68.3, 35.4, 30.9, 30.4, 22.0, 14.0. HRMS calcd for C27H33N4O2[M+H]+: 445.2604, found 445.2624.

Synthesis of MD-124

0352<chemistry id="chem0291" num="0291"><img file="EP4603484A2_D0291.tif" /></chemistry>

0353Synthesis of 4,4'-(((5-(trifluoromethyl)-1,3-phenylene)bis(oxy))bis(methylene)) dibenzonitrile (36). A mixture of 5-(Trifluoromethyl)-1,3-diol (35, 0.7 g, 4.2 mmol), 4-cyanobenzyl bromide (24, 1.80 g, 9.21 mmol) and anhydrous K2CO3 (1.73 g, 12.6 mmol) in 20 mL DMF was stirred at room temperature overnight. Then the reaction mixture was diluted with ice water (50 mL) and stirred for 30 min. The grey precipitate was filtered, washed with water, and dried in air. Then the yellow solid was dissolved in a dichloromethane (100 mL), dried over anhydrous Na2SO4, filtered, concentrated in vacuum to afford crude product. The crude product was triturated with hexane, filtered and dried in vacuum to yield 4,4'-(((5-(trifluoromethyl)-1,3-phenylene)bis(oxy))bis(methylene))dibenzonitrile(36) as a grey solid (36, 1.48 g, 87.0%). 1H NMR (CDCl3): δ 7.70 (d, J = 8.4 Hz, 4H), 7.54 (d, J = 8.4 Hz, 4H), 6.85 (d, J = 2.0 Hz, 2H), 6.71 (t, J= 2.0 Hz, 1H), 5.13 (s, 4H). 13C NMR (CDCl3): 159.8, 141.5, 132.7, 127.8, 118.7, 112.3, 105.4, 104.9, 104.8, 69.4. HRMS- calcd for C23H15N2O2F3Na [M+Na]+: 431.0961, found 431.0983.

0354Synthesis of 4,4'-(((5-(trifluoromethyl)-1,3-phenylene)bis(oxy))bis(methylene)) dibenzimidamide dihydrochloride(MD-124). Dinitrile (36, 0.35 g, 0.85 mmol) was converted to 4,4'-(((5-(trifluoromethyl)-1,3-phenylene)bis(oxy))bis(methylene))dibenzimidamide dihydrochloride as pale-yellow solid following method C (MD-124, 0.3 g, 70%). 1H NMR (DMSO-d6): 9.43 (s, 4H), 9.20 (s, 4H), 7.87 (d, J = 8.4 Hz, 4H), 7.68 (d, J = 8.4 Hz, 4H), 7.03 (s, 1H), 6.99 (s, 2H), 5.32 (s, 4H). 13C NMR (DMSO-d6): δ 165.4, 159.7, 142.5, 131.1 (q, JC-F = 32 Hz), 128.4, 127.8, 127.6 (q, JC-F = 240 Hz), 122.4, 105.9, 104.2, 68.9. HRMS calcd for C23H22F3N4O2 [M+H]+: 443.1695, found 443.1687.

Synthesis of MD-125

0355<chemistry id="chem0292" num="0292"><img file="EP4603484A2_D0292.tif" /></chemistry>

0356Synthesis of p-[N', N"-Di(Boc)guanidino]phenol (39). p-aminophenol (37, 1.64 g, 15.0 mmol) and N,N'-Di(Boc)-S-methylisothiourea (38, 2.90 g, 10.0 mmol) were stirred in THF (100 mL) for 10 minutes after which the reaction was cooled to 0°C. HgCl2 (2.99 g, 11.0 mmol) was added slowly to this solution and stirred for 20 h. The reaction mixture was concentrated and purified with column chromatography using 5:1 Hexane: EA as eluant to give p-[N', N"-Di(Boc)guanidino]phenol (39) as a white solid (3.16 g, 60%).2 1H NMR (CDCl3): δ 11.61 (s, 1H), 9.96 (s, 1H), 7.01 (d, J = 8.8 Hz, 2 H), 6.58 (d, J = 8.8 Hz, 2 H),1.53 (s, 9 H), 1.44 (s, 9 H). 13C NMR (CDCl3): δ 156.1, 155.7, 153.3, 126.7, 116.4, 84.0, 80.4, 28.3, 28.2. HRMS calcd for C17H26N3O5 [M+H]+: 352.1872, found 352.1863.

0357Synthesis of 1,1'-((((5-methyl-1,3-phenylene)bis(methylene))bis(oxy))bis(4,1-phenylene)) diguanidine di(trifluoroacetate). Reaction of 1,3-bis (bromomethyl)-5-methylbenzene (0.36 g, 1.3 mmol), p-[N',N"-Di(Boc)guanidino]phenol (39, 1.0 g, 2.84 mmol) and K2CO3 (0.54 g, 3.9 mmol) yielded 1, 3-Bis 2-5-methylbenzene (40) as white solid (40, 0.74 g, 70%) using method A. Compound 40 (32 mg, 0.039 mmol) in DCM (2 mL) was treated with TFA (1 mL) for 2 h The solvent was removed in vacuo to yield 1, 3-Bis 2-5-methylbenzene di(trifluoroacetate) (MD-125) salt as a white solid (MD-125, 20 mg, 80%). 1H NMR (MeOD): δ 7.33 (s, 1H), 7.23 (s, 2H), 7.22- 7.20 (m, 4H), 7.09- 7.07 (m, 4H), 5.09 (s, 4H), 2.36 (s, 3H). 13C NMR (MeOD): δ 159.8, 158.5, 139.8, 138.7, 128.8, 128.8, 128.6, 124.8, 117.2, 71.1, 21.4. HRMS calcd for C23H27N6O2 [M+H]+: 419.2195, found 419.2212.

Synthesis of MD-126

0358<chemistry id="chem0293" num="0293"><img file="EP4603484A2_D0293.tif" /></chemistry>

0359Synthesis of 4,4'-(((5-methoxy-1,3-phenylene)bis(oxy))bis(methylene))dibenzonitrile(42). A mixture of 5-methoxyresorcinol (41, 1.22 g, 8.7 mmol), 4-cyanobenzyl bromide (24, 3.74 g, 18 mmol) and anhydrous K2CO3 (3.6 g, 26.02 mmol) in 100 mL DMF was stirred at room temperature overnight. Then the reaction mixture was diluted with ice water (50 mL) and extracted with ethyl acetate (3 x 100 mL) followed by water and brine wash. The combined organic layer is dried over anhydrous Na2SO4, filtered, concentrated with rotavapor and purified with column chromatography using 5:1 hexane: EA as elution buffer to yield of 4,4'-(((5-methoxy-1,3-phenylene)bis(oxy))bis(methylene))dibenzonitrile (42) as a white solid (42, 2.94 g, 71.0%). 1H NMR (CDCl3): δ 7.64 (d, J = 8.4 Hz, 4H), 7.51 (d, J = 8.4 Hz, 4H), 6.18 (t, J = 2.0 Hz, 1H), 6.16 (d J = 2.0 Hz, 2H), 5.06 (s, 4H), 3.75 (s, 3H). 13C NMR (CDCl3): δ 161.8, 160.3, 142.3, 132.6, 127.7, 118.8, 111.9, 94.7, 94.5, 69.11, 55.6. HRMS calcd for C23H18N2O3Na [M+Na]+: 393.1215, found 393.1201.

0360Synthesis of 4,4'-(((5-methoxy-1,3-phenylene)bis(oxy))bis(methylene))dibenzimidamide dihydrochloride(MD-126). Dinitrile (42, 0.37 g, 0.99 mmol) was converted to 4,4'-(((5-methoxy-1,3-phenylene)bis(oxy))bis(methylene))dibenzimidamide dihydrochloride as yellow solid following method C (MD-126, 0.35 g, 75%) using ammonia gas. 1H NMR (DMSO-d6): δ 9.44 (s, 4H), 9.23 (s, 4H), 7.86 (d, J = 8.0 Hz, 4 H), 7.65 (d, J = 8.0 Hz, 4 H), 6.31 (s, 1H), 6.22 (s, 2H), 5.21 (s, 4 H), 3.70 (s, 3 H). 13C NMR (DMSO-d6): δ 165.4, 161.2, 159.8, 143.2, 128.3, 127.6, 94.7, 94.1, 68.4, 55.3. HRMS calcd for C23H25N4O3 [M+H]+: 405.1927, found 405.1923.

1, 3-Bis {(4-amidino-2-fluoro)-benzyloxy}-5-(methoxy)benzene dihydrochloride (MD-127)

0361<chemistry id="chem0294" num="0294"><img file="EP4603484A2_D0294.tif" /></chemistry>

0362A mixture of 5-(Trifluoromethyl)-1,3-diol (0.42 g, 2.4 mmol), 4-cyano2-fluorobenzyl bromide (1.07 g, 5.04 mmol) and anhydrous K2CO3 (0.99 g, 7.2 mmol) in 20 ml DMF was stirred at 45°C for 4h [TLC (Hex: EtOAc 4:1) monitored]. Then the reaction mixture was diluted with ice water (30 ml) and stirred for 30 min. The white precipitate was filtered, washed with water, and dried in air. Then the grey white was dissolved in a dichloromethane (50 ml), dried over anhydrous Na2SO4, filtered, concentrated with rotavapor and dried in vacuum to yield 1, 3-Bis {(4-cyano 2-fluoro)-benzyloxy}-5-trifluoromethylbenzene as a white solid (0.73 g, 70 %); 1H NMR (CDCl3) : 7.67 (t, J = 7.5 Hz, 2H), 7.51 (s, 2H), 7.42 (d, J = 9.3 Hz, 2H), 6.89 (s, 2H), 6.75 (s, 1H), 5.19 (s, 4H); 13C NMR (DMSO-d6): 159.53(d, JC-F =251.1 Hz), 159.45, 130.13 (d, JC-F =4.4 Hz), 129.29(d, JC-F =14.0 Hz), 128.54 (d, JC-F = 4.1 Hz), 119.16 (d, JC-F =24.4 Hz), 117.30 (d, JC-F = 2.8 Hz), 113.58 (d, JC-F =9.4Hz), 105.06, 104.97(d, JC-F(CF3) = 4.0 Hz), 63.42 (d, JC-F = 4.4 Hz); MS: HRMS-ESI-POS.: calc. for C23H13N2O2F5Na m/z 467.077 (M++Na), found m/z 467.0468 . <chemistry id="chem0295" num="0295"><img file="EP4603484A2_D0295.tif" /></chemistry>

0363Dinitrile (0.30 g, 0.68 mmol) was added to anhydrous EtOH saturated with hydrogen chloride (20 mL) at 0 °C in a dry flask. The reaction mixture was then sealed, slowly warmed to ambient temperature, and stirred for 7 days. Ethanol was removed using rotary evaporator. Anhydrous diethyl ether (20 mL) was added to the reaction mixture and the precipitated imidate ester dihydrochloride was filtered off and dried under high vacuum. Ammonia gas (using a cylinder) was passed through imidate ester in EtOH (10 mL) and stirred for a day. The reaction mixture was concentrated in vacuum. Then anhydrous ether was added, and the product was filtered and dried in the oil pump. The free base was converted to its dihydrochloride salt by stirring the diamidine with saturated ethanolic HCl (2 mL) for 2-3h. The solvent was removed thoroughly and the obtained product was dried in vacuum at 80 °C for 12 h to yield 1, 3-Bis {(4-amidino2-fluoro)-benzyloxy}-5-trifluoromethylbenzene dihydrochloride as a white solid (0.3 g, 60%). 1H NMR (DMSO-d6); 1H NMR (DMSO-d6): 9.42 (s, 4H), 9.23 (s, 4H), 7.83 (t, J= 7.2 Hz, 4 H), 7.76 (d, J= 10.5 Hz, 2 H), 7.70 (d, J = 7.9 Hz, 2 H), 7.08 (s, 1H), 7.04 (s, 2H), 5.35 (s, 4 H); MS: HRMS-ESI-POS.: calc. for C23H20N4O2F5m/z 479.1506 (M++1), found m/z 479.1512.

1, 3-Bis {(4-amidino)-phenethyl}-5-trifluoromethylbenzene dihydrochloride(MD-128)

0364<chemistry id="chem0296" num="0296"><img file="EP4603484A2_D0296.tif" /></chemistry>

0365To 3,5-dibromobenzotrifluoride (1.57 g, 5.2 mmol) was added 1:1 DMF-Et3N (10 ml). To this solution, 3 mole% Pd(PPh3)4 and 4-Ethynylbenzonitrile (1.32 g, 10.4 mmol) were added and stirred for 5 minutes. Further, 6 mol% Na ascorbate solution, 1 mol% CuSO4 solution in DMF were added to the reaction mixture and stirred for 4h at 80°C. The reaction mixture was extracted with ethyl acetate followed by ammonium chloride and brine wash. The combined organic layer was dried over anhydrous Na2SO4 and then concentrated invacuo. The product was purified using column chromatography and obtained using 5:1 Hexane: Ethyl acetate system as a white solid (1.23 g, 60%). 1H NMR (CDCl3) 7.88 (s, 1H), 7.79 (s, 2H), 7.70 - 7.61 (m, 8H); 13C NMR (CDCl3): δ 137.70, 132.39, 132.36, 128.79, 127.19, 124.06, 118.40, 112.55, 90.90, 90.03; MS: HRMS-ESI-POS.: calc. for C25H11N2F3Na m/z 419.0772 (M++Na), found m/z 419.0771 . <chemistry id="chem0297" num="0297"><img file="EP4603484A2_D0297.tif" /></chemistry>

0366To 10% Pd//0C in THF (30ml) under argon gas was added 4,4'-((5-trifluoromethyl-1,3-phenylene)bis(ethyne-2,1-diyl))dibenzonitrile (1.23 g, 3.1 mmol). The argon gas was exchanged for H2 gas and the reaction mixture was stirred overnight. The reaction mixture was quenched with CH2Cl2 and filtered through celite. Extraction was carried out with CH2Cl2 followed by water wash. The combined organic layer was dried over anhydrous Na2SO4 and then concentrated invacuo to give the product as a white solid (1.22 g, 97.3%). 1H NMR (CDCl3) δ 7.58 (d, J = 8.2 Hz, 4H), 7.22 (d, J = 8.3 Hz, 6H), 7.00 (s, 1H), 2.94 (s, 8H); ); 13C NMR (DMSO-d6): 146.56, 141.85, 132.40, 132.18, 129.40, 123.38 (dd, JC-F(CF3) = 7.7, 3.5 Hz), 123.19, 123.15, 123.12, 119.04, 110.30, 37.78, 37.03); MS: HRMS-ESI-POS.: calc. for C25H19N2F3Na m/z 427.1377 (M++Na), found m/z 427.1398 . <chemistry id="chem0298" num="0298"><img file="EP4603484A2_D0298.tif" /></chemistry>

0367Dinitrile (0.31 g, 0.76 mmol) was added to anhydrous EtOH saturated with hydrogen chloride (20 mL) at 0 °C in a dry flask. The reaction mixture was then sealed, slowly warmed to ambient temperature, and stirred for 7 days. Ethanol was removed using rotary evaporator. Anhydrous diethyl ether (20 mL) was added to the reaction mixture and the precipitated imidate ester dihydrochloride was filtered off and dried under high vacuum. Ammonia gas (using a cylinder) was passed through imidate ester in EtOH (10 mL) and stirred for a day. The reaction mixture was concentrated in vacuum. Then anhydrous ether was added, and the product was filtered and dried in the oil pump. The free base was converted to its dihydrochloride salt by stirring the diamidine with saturated ethanolic HCl (2 mL) for 2-3h. The solvent was removed thoroughly and the obtained product was dried in vacuum at 80 °C for 12 h to yield 1, 3-Bis {(4-amidino)-benzyloxy}-5-trifluoromethylbenzene dihydrochloride as a white solid (0.31 g, 62%). 1H NMR (DMSO-d6): 1H NMR (DMSO-d6) δ 9.24 (s, 4H), 9.12 (s, 4H), 7.76 (d, J = 8.2 Hz, 4H), 7.51 (m, 5H), 7.46 (s, 2H), 2.99 (s, 8H); NMR (CDCl3) δ 7.58 (d, J = 8.2 Hz, 4H), 7.22 (d, J = 8.3 Hz, 6H), 7.00 (s, 1H), 2.94 (s, 8H); ); 13C NMR (DMSO-d6):165.40, 147.92, 142.59, 132.70, 129.05, 128.13, 125.75, 122.75, 36.46, 56.13; MS: HRMS-ESI-POS.: calc. for C25H26N4F3m/z 439.2110 (M++1), found m/z 439.2111 .

1, 3-Bis {(4-amidino)-phenoxy methyl}-benzene dihydrochloride (DB 2559)

0368A mixture of 1,3-bis (bromomethyl)-benzene (1.30 g, 5 mmol) and 4-hydroxybenzonitrile (1.19, 10 mmol) used reacted using Method A, yielding 1, 3-bis {(4-cyano)-phenoxy methyl}-benzene as white solid (2.6 g, 76%); 1H NMR (DMSO-d6): 7.78 (d, 4H, J = 8.8 Hz), 7.55 (s, 1H), 7.45 (s, 3H), 7.19 (d, 4H, J = 8.8 Hz), 5.23 (s, 4H); 13C NMR (DMSO-d6): 161.7, 136.5, 134.2, 128.8, 127.6, 127.2, 119.1, 115.9, 103.1, 69.5; MS: HRMS-ESI-POS.: calc. for C22H22N4O2Na m/z 363.1109(M++Na), found m/z 363.1105.

0369Dinitrile (0.34 g, 1 mmol) was converted to 1, 3-bis {(4-amidino) phenoxy methyl}-benzene dihydrochloride as white solid (0.35 g, 74%) following Method B; mp 168-70 °C; 1H NMR (DMSO-d6): 9.35 (s, 4H), 9.18 (s, 4H), 7.91 (d, 4H, J = 8.8 Hz), 7.59 (s, 1H), 7.46 (s, 3H), 7.23 (d, 4H, J = 8.8 Hz), 5.27 (s, 4H); 13C NMR (DMSO-d6): 164.7, 162.5, 136.7, 130.2, 128.8, 127.6, 127.1, 119.7, 115.1, 69.5; MS: HRMS-ESI-POS.: calc. for C22H23N4O2m/z 375.1816 (M++1), found m/z 375.1816; analysis calc. for C22H22N4O2.2HCl.1.25H2O: C, 56.23; H, 5.68; N, 11.92; Found: C, 56.48; H, 5.66; N, 11.85.

1, 3-Bis {(4-(2-imidazolino))-phenoxy methyl}-benzene dihydrochloride (DB 2538)

0370Dinitrile (0.34 g, 10 mmol) was converted to imidate dihydrochloride, which was reacted with 1,2- diamino ethane to yield diimidazoline dihydrochloride as white solid (0.36 g, 72%) following Method D; mp 245-7 °C; 1H NMR (DMSO-d6): 10.73 (s, 4H), 8.12 (d, 4H, J =8.4Hz), 7.58 (s, 1H), 7.46 (s, 3H), 7.26 (d, 4H, J = 8.4Hz), 5.28 (s, 4H), 3.96 (s, 8H); 13C NMR (DMSO-d6): 163.9, 162.9, 136.6, 131.0, 128.8, 127.7, 127.2, 115.4, 114.3, 69.5, 44.0; MS: HRMS-ESI-POS.: calc. for C26H27N4O2m/z 427.2148 (M++1), found m/z 427.2134; analysis calc. for C26H26N4O2.2HCl.0.75H2O: C, 60.97; H, 5.81; N, 10.97; Found: C, 60.88; H, 5.89; N, 10.90.

1, 3-Bis {(4-(2-imidazolino))-phenoxy methyl}-5-methylbenzene dihydrochloride (MD-129)

0371Dinitrile (0.354 g, 1 mmol) was converted to 1, 3-bis {4-(2-imidazolino)-phenoxy methyl-5-methylbenzene dihydrochloride as white solid following Method C (0.38 g, 72%), mp 274-6 °C; 1H NMR (DMSO-d6): 10.9(s, 4H), 8.09 (d, 4H, J = 8.0 Hz), 7.68 (d, 4H, J = 8.0Hz), 6.52 (s, 1H), 6.49 (s, 2H), 5.22 (s, 4H), 4.0 (s, 8H), 2.42 (s, 3H); 13C NMR (DMSO-d6): 164.4, 159.0, 144.1, 128.9, 127.7, 121.4, 108.3, 99.3, 68.2, 44.2, 21.4; MS: HRMS-ESI-POS.: calc. for C27H29N4O2m/z 441.2291(M++1), found m/z 441.2292; analysis calc. for C27H24N4O2.2HCl.1.55H2O: C, 60.09; H, 6.17; N, 10.39; Found: C,60.38; H,5.99; N, 10.33.

1, 3-Bis{ (4-amidino)-phenoxy methyl}-2-fluorobenzene dihydrochloride (DB 2573)

0372Reaction of 1,3-bis (bromomethyl)-2-fluorobenzene (1.4 g, 5 mmol) and 4-hydroxybenzonitrile (1.19 g, 10 mmol) yielded 1, 3-bis (4-cyano-phenoxy methyl)-2-fluorobenzene as white solid (2.53 g, 70%), following method A; mp 173-5 °C; 1H NMR (DMSO-d6): 7.78 (d, 4H, J = 8.4Hz), 7.59 (t, 2H, J = 7.2Hz), 7.29 (t, 1H, J = 7.2Hz), 7.23 (d, 4H, J = 8.4Hz), 5.3 (s, 4H); 13C NMR (DMSO-d6): 161.4, 158.4 (d, JC-F = 248Hz), 134.0, 130.7 (d, JC-F = 4.1Hz), 124.2 (d, JC-F = 4.1Hz),123.1 (d, JC-F = 13.5Hz), 118.7, 115.6, 103.3,63.8 (d, JC-F = 3.3Hz); MS: HRMS-ESI-POS.: calc. for C22H15FN2O2Na m/z 381.1015 (M++Na), found m/z 381.1005.

0373Dinitrile (0.358 g, 1 mmol) was converted to 1, 3-bis {4-amidino (phenoxy methyl)-2-fluorobenzene dihydrochloride as white solid following Method B (0.36 g, 71%); mp. 175-7 °C; 1H NMR (DMSO-d6): 9.22 (s, 4H), 8.95 (s, 4H), 7.87 (d, 4H, J = 9.2Hz), 7.64 (t, 2H, J= 7.6 Hz), 7.31 (t, 1H, J = 7.6 Hz), 7.29 (d, 4H, J = 9.2 Hz), 5.31 (s, 4H); 13C NMR (DMSO-d6): 164.7, 162.4, 158.8 (d, JC-F = 248 Hz), 131.2 (d, JC-F = 3.7 Hz), 130.3, 124.6 (d, JC-F = 3.7 Hz), 123.4 (d, JC-F = 14.5 Hz), 119.9, 115.0, 64.1 (d, JC-F = 2.98 Hz), MS: HRMS-ESI-POS.: calc. for C22H22FN4O2m/z 393.1721 (M++Na), found m/z 393.1707; analysis calc. for C22H21FN4O2.2HCl.1.5H2O. 0.2C4H10O 9ether): C, 54.07; H, 5.57; N, 11.07; Found: C, 54.38; H, 5.27; N, 10.89.

1, 3-Bis {(4-(2-imidazolino))-phenoxy methyl}-2-fluorobenzene dihydrochloride (DB 2510)

0374Dinitrile (0.358 g, 1 mmol) was converted to di-imidazoline dihydrochloride as white solid following Method D (0.38 g, 70%); mp. 250-2 °C; 1H NMR (DMSO-d6): 10.81 (s, 4H), 8.15 (d, 4H, J= 7.6 Hz), 7.64 (t, 2H, J = 7.2 Hz), 7.33-7.30 (m, 5H, J = 7.6 Hz), 5.23 (s, 4H), 3.39 (s. 8H); 13C NMR (DMSO-d6): 163.8, 162.7, 154.6 (d, JC-F = 248 Hz), 130.0 (d, JC-F = 4.2 Hz), 124.4 (d, JC-F = 2.25Hz), 123.2 (d, JC-F = 15.2 Hz),115.2, 114.4, 64.5 (d, JC-F = 3.5Hz), 43.9; MS: HRMS-ESI-POS.: calc. for C26H26FN4O2m/z 445.2034 (M++Na), found m/z 440.2047; analysis calc. for C26H25FN4O2.2HCl.1.75H2O: C, 56.88; H, 5.60; N, 10.20; Found: C, 58.99; H, 5.63; N, 10.41.

1, 3-Bis {(4-amidino-2-fluoro)-phenoxy methyl}-2-fluorobenzene dihydrochloride (DB 2558)

0375Reaction of 1,3-bis(bromomethyl)-2-fluorobenzene (1.4 g, 5 mmol) and 2-fluoro-4-hydroxybenzonitrile (1.37 g, 10 mmol) following Method A yielded 1, 3-bis (2-fluoro-4-cyano-phenoxymethyl)-2-fluorobenzene as white solid (2.8g, 71%); mp 185-7 °C; 1H NMR (DMSO-d6): 7.88 (d, 2H, J = 8.4 Hz), 7.72 (d, 8.4 Hz), 7.64 (t, 2H, J= 7.6 Hz), 7.54 (t, 2H, J = 7.6 Hz), 7.33 (t, 1H, J = 7.6 Hz), 7.23 (d, 4H, J = 8.4 Hz), 5.37 (s, 4H); 13C NMR (DMSO-d6): 158.50 (d, JC-F =250 Hz), 151.0 (d, JC-F =248 Hz), 150.1 (d, JC-F =11.0Hz), 131.1 (d, JC-F = 4.4 Hz), 130.1 (d, JC-F =3.75Hz), 124.4 (d, JC-F = 4.28Hz), 122.7 (d, JC-F =15.4Hz), 119.6 (d, JC-F = 21.4 Hz), 117.6 (d, JC-F = 3.4 Hz),115.91 (d, JC-F = 2.25 Hz), 103.3 (d, JC-F = 8.73 Hz), 64.84 (d, JC-F = 4.21 Hz); MS: HRMS-ESI-POS.: calc. for C22H13F3N2O2Na m/z 417.0827 (M++Na), found m/z 417.0832

0376Dinitrile (0.394g, 1 mmol) was converted to 1, 3-bis (4-amidino-2-fluoro-phenoxy methyl)-2-fluorobenzene dihydrochloride as white solid following (Method B) (0.303 g, 71%); mp. 2255-7°C; 1H NMR (DMSO-d6): 9.27 (br, 8H), 7.88 (dd, 2H, J = 2.4 Hz, J = 12.0 Hz), 7.78 (dd, 2H, 2H, J = 1.6Hz, J = 8.4 Hz), 7.66 (t, 2H, 2H, J = 7.6 Hz), 7.61 (d, 2H, J = 8.8 Hz), 7.34 (d, 1H, J = 7.6 Hz), 5.40 (s, 4H); 13C NMR (DMSO-d6): 164.3, 159.35 (d, JC-F = 249 Hz), 151.31 (d, JC-F = 245 Hz), 150.88 (d, JC-F = 11.0 Hz), 152.1 (d, JC-F = 4.5 Hz), 126.33 (d, JC-F = 3.0 Hz), 125.14 (d, JC-F = 3.0Hz), 123.44 (d, JC-F = 14.0 Hz), 120.65 (d, JC-F = 7 Hz), 116.71 (d, JC-F = 21.0 Hz), 115.5, 65.42 (d, JC-F = 2.98 Hz), MS: HRMS-ESI-POS.: calc. for C22H20F3N4O2 m/z 429.1533 (M++1), found m/z 429.1536; analysis calc. for C22H19F3N4O2.2HCl.0.75H2O; C, 51.32; H, 4.40; N, 10.88; Found: C, 51.47; H, 4.39; N, 10.69.

1, 3-Bis {4-(2-imidazolino)-2-fluoro)-phenoxy methyl}-2-fluorobenzene dihydrochloride (DB 2554)

0377Dinitrile (0.394 g, 1 mmol) was converted to di-imidazoline dihydrochloride as white solid following Method D (0.4g, 70%); mp. 218-20 °C; 1H NMR (DMSO-d6): 10.78 (br, 4H), 8.12 (d, 2H, J=12.0Hz), 8.02 (d, 2H, J=9.2Hz), 7.63 (t, 2H, J=7.6Hz), 7.58 (t, 2H, J=8.4Hz), 7.32 (t, 1H, J = 7.6Hz), 5.43 (s, 4H), 3.99 (s, 8H); 13C NMR (DMSO-d6): 164.2, 159.12 (d, JC-F = 250 Hz), 151.68 (d, JC-F = 247 Hz), 151.3 (d, JC-F = 10.5 Hz), 131.74 (d, JC-F = 4.5 Hz), 126.6 (d, JC-F = 3.3 Hz), 124.91 (d, JC-F = 4.5 Hz), 123.18 (d, JC-F =14.5 Hz), 116.61 (d, JC-F = 21.0 Hz), 116.3, 115.18 (d, JC-F = 7.5 Hz), 65.73 (d, JC-F = 4.0 Hz), MS: HRMS-ESI-POS.: calc. for C26H24F3N4O2m/z 481.1846 (M++1), found m/z 481.1857; analysis calc. for C26H23F3N4O2.2HCl.1.1H2O; C, 54.47; H, 4.78; N, 9.77; Found: C, 54.10; H, 4.76; N, 9.65.

1, 3-Bis {[4-(2-imidazolyl)-2-methoxy)-phenoxy methyl]}-2-fluorobenzene dihydrochloride (DB 2555)

0378Reaction of 1,3-bis (bromomethyl)-2-fluorobenzene (1.4g, 5 mmol) and 4-hydroxy- 2-methoxybenzonitrile (1.37 g, 10 mmol) following Method A yielded 1, 3-Bis {(4-cyano-2-methoxy)-phenoxy methyl}-2-fluorobenzene as white solid (2.8 g, 71%); mp 185-7 °C; 1H NMR (DMSO-d6): 7.59 (t, 2H, J = 7.2Hz), 7.45-7.41 (m, 4H), 731-7.27 (m 3H), 5.25 (s, 4H), 3.82 (s, 6H); 13C NMR (DMSO-d6): 159.2 (d, JC-F = 247Hz), 152.01, 149.59, 131.91(d, JC-F = 3Hz) 126.74, 125.02 (d, JC-F = 4.0Hz), 123.77 (d, JC-F = 14Hz),119.64, 115.22, 113.88, 103.69, 64.76, 56.41; MS: HRMS-ESI-POS.: calc. for C24H19FN2O4Na m/z 441.1226 (M++Na), found m/z 441.1237.

0379Dinitrile (0.418 g, 1 mmol) was converted to di-imidazoline dihydrochloride as white solid (0.43 g, 70%) following Method D; mp. 237-9 °C; 1H NMR (DMSO-d6): 10.79 (s, 4H), 7.84 (d, 2H, J = 2.0 Hz), 7.77 (dd, 2H, J = 2.0 Hz, J = 8.4 Hz), 7.62 (t, 2H, J = 7.6Hz), 7.40 (d, J = 8.4Hz), 7.32 (t, 1H, J = 7.6Hz), 5.29 (s, 4H), 3.97 (s, 8H), 3.86 (s, 6H); 13C NMR (DMSO-d6): 164.1, 159.01 (d, JC-F =250Hz), 152.4, 148.9, 131.5 (d, JC-F = 3.0 Hz), 124.9 (d, JC-F = 4.0 Hz), 123.0 (d, JC-F = 15.0 Hz), 122.8, 114.4, 112.8, 112.1, 64.4 (d, JC-F = 3.5 Hz), 56.2, 44.1; MS: HRMS-ESI-POS.: calc. for C28H30FN4O4m/z 505.2246 (M++1), found m/z 505.2248; analysis calc. for C28H29F3N4O4.2HCl.1.85H2O; C, 54.83; H, 5.83; N, 8.90; Found: C, 55.01; H, 5.67; N, 9.02.

Example 2. Antibacterial Activity against E. coli

0380The sensitization fold of select compounds of the present invention was determined. E. coli bacteria were cultured in nutrient broth at 37 °C overnight prior to treatment. Bacteria were then incubated with various concentrations of erythromycin with or without the compounds shown below for 20 hours. Bacterial density was measured based on OD600. Magnitude of the sensitization (sensitization fold) was calculated based on the IC90 of erythromycin using the following formula: <maths id="math0001"><formula-text>Sensitization fold (SF) = IC90 of erythromycin without compounds/IC90 of erythromycin with compounds</formula-text></maths>

0381The cytotoxicity in H9c2 (ATCC®CRL-1446™) cells was also determined. The H9c2 cells were maintained in DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% fetal bovine serum (MidSci; S01520HI) and 1% penicillin-streptomycin (Sigma-Aldrich; P4333) at 37 °C with 5% CO2. The H9c2 cells were seeded in 96-well plate one day before the experiment. Different concentrations of di-amidine compounds were added into the H9c2 cells. The cells were then incubated with the compounds for 24 hours at 37 °C with 5% CO2.The cell viability was tested by the CCK-8. Specifically, after 24 hour incubation, 10 µL CCK-8 was added to each well. After 3 hours incubation at 37 °C, the absorbance at 450 nm was recorded by a plate reader. The results for the sensitization fold and cytotoxicity are shown in Table 1. <tables id="tabl0001" num="0001"><table frame="all"><title>Table 1. MIC Sensitization Activity on E. coli</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="15mm" align="center" /><colspec colnum="2" colname="col2" colwidth="81mm" align="center" /><colspec colnum="3" colname="col3" colwidth="45mm" align="center" /><colspec colnum="4" colname="col4" colwidth="21mm" align="center" /><thead valign="top"><row><entry>Compd ID</entry><entry>Structure</entry><entry>Sensitization ability</entry><entry>Cytotoxicity (IC50)</entry></row></thead><tbody><row><entry>A</entry><entry><chemistry id="chem0299" num="0299"><img file="EP4603484A2_D0299.tif" /></chemistry></entry><entry>At 25 µM, sensitize E.coli towards rifampicin for 256-fold;</entry><entry>50 µM</entry></row><row><entry>B</entry><entry><chemistry id="chem0300" num="0300"><img file="EP4603484A2_D0300.tif" /></chemistry></entry><entry>At 25 µM, sensitize E.coli towards rifampicin for 16-fold;</entry><entry>100 µM</entry></row><row><entry>C</entry><entry><chemistry id="chem0301" num="0301"><img file="EP4603484A2_D0301.tif" /></chemistry></entry><entry>At 4 µM, sensitize E.coli towards rifampicin for 516-fold;</entry><entry>50 µM</entry></row><row><entry /><entry /><entry /><entry /></row><row><entry>D</entry><entry><chemistry id="chem0302" num="0302"><img file="EP4603484A2_D0302.tif" /></chemistry></entry><entry>At 15 µM, sensitize E.coli towards rifampicin for 32-fold;</entry><entry>>100 µM</entry></row><row><entry>M</entry><entry><chemistry id="chem0303" num="0303"><img file="EP4603484A2_D0303.tif" /></chemistry></entry><entry>At 25 µM, sensitize E.coli towards rifampicin for 516-fold; At 15 µM, sensitize E.coli towards rifampicin for 32-fold.</entry><entry>100 µM</entry></row><row><entry>N</entry><entry><chemistry id="chem0304" num="0304"><img file="EP4603484A2_D0304.tif" /></chemistry></entry><entry>At 25 µM, sensitize E.coli towards rifampicin for 64-fold.</entry><entry>100 µM</entry></row><row><entry>O</entry><entry><chemistry id="chem0305" num="0305"><img file="EP4603484A2_D0305.tif" /></chemistry></entry><entry>At 10 µM, sensitize E.coli towards rifampicin for 256-fold.</entry><entry>>100 µM</entry></row><row><entry>P</entry><entry><chemistry id="chem0306" num="0306"><img file="EP4603484A2_D0306.tif" /></chemistry></entry><entry>At 25 µM, sensitize E.coli towards rifampicin for 32-fold;</entry><entry>50 µM</entry></row><row><entry>Q</entry><entry><chemistry id="chem0307" num="0307"><img file="EP4603484A2_D0307.tif" /></chemistry></entry><entry>At 25 µM, sensitize E.coli towards rifampicin for 32-fold;</entry><entry>50 µM</entry></row><row><entry>R</entry><entry><chemistry id="chem0308" num="0308"><img file="EP4603484A2_D0308.tif" /></chemistry></entry><entry>At 25 µM, sensitize E.coli towards rifampicin for 32-fold;</entry><entry>>100 µM</entry></row><row><entry>T</entry><entry><chemistry id="chem0309" num="0309"><img file="EP4603484A2_D0309.tif" /></chemistry></entry><entry>At 25 µM, sensitize E.coli towards rifampicin for 32-fold;</entry><entry>>100 µM</entry></row><row><entry>U</entry><entry><chemistry id="chem0310" num="0310"><img file="EP4603484A2_D0310.tif" /></chemistry></entry><entry>At 10 µM, sensitize E.coli towards rifampicin for 32-fold;</entry><entry>100 µM</entry></row></tbody></tgroup></table></tables>

Example 3. Sensitization of Escherichia Coli (Gram Negative Bacterium) to Clarithromycin

0382The minimum inhibitory concentration (MIC) of clarithromycin on E. coli is 50 mcg/ml. Bacteria were cultured with clarithromycin at various concentrations in the presence or absence of the bacterial sensitizer, Compound D, for 24 hours at 37 °C. Then bacterial growth density was determined by measuring OD600 and the results are shown in Table 2. <chemistry id="chem0311" num="0311"><img file="EP4603484A2_D0311.tif" /></chemistry><tables id="tabl0002" num="0002"><table frame="all"><title>Table 2. MIC of clarithromycin on E. coli with different concentrations.</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="53mm" align="center" /><colspec colnum="2" colname="col2" colwidth="32mm" align="center" /><colspec colnum="3" colname="col3" colwidth="27mm" align="center" /><thead valign="top"><row><entry>Conc of Compound D (mcg/ml)</entry><entry>Sensitization fold</entry><entry>MIC (mcg/ml)</entry></row></thead><tbody><row><entry>0.5</entry><entry>2</entry><entry>25</entry></row><row><entry>1</entry><entry>16</entry><entry>3.2</entry></row><row><entry>1.5</entry><entry>32</entry><entry>1.6</entry></row><row><entry>2.0</entry><entry>64</entry><entry>0.8</entry></row><row><entry>2.5</entry><entry>512</entry><entry>0.1</entry></row><row><entry>3</entry><entry>>512</entry><entry><0.1</entry></row><row><entry>3.5</entry><entry>>512</entry><entry><0.1</entry></row></tbody></tgroup></table></tables>

Example 4. Sensitization of Escherichia Coli (Gram Negative Bacterium) to Novobiocin

0383The minimum inhibitory concentration (MIC) of novobiocin on E. coli is 100 mcg/ml. Bacteria were cultured with novobiocin at various concentrations in the presence or absence of bacterial sensitizer, Compound D, for 24 hours at 37 °C. Then bacterial growth density was determined by measuring OD600 and the results are shown in Table 3. <chemistry id="chem0312" num="0312"><img file="EP4603484A2_D0312.tif" /></chemistry><tables id="tabl0003" num="0003"><table frame="all"><title>Table 3. MIC of novobiocin on E. coli with different concentrations.</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="53mm" align="center" /><colspec colnum="2" colname="col2" colwidth="32mm" align="center" /><colspec colnum="3" colname="col3" colwidth="27mm" align="center" /><thead valign="top"><row><entry>Conc of Compound D (mcg/ml)</entry><entry>Sensitization fold</entry><entry>MIC (mcg/ml)</entry></row></thead><tbody><row><entry>0.5</entry><entry>2</entry><entry>50</entry></row><row><entry>1</entry><entry>8</entry><entry>12.5</entry></row><row><entry>1.5</entry><entry>64</entry><entry>1.6</entry></row><row><entry>2.0</entry><entry>128</entry><entry>0.8</entry></row><row><entry>2.5</entry><entry>512</entry><entry>0.2</entry></row><row><entry>3</entry><entry>>512</entry><entry><0.2</entry></row><row><entry>3.5</entry><entry>>512</entry><entry><0.2</entry></row></tbody></tgroup></table></tables>

Example 5. Sensitization of Escherichia Coli (Gram Negative Bacterium) to Rifampicin

0384The minimum inhibitory concentration (MIC) of rifampicin on A. baumannii is 5 mcg/ml. Bacteria were cultured with the antibiotic at various concentrations in the presence or absence of bacterial sensitizer, Compound D, for 24 hours at 37 °C. Then bacterial growth density was determined by measuring OD600 and the results are shown in Table 4. <chemistry id="chem0313" num="0313"><img file="EP4603484A2_D0313.tif" /></chemistry><tables id="tabl0004" num="0004"><table frame="all"><title>Table 4. MIC of rifampicin on A. baumannii with different concentrations.</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="53mm" align="center" /><colspec colnum="2" colname="col2" colwidth="30mm" align="center" /><colspec colnum="3" colname="col3" colwidth="25mm" align="center" /><thead valign="top"><row><entry>Conc of Compound D (mcg/ml)</entry><entry>Sensitization fold</entry><entry>MIC (mcg/ml)</entry></row></thead><tbody><row><entry>0.5</entry><entry>4</entry><entry>1.25</entry></row><row><entry>1</entry><entry>32</entry><entry>0.16</entry></row><row><entry>1.5</entry><entry>256</entry><entry>0.02</entry></row><row><entry>2.0</entry><entry>512</entry><entry>0.01</entry></row><row><entry>2.5</entry><entry>>512</entry><entry><0.01</entry></row><row><entry>3</entry><entry>>512</entry><entry><0.01</entry></row><row><entry>3.5</entry><entry>>512</entry><entry><0.01</entry></row></tbody></tgroup></table></tables>

Example 6: Highly potent small molecule sensitizers of Gram-negative bacteria towards existing antibiotics

0385Instruments and reagents. All solvents were of reagent grade and were purchased from Fisher Scientific and Aldrich. Reagents and antibiotics were purchased from Aldrich, Oakwood, or VWR. The stationary phase of chromatographic purification is silica (230 × 400 mesh, Sorbtech). Silica gel TLC plate was purchased from Sorbtech. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded on a Bruker Avance 400 MHz NMR spectrometer. Mass spectral analyses were performed on an ABI API 3200 (ESI-Triple Quadruple). HPLC was performed on a Shimadzu Prominence UFLC (column: Waters C18 3.5 µM, 4.6×100 mm). OD600 and fluorescence intensity was recorded on Perkin Elmer Enspire UV/ Vis/Fluorescence plate reader

0386Bacteria strains:E. coli (ATCC 25922), A. baumannii (ATCC 17978), K. pneumoniae (43816), S. maltophilia (ATCC 31559), S. typhimurium (ATCC 14028), C. werkmanii (ATCC 51114), S. aureus (ATCC 12600) and methicillin-resistant staphylococcus aureus (MRSA, ATCC 33592) strains were purchased from ATCC. NR698 was provided.

0387Bacteria culture and MICs determination: Gram-negative bacteria were cultured in Mueller Hinton II cation-adjusted broth. Gram-positive bacteria were cultured in LB broth. Mycobacterium smegmatis was cultured in Middlebrook 7H9 Broth. MICs of antibiotics itself were determined by performing two-fold serial dilutions of antibiotics. MICs of antibiotics in the presence of bacterial sensitizers were determined by performing two-fold serial dilutions of antibiotics with or without a constant concentration of bacterial sensitizers. The MICs tests were performed on 96-well plates with a final volume of 200 µl Mueller Hinton II cation-adjusted broth in each well. Each well was inoculated with 5 x 105 CFU/ml bacteria and was incubated for 24 h at 37 °C with continuous shaking of 200 rpm. The bacterial density was then determined by OD600. Bacterial growth % = OD600 of antibiotic treatment group/ OD600 of antibiotic non-treatment group. MICs was determined as the concentrations that inhibit more than 90% of bacteria growth.

0388Sensitization fold determination and FIC index calculations: Sensitization fold = MIC of antibiotic only /MIC of antibiotic with bacterial sensitizer. For example, the MIC of rifampin on E.coli is 10 µg/ml, the MIC of rifampicin in the presence of 5 µg/ml MD-124 is measured to be 0.019 µg/ml, so the sensitization fold of 5 µg/ml MD-124 on E. coli towards rifampicin is 10 µg/ml/0.019 µg/ml = 512-fold. Since the MICs were determined by performing two-fold serial dilutions of antibiotic, so the sensitization fold can is the times of 2.

0389FIC index between compound a and b was calculated according to the formula below: <maths id="math0002"><math display="block"><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">FIC</mi></mstyle><mo>=</mo><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">FICa</mi></mstyle><mo>+</mo><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">FICb</mi></mstyle><mo>=</mo><mfrac><mrow><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">MIC</mi></mstyle><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">of</mi></mstyle><mspace width="1ex" /><mi mathvariant="bold-italic" mathsize="normal">a</mi><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">in</mi></mstyle><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">combination</mi></mstyle></mrow><mrow><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">MIC</mi></mstyle><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">of</mi></mstyle><mspace width="1ex" /><mi mathvariant="bold-italic" mathsize="normal">a</mi><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">alone</mi></mstyle></mrow></mfrac><mo>+</mo><mfrac><mrow><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">MIC</mi></mstyle><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">of</mi></mstyle><mspace width="1ex" /><mi mathvariant="bold-italic" mathsize="normal">b</mi><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">in</mi></mstyle><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">combination</mi></mstyle></mrow><mrow><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">MIC</mi></mstyle><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">of</mi></mstyle><mspace width="1ex" /><mi mathvariant="bold-italic" mathsize="normal">b</mi><mspace width="1ex" /><mstyle mathvariant="bold" mathsize="normal"><mi mathvariant="italic">alone</mi></mstyle></mrow></mfrac></math><img file="EP4603484A2_D0314.tif" /></maths>

0390FIC ≤ 0.5: Synergy; FIC between 0.5 and 1: Additive; FIC between 1 and 2: no interaction; FIC >4: antagonism.

0391Bacterial resistance frequency study:E. coli was grown overnight in Mueller Hinton II cation-adjusted broth medium and concentrated to ~5 × 109 CFUs/ml in Mueller Hinton II cation-adjusted broth. Then a 200 µl volume of ~5 × 109 CFUs/ml (equal to 1 × 109 CFUs) was then transferred onto solid Mueller Hinton agar plates (100 mm Petri dishes) containing antibiotic 2- to 6-times the MIC, with or without 10 µg/ml MD-124. Then the plates were incubated at 37 °C for 48 h. Then the colonies formed on the plate were recorded and resistant frequency was calculated. Resistance frequency towards antibiotics or MD-124 and antibiotics combination were calculated by dividing the number of colonies formed after a 48 h by total CFUs inoculated on the plates initially.

0392The resistance frequency calculation towards MD-124: For trovafloxacin and MD-124 combination, 2, 3 and 4 times of MIC of trovafloxacin was used and each combination has 3 replicates. So, for trovafloxacin and MD-124 combination, it is 3 combination conditions with each condition having 3 replicates, and the amount of CFUs tested is: 109 CFUs per agar plates × 3 replicates per combination condition × 3 combination conditions = 9 × 109 CFUs. The amount of CFUs tested for the novobiocin/MD-124 and clindamycin/MD-124 combination is the same. So, together 2.7 × 1010 CFUs were tested in the MD-124 and antibiotics combination. There are colonies that were resistant MD-124 and antibiotic combination. To find out whether those resistant strains are resistant to MD-124 or antibiotics, those colonies were then subjected to another antibiotic combination: MD-124 and rifampicin. It turned out that MD-124 was still able to sensitize those resistant strains towards rifampicin with the same potency on wild-type E. coli, which demonstrated those 6 combinational therapy resistant strains are not resistant to MD-124. No strain was found to be resistant to 10 µg/ml MD-124 out of 2.7 × 1010 CFUs.

0393The resistance frequency towards MD-124 was calculated to be: <maths id="math0003"><math display="block"><mfrac><mrow><mo><</mo><mn>1</mn></mrow><mrow><mn>2.7</mn><mo>×</mo><msup><mn>10</mn><mn>10</mn></msup></mrow></mfrac><mo><</mo><mn>3.7</mn><mo>×</mo><msup><mn mathvariant="italic">10</mn><mrow><mo>−</mo><mn>11</mn></mrow></msup></math><img file="EP4603484A2_D0315.tif" /></maths>

0394Lysozyme assay to evaluate the disruption of Gram-negative bacteria out membrane by bacterial sensitizers. Lysozyme assay was performed based on literature reported method. E. coli was cultured in Mueller Hinton II cation-adjusted broth for overnight, centrifuged at 3000 g for 10 min, washed with HEPES buffer (pH = 7.2) and then centrifuged again to obtain bacteria pallet. The pallet was then gently resuspended in HEPES buffer with 5 mM NaCN to obtain an E. coli suspension with OD600 between 0.8~1.0. On a 96-well plate, each well was supplied with 100 µl lysozyme solution (100 µg/ml) containing 50 or 100 µg/ml bacterial sensitizers in HEPES buffer. To each well was added 100 µl E. coli suspension. The final concentration of lysozyme was 50 µg/ml. The plate was incubated at room temperature for 10 min and the OD600 was recorded. E. coli was also incubated with bacterial sensitizers in the absence of lysozyme to test if bacterial sensitizers would directly induce bacterial lysis. E. coli that was incubated with lysozyme alone or E. coli without any treatment were also used as negative control.

0395Evaluation of the influence of exogenous LPS and Mg2+ on bacterial sensitizers. The MICs of bacterial sensitizer and antibiotic combination in the presence of LPS (ranging from 0 to 40 µM) or Mg2+ (ranging from 0 to 20 mM) was determined as described above (Bacteria culture and MICs determination section).

0396Construction of MCR-1 and NDM-1 expressing E.coli strain.E. coli (ATCC 25922) was transformed with pGDP2 MCR-1 (Addgene, pGDP2 MCR-1, plasmid #118404) to generate colistin resistant strains. E. coli (ATCC 25922) was transformed with pGDP1 NDM-1 (Addgene, plasmid # 112883, pGDP1 NDM-1) to generate strains that are resistant to a broad range of β-lactam antibiotics. The successful construction of the MCR-1 and NDM-1 over-expression E.coli strains were validated by their increased resistance towards polymyxin B and β-lactam antibiotics (ampicillin, ceftazidime and meropenem) respectively.

0397Direct comparison of the antibiotic uptake in the presence and absence of MD-100 through HPLC study.E. coli (ATCC 25922) was cultured in Mueller Hinton II cation-adjusted broth for overnight at 37 °C to reach a density of OD600 of 0.8 to 1.0. To 20 ml fresh Mueller Hinton II cation-adjusted broth was added 50 µl E. coli stock, 200 µl 5 mg/ml O-CH3 novobiocin and 100 µl 10 mM MD-100. In the other group, the same amount of E. coli stock, O-CH3 novobiocin was used in the absence of MD-100. Then E. coli was incubated for 20 h at 37 °C with continuous shaking of 200 rpm. After, the E. coli suspension was centrifuged at 3000 g for 10 min and the culture media was removed to obtain bacteria pallet. The pallets from the two groups was re-suspended in PBS to reach the same OD600 of 2.0. To this E. coli suspension was spiked with 10 µM internal standard. 1 ml E. coli from each group in PBS was lysed by sonication on ice for 15 min, followed by adding 2 ml MeOH, the mixture was then centrifuged at 3000 g for 5 min and the supernatant was analyzed by HPLC. 20 µl of each sample was injected into Shimadzu Prominence UFLC (column: Waters C18, 3.5 µM, 4.6×100 mm, injection loop volume: 20µl). The mobile phase was acetonitrile (ACN)/H2O (with 0.05% trifluoroacetic acid in the aqueous) with ratios defined as: 20%~55% ACN, 0~10min; 55%~65% ACN, 10~20 min; 65%~20% ACN, 20~25 min. The internal standard used here is novobiocin because novobiocin have a very similar structure and chemical property compared with the analyte O-CH3 novobiocin.

0398Dansyl-PMBN displacement assay. Dansyl-PMBN was synthesized according to literature procedure. Dansyl-PMBN was dissolved in H2O to make 500 µM stock. Bacterial sensitizers were dissolved in ethanol to make 10 mM stock solutions. E. coli (ATCC 25922) was cultured in Mueller Hinton II cation-adjusted broth for overnight 37 °C. The E. coli stock was centrifuged at 3000 g for 10 min, washed with HEPES buffer (pH = 7.2) and then centrifuged again to obtain bacteria pallet. The pallet was then gently resuspended in HEPES buffer to obtain a E. coli suspension with OD600 about 0.3. The experiment was performed on 96-well plates. Each well was supplied with 100 µl coli suspension with 10 µM Dansyl-PMBN, then to each well, different concentrations of bacterial sensitizers were added to achieve a final concentration ranging from 0 to 200 µM. Then the mixture was incubated at room temperature for 3 min and the fluorescence intensities with different concentration of bacterial sensitizers were recorded (Ex = 340 nm; Em = 520 nm).

0399Cytotoxicity test of bacterial sensitizers on mammalian cells. Cell viability was assessed by using Cell Counting Kit-8 (CCK-8, Dojindo, Japan). HEK293 or NIH3T3 cells were seeded in a 96-well plate one day before the experiment to reach 80% confluency. Cells were then incubated with various concentration of bacterial sensitizers at 37 °C with 5% CO2 for 24 h, then 10 µL of CCK-8 solution was added to each well, and the plate was incubated for an additional at 37 °C 2 h with 5% CO2. The optical density at 450 nm was recorded by plate reader; and the results were calculated as a percentage of viability compared with the untreated control.

Development of Gram-Negative Bacteria Sensitizers

0400Compounds were synthesized and tested for their ability of sensitizing E.coli towards narrow-spectrum antibiotics (Tables 5A and 5B). Table 5A shows the structures of the compounds and Table 5B shows the activities, sensitization, and cytotoxicity of compounds. <tables id="tabl0005" num="0005"><table frame="all"><title>Table 5A</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="27mm" align="center" /><colspec colnum="2" colname="col2" colwidth="98mm" align="center" /><thead valign="top"><row><entry>Compound ID</entry><entry>Structure</entry></row></thead><tbody><row><entry>DB2514</entry><entry><chemistry id="chem0314" num="0314"><img file="EP4603484A2_D0316.tif" /></chemistry></entry></row><row><entry>DB2457</entry><entry><chemistry id="chem0315" num="0315"><img file="EP4603484A2_D0317.tif" /></chemistry></entry></row><row><entry>DB2542</entry><entry><chemistry id="chem0316" num="0316"><img file="EP4603484A2_D0318.tif" /></chemistry></entry></row><row><entry>DB2559</entry><entry><chemistry id="chem0317" num="0317"><img file="EP4603484A2_D0319.tif" /></chemistry></entry></row><row><entry>DB2558</entry><entry><chemistry id="chem0318" num="0318"><img file="EP4603484A2_D0320.tif" /></chemistry></entry></row><row><entry>DB2583</entry><entry><chemistry id="chem0319" num="0319"><img file="EP4603484A2_D0321.tif" /></chemistry></entry></row><row><entry>DB2447</entry><entry><chemistry id="chem0320" num="0320"><img file="EP4603484A2_D0322.tif" /></chemistry></entry></row><row><entry>DB1824</entry><entry><chemistry id="chem0321" num="0321"><img file="EP4603484A2_D0323.tif" /></chemistry></entry></row><row><entry>DB2573</entry><entry><chemistry id="chem0322" num="0322"><img file="EP4603484A2_D0324.tif" /></chemistry></entry></row><row><entry>DB2449</entry><entry><chemistry id="chem0323" num="0323"><img file="EP4603484A2_D0325.tif" /></chemistry></entry></row><row><entry>DB2362</entry><entry><chemistry id="chem0324" num="0324"><img file="EP4603484A2_D0326.tif" /></chemistry></entry></row><row><entry>MD-129</entry><entry><chemistry id="chem0325" num="0325"><img file="EP4603484A2_D0327.tif" /></chemistry></entry></row><row><entry>DB2538</entry><entry><chemistry id="chem0326" num="0326"><img file="EP4603484A2_D0328.tif" /></chemistry></entry></row><row><entry>DB2510</entry><entry><chemistry id="chem0327" num="0327"><img file="EP4603484A2_D0329.tif" /></chemistry></entry></row><row><entry>DB2554</entry><entry><chemistry id="chem0328" num="0328"><img file="EP4603484A2_D0330.tif" /></chemistry></entry></row><row><entry>DB2555</entry><entry><chemistry id="chem0329" num="0329"><img file="EP4603484A2_D0331.tif" /></chemistry></entry></row><row><entry>MD-100</entry><entry><chemistry id="chem0330" num="0330"><img file="EP4603484A2_D0332.tif" /></chemistry></entry></row><row><entry>MD-101</entry><entry><chemistry id="chem0331" num="0331"><img file="EP4603484A2_D0333.tif" /></chemistry></entry></row><row><entry>MD-102</entry><entry><chemistry id="chem0332" num="0332"><img file="EP4603484A2_D0334.tif" /></chemistry></entry></row><row><entry>MD-103</entry><entry><chemistry id="chem0333" num="0333"><img file="EP4603484A2_D0335.tif" /></chemistry></entry></row><row><entry>MD-104</entry><entry><chemistry id="chem0334" num="0334"><img file="EP4603484A2_D0336.tif" /></chemistry></entry></row><row><entry>MD-105</entry><entry><chemistry id="chem0335" num="0335"><img file="EP4603484A2_D0337.tif" /></chemistry></entry></row><row><entry>MD-106</entry><entry><chemistry id="chem0336" num="0336"><img file="EP4603484A2_D0338.tif" /></chemistry></entry></row><row><entry>MD-107</entry><entry><chemistry id="chem0337" num="0337"><img file="EP4603484A2_D0339.tif" /></chemistry></entry></row><row><entry>108</entry><entry><chemistry id="chem0338" num="0338"><img file="EP4603484A2_D0340.tif" /></chemistry></entry></row><row><entry>109</entry><entry><chemistry id="chem0339" num="0339"><img file="EP4603484A2_D0341.tif" /></chemistry></entry></row><row><entry>MD-110</entry><entry><chemistry id="chem0340" num="0340"><img file="EP4603484A2_D0342.tif" /></chemistry></entry></row><row><entry>MD-111</entry><entry><chemistry id="chem0341" num="0341"><img file="EP4603484A2_D0343.tif" /></chemistry></entry></row><row><entry>MD-112</entry><entry><chemistry id="chem0342" num="0342"><img file="EP4603484A2_D0344.tif" /></chemistry></entry></row><row><entry>MD-113</entry><entry><chemistry id="chem0343" num="0343"><img file="EP4603484A2_D0345.tif" /></chemistry></entry></row><row><entry>MD-114</entry><entry><chemistry id="chem0344" num="0344"><img file="EP4603484A2_D0346.tif" /></chemistry></entry></row><row><entry>MD-115</entry><entry><chemistry id="chem0345" num="0345"><img file="EP4603484A2_D0347.tif" /></chemistry></entry></row><row><entry>MD-116</entry><entry><chemistry id="chem0346" num="0346"><img file="EP4603484A2_D0348.tif" /></chemistry></entry></row><row><entry>MD-117</entry><entry><chemistry id="chem0347" num="0347"><img file="EP4603484A2_D0349.tif" /></chemistry></entry></row><row><entry>MD-118</entry><entry><chemistry id="chem0348" num="0348"><img file="EP4603484A2_D0350.tif" /></chemistry></entry></row><row><entry>MD-119</entry><entry><chemistry id="chem0349" num="0349"><img file="EP4603484A2_D0351.tif" /></chemistry></entry></row><row><entry>MD-120</entry><entry><chemistry id="chem0350" num="0350"><img file="EP4603484A2_D0352.tif" /></chemistry></entry></row><row><entry>MD-123</entry><entry><chemistry id="chem0351" num="0351"><img file="EP4603484A2_D0353.tif" /></chemistry></entry></row><row><entry>MD-124</entry><entry><chemistry id="chem0352" num="0352"><img file="EP4603484A2_D0354.tif" /></chemistry></entry></row><row><entry>MD-125</entry><entry><chemistry id="chem0353" num="0353"><img file="EP4603484A2_D0355.tif" /></chemistry></entry></row><row><entry>MD-126</entry><entry><chemistry id="chem0354" num="0354"><img file="EP4603484A2_D0356.tif" /></chemistry></entry></row><row><entry>MD-127</entry><entry><chemistry id="chem0355" num="0355"><img file="EP4603484A2_D0357.tif" /></chemistry></entry></row><row><entry>MD-128</entry><entry><chemistry id="chem0356" num="0356"><img file="EP4603484A2_D0358.tif" /></chemistry></entry></row></tbody></tgroup></table></tables>

0401Bacteria strains (as indicated in Table 5B) were cultured with rifampicin at various concentrations in the presence or absence of 10 µM of the indicated compound for 20 h at 37 °C. The MIC, sensitization, cytotoxicity, and MIC on mycobacteria were tested according to methods described herein. As described herein, the sensitization fold refers to the ability of the compound to lower the MIC of the antibiotic (e.g., rifampicin or erythromycin) on certain bacteria strains. The sensitization activities of compounds on B. subtilis were tested using erythromycin. The sensitization activities of compounds on MRSA were tested using rifampicin. The sensitization activities of compounds on E . coli were tested using rifampicin. The results are shown in Table 5B. <tables id="tabl0006" num="0006"><img file="EP4603484A2_D0359.tif" /></tables><tables id="tabl0007" num="0007"><img file="EP4603484A2_D0360.tif" /></tables><tables id="tabl0008" num="0008"><img file="EP4603484A2_D0361.tif" /></tables><tables id="tabl0009" num="0009"><img file="EP4603484A2_D0362.tif" /></tables><tables id="tabl0010" num="0010"><img file="EP4603484A2_D0363.tif" /></tables><tables id="tabl0011" num="0011"><img file="EP4603484A2_D0364.tif" /></tables><tables id="tabl0012" num="0012"><img file="EP4603484A2_D0365.tif" /></tables><tables id="tabl0013" num="0013"><img file="EP4603484A2_D0366.tif" /></tables><tables id="tabl0014" num="0014"><img file="EP4603484A2_D0367.tif" /></tables><tables id="tabl0015" num="0015"><img file="EP4603484A2_D0368.tif" /></tables><tables id="tabl0016" num="0016"><img file="EP4603484A2_D0369.tif" /></tables><tables id="tabl0017" num="0017"><img file="EP4603484A2_D0370.tif" /></tables><tables id="tabl0018" num="0018"><img file="EP4603484A2_D0371.tif" /></tables><tables id="tabl0019" num="0019"><img file="EP4603484A2_D0372.tif" /></tables>

0402Select data from Table 5B are described below (Table 6).

0403Sensitization fold of 10 µM compounds was tested on bacteria using rifampicin as the antibiotic; IC50 was tested on HEK293 cells. MD-129, 113,102,106 and 112 showed no sensitization activity at up to 10 µM. <chemistry id="chem0357" num="0357"><img file="EP4603484A2_D0373.tif" /></chemistry>

0404E. coli was cultured with rifampicin at various concentrations in the presence or absence of 5 µg/ml MD-124 for 20 h at 37 °C. Then bacterial growth density was determined by measuring OD600. Several compounds were capable of sensitizing E.coli towards narrow-spectrum antibiotics, with some by 32-fold at 10 µg/ml or less (Table 7). <tables id="tabl0020" num="0020"><table frame="all"><title>Table 6</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="18mm" align="center" /><colspec colnum="2" colname="col2" colwidth="32mm" align="center" /><colspec colnum="3" colname="col3" colwidth="21mm" align="center" /><thead valign="top"><row><entry /><entry>Sensitization fold</entry><entry>IC50 (µM)</entry></row></thead><tbody><row><entry>MD-100</entry><entry>8</entry><entry>100</entry></row><row><entry>MD-125</entry><entry>8</entry><entry>100</entry></row><row><entry>MD-109</entry><entry>8</entry><entry>100</entry></row><row><entry>MD-103</entry><entry>2</entry><entry>100</entry></row><row><entry>MD-126</entry><entry>2</entry><entry>100</entry></row><row><entry>MD-124</entry><entry>512</entry><entry>100</entry></row><row><entry>MD-120</entry><entry>32</entry><entry>100</entry></row><row><entry>MD-108</entry><entry>16</entry><entry>50</entry></row><row><entry>MD-117</entry><entry>32</entry><entry>25~50</entry></row><row><entry>MD-105</entry><entry>16</entry><entry>25~50</entry></row><row><entry>MD-123</entry><entry>256</entry><entry>25</entry></row><row><entry>MD-115</entry><entry>256</entry><entry>25~50</entry></row></tbody></tgroup></table></tables>

0405BW-MD-124 (MD-124) showed superior bacterial sensitization activities and was chosen for further biological evaluation (<figref idref="f0001">Figure 1A</figref>). MD-124 at a concentration of 5 µg/ml was able to sensitize E. coli toward rifampicin by 512-fold, lowering the MIC of rifampicin from 10 to 0.02 µg/ml (<figref idref="f0001">Figure 1B</figref>).E. coli (5 × 105 CFUs/ml) was then cultured in the absence and presence of 5 µg/ml MD-124 and OD600 at different time points were recorded. MD-124 itself at the same concentration showed no effect on bacterial growth (<figref idref="f0002">Figure 1C</figref>). These results demonstrate that MD-124 has no direct bacteriostatic effect and works as adjuvant to other antibiotics. <tables id="tabl0021" num="0021"><table frame="all"><title>Table 7</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="32mm" /><colspec colnum="2" colname="col2" colwidth="86mm" /><colspec colnum="3" colname="col3" colwidth="30mm" /><colspec colnum="4" colname="col4" colwidth="15mm" /><thead valign="top"><row><entry>Compound Name</entry><entry>Structure</entry><entry>Sensitization fold</entry><entry>IC50</entry></row></thead><tbody><row><entry>DB2560 (MD-100)</entry><entry><chemistry id="chem0358" num="0358"><img file="EP4603484A2_D0374.tif" /></chemistry></entry><entry>32a</entry><entry>100 µM</entry></row><row><entry>DB1213</entry><entry><chemistry id="chem0359" num="0359"><img file="EP4603484A2_D0375.tif" /></chemistry></entry><entry>32a</entry><entry>50 µM</entry></row><row><entry>DB 1079</entry><entry><chemistry id="chem0360" num="0360"><img file="EP4603484A2_D0376.tif" /></chemistry></entry><entry>64b</entry><entry>12 µM</entry></row><row><entry>DB704</entry><entry><chemistry id="chem0361" num="0361"><img file="EP4603484A2_D0377.tif" /></chemistry></entry><entry>16a</entry><entry>100 µM</entry></row><row><entry namest="col1" nameend="col4" align="left">Sensitization fold was tested on E.coli using rifampicin as antibiotic. a: 10 µg/ml bacterial sensitizer was used; b: 5 µg/ml bacterial sensitizer was used</entry></row></tbody></tgroup></table></tables>

0406A checkerboard assay shows that MD-124 sensitizes E. coli toward rifampicin in a concentration-dependent manner, reaching over 16,000-fold when ~10 µg/ml MD-124 was used with a MIC of rifampicin being 0.6 ng/ml (<figref idref="f0002">Figure 1D</figref>). The fractional inhibitory concentration (FIC) index was calculated to be 0.09 based on the checkerboard assay (The MIC of MD-124 itself on E. coli is 50 µg/ml), indicating the strong synergistic effect between MD-124 and rifampicin. The sensitization ability of MD-124 changed drastically in the range of 3 to 12 µg/ml, and as a result, a checkerboard assay of MD-124 varying from 0 to 10 µg/ml was performed (<figref idref="f0003">Figure 1E</figref>). 5 µg/ml MD-124 sensitizes E. coli toward a broad range of existing antibiotics including narrow spectrum antibiotics such as clarithromycin (256-fold), erythromycin (128-fold), novobiocin (64-fold) and broad-spectrum antibiotics like trovafloxacin (32-fold), polymyxin B (32-fold) and chloramphenicol (8-fold) (<figref idref="f0005">Figure 1H</figref>and Table 8). A greater sensitization fold was achieved when MD-124 was used with narrow-spectrum antibiotics than broad-spectrums. When combined with MD-124, the MIC of various narrow-spectrum antibiotics tested was lowered to around 1 µg/ml or below, which is similar to the MIC with broad-spectrum antibiotics on E. coli(<figref idref="f0005">Figure 1H</figref>and Table 8). Compared with previously discovered bacterial sensitizers such as pentamidine and polymyxin B nonapeptide (PMBN), MD-124 showed much more potent sensitization activity (<figref idref="f0004">Figure 1G</figref>). For example, 20 µg/ml pentamidine and PMBN were shown to sensitize E.coli towards rifampicin by 4 and 16 -fold respectively, while 5 µg/ml MD-124 was able to sensitize by 512-fold. Besides E. coli, MD-124 also showed sensitization effect in various other Gram-negative bacterial strains such as A. baumannii, K. pneumoniae and S. typhimurium, the resistant strains of which are listed as WHO priority 1 pathogens in urgent need of new antibiotics (<figref idref="f0003">Figure 1F</figref>).<tables id="tabl0022" num="0022"><table frame="all"><title>Table 8</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="30mm" /><colspec colnum="2" colname="col2" colwidth="29mm" align="center" /><colspec colnum="3" colname="col3" colwidth="42mm" align="center" /><colspec colnum="4" colname="col4" colwidth="31mm" align="center" /><thead valign="top"><row><entry align="center">Antibiotics (AB)</entry><entry>MIC of AB only</entry><entry>MIC of AB with MD-124</entry><entry>Sensitization fold</entry></row></thead><tbody><row><entry align="center">Rifampicin</entry><entry>10</entry><entry>0.019</entry><entry>516</entry></row><row><entry align="center">Rifapentine</entry><entry>25</entry><entry>0.8</entry><entry>32</entry></row><row><entry align="center">Rifaximin</entry><entry>12.5</entry><entry>0.2</entry><entry>64</entry></row><row><entry align="center">Clarithromycin</entry><entry>50</entry><entry>0.2</entry><entry>256</entry></row><row><entry align="center">Erythromycin</entry><entry>50</entry><entry>0.4</entry><entry>128</entry></row><row><entry align="center">Azithromycin</entry><entry>6.2</entry><entry>0.4</entry><entry>16</entry></row><row><entry align="center">Novobiocin</entry><entry>100</entry><entry>1.6</entry><entry>64</entry></row><row><entry align="center">Clindamycin</entry><entry>200</entry><entry>3.2</entry><entry>64</entry></row><row><entry align="center">Fusidic acid</entry><entry>>200</entry><entry>6.25</entry><entry>32</entry></row><row><entry align="center">Polymyxin B</entry><entry>1.2</entry><entry>0.04</entry><entry>32</entry></row><row><entry align="center">Chloramphenicol</entry><entry>12.5</entry><entry>1.6</entry><entry>8</entry></row><row><entry align="center">Trovafloxacin</entry><entry>0.05</entry><entry>0.0015</entry><entry>32</entry></row><row><entry align="center">Besifloxacin</entry><entry>0.1</entry><entry>0.0125</entry><entry>8</entry></row><row><entry align="center">Moxifloxacin</entry><entry>0.05</entry><entry>0.0062</entry><entry>8</entry></row><row><entry align="center">Levofloxacin</entry><entry>0.05</entry><entry>0.0062</entry><entry>8</entry></row><row><entry align="center">Ciprofloxacin</entry><entry>0.05</entry><entry>0.0125</entry><entry>4</entry></row><row><entry align="center">Nafcillin</entry><entry>>300</entry><entry>75</entry><entry>>4</entry></row><row><entry align="center">Cloxacillin</entry><entry>>300</entry><entry>75</entry><entry>>4</entry></row><row><entry align="center">Meropenem</entry><entry>0.063</entry><entry>0.063</entry><entry>1</entry></row><row><entry align="center">Tetracycline</entry><entry>1.2</entry><entry>0.6</entry><entry>2</entry></row><row><entry align="center">Trimethoprim</entry><entry>2.5</entry><entry>1.25</entry><entry>2</entry></row><row><entry namest="col1" nameend="col4" align="left">Unit for AB: µg/ml; MD-124 concentration: 5 µg/ml.</entry></row></tbody></tgroup></table></tables>

Resistance Frequency of MD-124

0407Because bacteria can quickly develop resistance to new antimicrobial agents, the frequency of resistance development for E. coli towards MD-124 was evaluated. Briefly, E. coli was cultured with various concentrations of antibiotic (2 to 7-fold of MIC) in the presence and absence of 10 µg/ml MD-124. Then, the bacterial resistance frequency towards MD-124/antibiotic combination and antibiotic itself was calculated (<figref idref="f0007">Figure 2D</figref>).E. coli showed 2 to 3 orders of magnitude lower resistance frequency towards MD-124/antibiotic combination than the antibiotic itself (<figref idref="f0006 f0007">Figure 2</figref>). For colonies that were resistant MD-124 and antibiotic combination, there is a need to determine whether the resistant strains were resistant to MD-124 or antibiotics used in the combination. As a result, the combination therapy resistant colonies were then subjected to another antibiotic combination: MD-124 and rifampicin (<figref idref="f0006">Figure 2B</figref>). MD-124 was still effective in sensitizing those strains towards rifampicin with the same potency as on wild-type E. coli. Such results demonstrate that these resistant strains are not resistant to MD-124. No strain was found to be resistant to 10 µg/ml MD-124 out of 2.7 × 1010 CFUs, giving a resistant frequency of < 1/2.7 × 1010 (< 3.7 ×10-11). The resistance frequency here is not defined based on direct inhibition/bactericidal effect like the case of traditional antibiotics but based on the sensitization effect of MD-124. These studies show: 1) MD-124 is able to lower the resistant frequency of bacteria towards antibiotics when used in combination; 2) bacteria show lower resistant frequency towards MD-124 than toward the antibiotic; and 3) even bacteria showing resistance towards one type of antibiotic/ MD-124 combination, a simple switch to another antibiotic/MD-124 combination would re-gain the sensitization effectiveness towards the resistant strains.

Mechanism of Bacterial Sensitization Activity

0408The mechanism of the bacterial sensitization activity was then investigated. Because MD-124 can sensitize Gram-negative bacterial towards a broad range of antibiotics and the outer membrane is the major barrier of antibiotic uptake, MD-124's ability to disrupt bacterial outer membrane was determined (<figref idref="f0008">Figure 3A</figref>). MD-124 and MD-100 were used to study the sensitization mechanisms. MD-124 showed compromised ability to sensitize an outer membrane "leaky" mutant of E. coli strain NR698 (<figref idref="f0008">Figure 3B</figref>), which is already susceptible to narrow-spectrum antibiotics such as clarithromycin and erythromycin. MD-124 at a concentration of 5 µg/ml was shown to sensitize wild-type E. coli towards clarithromycin by 256-fold, and NR698 by 4-fold. The same phenomenon was observed when MD-100 was used on wild-type and NR698 E. coli(<figref idref="f0018">Figure 7</figref>). Such results demonstrate if a bacterial strain already has increased permeability because of compromised outer membrane integrity, the sensitization ability of MD-124 and MD-100 would be diminished. This is consistent with the sensitization mechanism of MD-124 being on the bacterial outer membrane. The disruption of bacterial outer membrane by MD-124 through the lysozyme assay was then determined. Briefly, lysozyme (14 KDa) can break down peptidoglycan and lead to bacterial lysis. However, lysozyme cannot penetrate intact Gram-negative bacterial outer membrane. With impaired Gram-negative bacterial membrane, lysozyme would be able to diffuse across the disrupted membrane and enzymatically cleave peptidoglycan, leading to bacterial lysis. In the presence of 25 µg/ml MD-124 or 50 µg/ml MD-100, lysozyme resulted in quick bacterial lysis while in the absence of the sensitizer, no cell lysis was observed (<figref idref="f0009">Figure 3C</figref>, left histogram in each pair). MD-124 and MD-100 themselves did not lead to bacterial lysis (<figref idref="f0009">Figure 3C</figref>, right histogram in each pair). These results indicate that MD-124 was able to disrupt membrane integrity. 25 µg/ml polymyxin B and 50 µg/ml pentamidine, which were used here as positive controls, also led to bacterial lysis when incubated together with lysozyme. 25 µg/ml MD-124 showed a similar potency as 25 µg/ml polymyxin B and was much more potent than 50 µg/ml pentamidine in disrupting bacterial outer membrane. The results also showed a positive correlation between the ability of the various bacterial sensitizers to disrupt outer membrane in the lysozyme assay and their ability to sensitize E. coli towards rifampicin (<figref idref="f0009">Figure 3D</figref>, the structure and sensitization fold of those bacterial sensitizers can be found in Scheme 1 and Table 6). Outer membrane disruption ability was based on lysozyme assay as described above and all bacterial sensitizer were used same concentration. 25 µg/ml bacterial sensitizers were used in the lysozyme assay. The bacterial sensitization activity was measured based on the sensitization fold on E.coli towards rifampicin, which was listed in detail in Table 1. MD-102,106 and 129 fails to sensitize E.coli, thus the sensitization fold was determined as 1.

0409Next, the intracellular concentration of an antibiotic in the presence and absence of MD-100 were compared to assess membrane permeabilization by MD-100. The concentration of antibiotic inside the bacteria was directly measured by analyzing bacterial lysates using HPLC after treatment with and without MD-100. As shown in <figref idref="f0010">Figure 3E</figref>, the relative intracellular concentration of an inactive novobiocin analog (O-methyl novobiocin, Scheme 2) was greatly increased in the presence MD-100. O-Methyl novobiocin, which is inactive, was used in order to avoid bacterial killing after intracellular enrichment. Collectively, these results show that MD-124 sensitizes bacteria by permeabilizing membrane and allowing for increased antibiotic entry. <chemistry id="chem0362" num="0362"><img file="EP4603484A2_D0378.tif" /></chemistry>

Molecular Mechanistic Studies of Bacterial Sensitizers

0410Various experiments were then conducted to examine the molecular target(s). Adding extra LPS to the culture media abolished the sensitization effect of MD-124 and MD-100 (<figref idref="f0011">Figure 4A</figref>, Table 9 and<figref idref="f0018">Figure 7B</figref>). Briefly, E. coli was treated with 5 µg/ml MD-124 (about 10 µM) with varying concentrations of LPS (from 0 to 40 µM) for 20 h. Then OD600 was measured. The MIC of rifampicin only is 10 µg/ml. <tables id="tabl0023" num="0023"><table frame="all"><title>Table 9</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="43mm" /><colspec colnum="2" colname="col2" colwidth="75mm" align="center" /><colspec colnum="3" colname="col3" colwidth="45mm" align="center" /><thead valign="top"><row><entry align="center">LPS conc. (µM)</entry><entry>MIC of rifampicin with 5 µg/ml MD-124</entry><entry>Sensitization fold</entry></row></thead><tbody><row><entry align="center">0</entry><entry>0.02</entry><entry>512</entry></row><row><entry align="center">2.5</entry><entry>1.25</entry><entry>8</entry></row><row><entry align="center">5</entry><entry>2.5</entry><entry>4</entry></row><row><entry align="center">10</entry><entry>2.5</entry><entry>4</entry></row><row><entry align="center">20</entry><entry>5</entry><entry>2</entry></row><row><entry align="center">40</entry><entry>5</entry><entry>2</entry></row><row><entry namest="col1" nameend="col3" align="left">Sensitization fold = MIC of rifampicin only /MIC of rifampicin with 10 µM MD-124 in the presence or absence of LPS.</entry></row></tbody></tgroup></table></tables>

0411Mg2+ dampened the bacterial sensitization activity of MD-124 on E. coli in a concentration dependent manner (<figref idref="f0011">Figure 4B</figref>, Table 10). Briefly, E.coli was treated with 5 µg/ml MD-124 (about 10 µM) with varying concentrations of Mg2+ (from 0 to 15 mM) for 20 h. Then OD600 was measured. The MIC of rifampicin only is 10 µg/ml.

0412Mg2+ can bridge between adjacent lipid A and enhance the membrane integrity. Thus, high concentrations of this divalent cation may displace the diamidine and thus exert antagonistic effects against MD-124. This phenomenon was also observed on MD-100. The culture medium for E.coli is Muller Hinton Broth (Cation adjusted), which already has at least 0.5 mM Mg2+, so the "zero concentration point of Mg2+" in <figref idref="f0011">Figure 4B</figref> represents the amount of exogenous Mg2+, not the total Mg2+ in the culture medium. The free magnesium concentration in human blood is between 0.55~0.75 mM, indicating that physiological concentrations of Mg2+ would not affect the sensitization ability of MD-124. A fluorescent conjugate of a polymyxin-B derivative (Dansyl-PMBN, Scheme 3), which would show increased fluorescent intensity after binding to the lipid A part of LPS, was used to further probe this issue. In the presence of another component that can also binding to lipid A, Dansyl-PMBN would be replaced, leading to decreased fluorescent intensity. <tables id="tabl0024" num="0024"><table frame="all"><title>Table 10</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="39mm" /><colspec colnum="2" colname="col2" colwidth="77mm" align="center" /><colspec colnum="3" colname="col3" colwidth="47mm" align="center" /><thead valign="top"><row><entry align="center">Mg2+ (mM)</entry><entry>MIC of rifampicin with 5 µg/ml MD-124</entry><entry>Sensitization fold</entry></row></thead><tbody><row><entry align="center">0</entry><entry>0.02</entry><entry>512</entry></row><row><entry align="center">1.25</entry><entry>0.02</entry><entry>512</entry></row><row><entry align="center">2.5</entry><entry>0.04</entry><entry>256</entry></row><row><entry align="center">5</entry><entry>1.25</entry><entry>8</entry></row><row><entry align="center">10</entry><entry>2.5</entry><entry>4</entry></row><row><entry align="center">15</entry><entry>5</entry><entry>2</entry></row><row><entry namest="col1" nameend="col3" align="left">Sensitization fold = MIC of rifampicin only /MIC of rifampicin with 10 µM MD-124 in the presence or absence of Mg2+.</entry></row></tbody></tgroup></table></tables><chemistry id="chem0363" num="0363"><img file="EP4603484A2_D0379.tif" /></chemistry>

0413With the incremental addition of MD-124 to a mixture of E. coli and 10 µM Dansyl-PMBN, the fluorescent intensity of Dansyl-PMBN steadily decreased in a concentration dependent fashion, indicating binding of MD-124 to lipid A (<figref idref="f0012">Figure 4C</figref>). Pentamidine and MD-100 were also able to displace Dansyl-PMBN although not as much as MD-124. A mutant of the lipid A strain was constructed with an over-expression mobilized colistin resistance -1 (mcr-1) gene, which would modify the phosphate group on lipid A, induce decreased negative charge density on Gram-negative bacteria outer membrane and lead to the resistance to colistin.26,27 Two mcr-1 over-expressing strains, mcr-1 A and mcr-1 B were used to test the response of MD-124 towards the modified lipid A. The MIC of polymyxin B on these two strains were 10 and 30 µg/ml respectively, while the MIC on the wild type was 1.2 µg/ml (Table 11).<tables id="tabl0025" num="0025"><table frame="all"><title>Table 11</title><tgroup cols="7"><colspec colnum="1" colname="col1" colwidth="15mm" /><colspec colnum="2" colname="col2" colwidth="24mm" align="center" /><colspec colnum="3" colname="col3" colwidth="21mm" align="center" /><colspec colnum="4" colname="col4" colwidth="23mm" align="center" /><colspec colnum="5" colname="col5" colwidth="28mm" align="center" /><colspec colnum="6" colname="col6" colwidth="23mm" align="center" /><colspec colnum="7" colname="col7" colwidth="28mm" align="center" /><thead valign="top"><row><entry align="center">Strains</entry><entry>MIC of Rif polymyxin B ( µg/ml)</entry><entry>MIC of Rif only ( µg/ml)</entry><entry>MIC of Rif with 3 µg/ml MD-124</entry><entry>Sensitization fold with 3 µg/ml MD-124</entry><entry>MIC of Rif with 5 µg/ml MD-124</entry><entry>Sensitization fold with 5 µg/ml MD-124</entry></row></thead><tbody><row><entry>mcr-1 A</entry><entry>10</entry><entry>5</entry><entry>0.32</entry><entry>16</entry><entry>NA</entry><entry>NA</entry></row><row><entry>mcr-1 B</entry><entry>30</entry><entry>5</entry><entry>1.25</entry><entry>4</entry><entry>0.16</entry><entry>32</entry></row></tbody></tgroup></table></tables>

0414While 3 µg/ml MD-124 sensitized wild type E. coli towards rifampin by 16-fold, it was only able to sensitize mcr-1 B strain by 4-fold, and 5 µg/ml MD-124 were required to re-gain 32-fold sensitization on mcr-1 B strain (Figure 4E). This showed decreased activity for MD-124 when lipid A was modified, supporting lipid A being the molecular target of MD-124. It is worth mentioning that 3 µg/ml MD-124 was still able to sensitize mcr-1 A (MIC 10 µg/ml) strains towards rifampin by 32-fold, which means mcr-1 stains with this level of resistance of polymyxin B did not achieve resistance towards MD-124 (Figure 4E). The clinical isolated mcr-1 over-expressing strains usually have a MIC of 10 µg/ml or below for polymyxin B, indicating MD-124's effectiveness on clinical those strains. Even those mcr-1 strains that showed greater resistance towards polymyxin B (MIC 30 µg/ml) only induced mild resistance towards MD-124, raising the concentration required for 32-fold sensitization from 3 to 5 µg/ml. Collectively, these results not simply demonstrate that lipid A is the molecular target of MD-124, but also suggest a therapeutic potential of MD-124 in the fight colistin resistant bacteria induced by mcr-1. MD-124 was also found to sensitize mcr-1 over-expressing stains towards many other antibiotics besides rifampicin (Table 16).

0415The sensitization effect of MD-124 on various clinically relevant strains and drug-resistant strains, especially the Gram-negative bacteria in ESKAPE category of pathogens, was then examined. Checkerboard assays revealed MD-124 was able to sensitize A. baumannii towards rifampicin, decreasing the MIC from 5 µg/ml to 0.04 and 0.01 µg/ml when 5 and 7 µg/ml of the sensitizer were used respectively (<figref idref="f0013">Figure 5A</figref>). The FIC index between MD-124 and rifampicin was calculated to be 0.14. Similar sensitization effect on A. baumannii was also observed with novobiocin through a checkerboard assay and the FIC index between MD-124 and novobiocin was determined to be 0.20 (<figref idref="f0013">Figure 5B</figref>). 5 µg/ml MD-124 also sensitized A. baumannii towards a variety of other antibiotics such as clarithromycin, fusidic acid and clindamycin, achieving 64, 128 and 8-fold sensitizations, respectively (Table 12).<tables id="tabl0026" num="0026"><table frame="all"><title>Table 12</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="29mm" /><colspec colnum="2" colname="col2" colwidth="27mm" align="center" /><colspec colnum="3" colname="col3" colwidth="52mm" align="center" /><colspec colnum="4" colname="col4" colwidth="55mm" align="center" /><thead valign="top"><row><entry align="center">Antibiotics (AB)</entry><entry>MIC of AB only</entry><entry>MIC of AB with 5 µg/ml MD-124</entry><entry>Sensitization fold with 5 µg/ml MD-124</entry></row></thead><tbody><row><entry align="center">Rifampicin</entry><entry>5</entry><entry>0.04</entry><entry>128</entry></row><row><entry align="center">Clarithromycin</entry><entry>25</entry><entry>0.4</entry><entry>64</entry></row><row><entry align="center">Novobiocin</entry><entry>25</entry><entry>0.8</entry><entry>32</entry></row><row><entry align="center">Fusidic acid</entry><entry>50</entry><entry>0.4</entry><entry>128</entry></row><row><entry align="center">Clindamycin</entry><entry>100</entry><entry>12.5</entry><entry>8</entry></row><row><entry align="center">Polymyxin B</entry><entry>1.6</entry><entry>0.04</entry><entry>4</entry></row><row><entry align="center">Chloramphenicol</entry><entry>100</entry><entry>25</entry><entry>4</entry></row><row><entry align="center">Ciprofloxacin</entry><entry>0.05</entry><entry>0.0125</entry><entry>4</entry></row><row><entry align="center">Trimethoprim</entry><entry>25</entry><entry>12.5</entry><entry>2</entry></row><row><entry align="center">Tetracycline</entry><entry>1.2</entry><entry>0.6</entry><entry>2</entry></row><row><entry align="center">Trovafloxacin</entry><entry>0.032</entry><entry>0.016</entry><entry>2</entry></row><row><entry align="center">Kanamycin</entry><entry>12.5</entry><entry>0.62</entry><entry>2</entry></row><row><entry align="center">Nafcillin</entry><entry>200</entry><entry>100</entry><entry>2</entry></row><row><entry namest="col1" nameend="col4" align="left">Unit for AB: µg/ml; MIC of MD-124 on A. baumannii is 25 µg/ml.</entry></row></tbody></tgroup></table></tables>

0416Another ESKAPE pathogens - K. pneumoniae, was also susceptible to MD-124. As shown in <figref idref="f0013 f0014 f0015">Figure 5</figref>C and D, MD-124 was able to sensitize K. pneumoniae towards rifampicin and clarithromycin by 512-fold or more; 10 µg/ml of MD-124 brought the MIC of rifampicin and clarithromycin from more than 20 µg/ml to 0.2 µg/ml or less. FIC index between MD-124 and rifampicin or clarithromycin was determined to be 0.15 and 0.16, respectively. Many other antibiotics can also be combined with 5 µg/ml MD-124 such as clindamycin, chloramphenicol, fusidic acid and novobiocin to inhibit K. pneumoniae growth (Table 13).<tables id="tabl0027" num="0027"><table frame="all"><title>Table 13</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="29mm" /><colspec colnum="2" colname="col2" colwidth="27mm" align="center" /><colspec colnum="3" colname="col3" colwidth="52mm" align="center" /><colspec colnum="4" colname="col4" colwidth="55mm" align="center" /><thead valign="top"><row><entry align="center">Antibiotics (AB)</entry><entry>MIC of AB only</entry><entry>MIC of AB with 5 µg/ml MD-124</entry><entry>Sensitization fold with 5 µg/ml MD-124</entry></row></thead><tbody><row><entry align="center">Rifampicin</entry><entry>40</entry><entry>0.016</entry><entry>252</entry></row><row><entry align="center">Clarithromycin</entry><entry>200</entry><entry>0.8</entry><entry>252</entry></row><row><entry align="center">Novobiocin</entry><entry>200</entry><entry>6.4</entry><entry>32</entry></row><row><entry align="center">Chloramphenicol</entry><entry>>100</entry><entry>1.6</entry><entry>>64</entry></row><row><entry align="center">Clindamycin</entry><entry>>200</entry><entry>25</entry><entry>>8</entry></row><row><entry align="center">Fusidic acid</entry><entry>100</entry><entry>25</entry><entry>4</entry></row><row><entry namest="col1" nameend="col4" align="left">Unit for AB: µg/ml; MIC of MD-124 on K. pneumoniae is 25 µg/ml.</entry></row></tbody></tgroup></table></tables>

0417Carbapenem-resistant Enterobacteriaceae is causing rising concerns and is listed as WHO priority 1 pathogens for R&D of new antibiotics. To test the effect of MD-124 on carbapenem-resistant bacteria, NDM-1 expressing E. coli strain was constructed to induce carbapenem-resistance. Compared with wild-type, NDM-1 expressing E. coli strain showed a 30 to 100-fold increase of MIC towards β-lactam antibiotics such as ampicillin, ceftazidime and carbapenem antibiotics meropenem (Table 14 and Table 12). <tables id="tabl0028" num="0028"><table frame="all"><title>Table 14</title><tgroup cols="3"><colspec colnum="1" colname="col1" colwidth="23mm" align="center" /><colspec colnum="2" colname="col2" colwidth="52mm" align="center" /><colspec colnum="3" colname="col3" colwidth="75mm" align="center" /><thead valign="top"><row><entry>Antibiotics</entry><entry>MIC on wild-type E.coli (µg/ml)</entry><entry>MIC on NDM-1 over-expression E.coli (µg/ml)</entry></row></thead><tbody><row><entry>Ampicillin</entry><entry>6</entry><entry>> 300</entry></row><row><entry>Ceftazidime</entry><entry>< 0.2</entry><entry>> 6.25</entry></row><row><entry>Meropenem</entry><entry>0.03</entry><entry>12.5</entry></row></tbody></tgroup></table></tables>

0418NDM-1 expressing E. coli strain did not show significant changes in MIC towards other family of antibiotics compared with the wild type (Table 15 vs Table 8). MD-124 was able to sensitize NDM-1 expressing E. coli strain with the same potency as for the wild-type E.coli. MD-124 sensitized NDM-1 expressing E. coli towards rifampicin in a concentration-dependent manner, decrease the MIC from 10 to 0.02 and 0.012 µg/ml when 5 and 10 µg/ml were used (<figref idref="f0015">Figure 5E</figref>). MD-124 also showed synergistic effect with rifampicin as the FIC index calculated to be 0.09. MD-124 sensitized carbapenem-resistant E. coli towards other narrow-spectrum antibiotics such as clarithromycin, novobiocin and broad-spectrum such as trovafloxacin, chloramphenicol (Table 15).<tables id="tabl0029" num="0029"><table frame="all"><title>Table 15</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="29mm" align="center" /><colspec colnum="2" colname="col2" colwidth="27mm" align="center" /><colspec colnum="3" colname="col3" colwidth="52mm" align="center" /><colspec colnum="4" colname="col4" colwidth="55mm" align="center" /><thead valign="top"><row><entry>Antibiotics (AB)</entry><entry>MIC of AB only</entry><entry>MIC of AB with 5 µg/ml MD-124</entry><entry>Sensitization fold with 5 µg/ml MD-124</entry></row></thead><tbody><row><entry>Rifampicin</entry><entry>10</entry><entry>0.02</entry><entry>516</entry></row><row><entry>Clarithromycin</entry><entry>25</entry><entry>0.4</entry><entry>64</entry></row><row><entry>Novobiocin</entry><entry>50</entry><entry>1.6</entry><entry>32</entry></row><row><entry>Clindamycin</entry><entry>200</entry><entry>3.2</entry><entry>64</entry></row><row><entry>Trovafloxacin</entry><entry>0.025</entry><entry>0.0008</entry><entry>32</entry></row><row><entry>Chloramphenicol</entry><entry>12.5</entry><entry>1.6</entry><entry>8</entry></row><row><entry>Polymyxin B</entry><entry>2.5</entry><entry>0.32</entry><entry>8</entry></row><row><entry>Tetracycline</entry><entry>12.5</entry><entry>3.2</entry><entry>4</entry></row><row><entry>Meropenem</entry><entry>12.5</entry><entry>6.2</entry><entry>2</entry></row><row><entry>Ampicillin</entry><entry>>300</entry><entry>300</entry><entry>>1</entry></row><row><entry namest="col1" nameend="col4" align="center">Unit for AB: µg/ml; MIC of MD-124 on NDM-1 expressing E.coli is 50 µg/ml.</entry></row></tbody></tgroup></table></tables>

0419Polymyxin and colistin-resistant strains induced by mcr-1 gene are threatening the last line of defense of antimicrobial treatment. It was observed that MD-124 sensitized mcr-1 expressing E. coli (MIC of polymyxin B is 30 µg/ml) towards rifampicin and several other antibiotics (<figref idref="f0015">Figure 5F</figref>, Table 16).<tables id="tabl0030" num="0030"><table frame="all"><title>Table 16</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="26mm" /><colspec colnum="2" colname="col2" colwidth="26mm" align="center" /><colspec colnum="3" colname="col3" colwidth="50mm" align="center" /><colspec colnum="4" colname="col4" colwidth="61mm" align="center" /><thead valign="top"><row><entry align="center">Antibiotics (AB)</entry><entry>MIC of AB only</entry><entry>MIC of AB with 5 µg/ml MD-124</entry><entry>Sensitization fold with 5 µg/ml MD-124</entry></row></thead><tbody><row><entry align="center">Rifampicin</entry><entry>5</entry><entry>0.16</entry><entry>32</entry></row><row><entry align="center">Clarithromycin</entry><entry>25</entry><entry>0.2</entry><entry>128</entry></row><row><entry align="center">Polymyxin B</entry><entry>30</entry><entry>1</entry><entry>30</entry></row><row><entry namest="col1" nameend="col4" align="left">Unit for AB: µg/ml; The MIC of polymyxin B on this mcr-1 over-expression E. coli strain is 30 µg/ml. MIC of MD-124 on this mcr-1 over-expression E. coli is 12.5 µg/ml.</entry></row></tbody></tgroup></table></tables>

0420MD-124 showed synergistic effect with rifampicin on mcr-1 expressing E. coli as the FIC index calculated to be 0.37. It is worth noting that compared with wild-type E. coli, MD-124 showed slightly deceased sensitization ability on this mcr-1 expressing strain (<figref idref="f0002">Figure 1D</figref>vs<figref idref="f0015">Figure 5F</figref>). However, 5 µg/ml MD-124 still brought the MIC of rifampicin and clarithromycin to 0.2 µg/ml or below on this mcr-1 induced polymyxin B resistant strain. Surprisingly, MD-124 sensitized this strain towards polymyxin B, bringing the MIC from 30 to 1 µg/ml. Such results mean that MD-124 was able to convert this polymyxin B resistant strain to a polymyxin B sensitive strain (<figref idref="f0019">Figure 8</figref>).

0421The effect of MD-124 in an ex vivo skin burn infection model was determined. To achieve topical application, compounds were formulated as hypromellose gel. Briefly, human skin (about 1cm × 1cm) was burnt with a soldering iron (95 °C) for 10 s; then 105 CFU E. coli was inoculated to the burnt skin and was cultured at 37 °C for 1 hour. After that, skin was loaded with hypromellose gel with different antibiotics and cultured at 37 °C for 24 hours. After 24 hours incubation, the skin sample was homogenized and the supernatants were serially diluted and plated on agar plates, from which bacterial counts on the skin was calculated. While neither 4‰ (w/w) novobiocin nor 1.5‰ MD-124 themselves achieved significant E. coli growth inhibition, novobiocin and MD-124 combination effectively decreased the bacterial load when compared with vehicle group (<figref idref="f0016">Figure 6A</figref>). 1‰ polymyxin B hypromellose gel was used as positive control. To further investigate the scope and effectiveness of MD-124, a MD-124 and clindamycin combination was tested on drug-resistant Gram-negative bacteria. MD-124 and clindamycin can also effectively treat skin infection caused by NDM-1 expressing E. coli, which reduce the bacteria load for more than 1,000-fold than clindamycin alone (<figref idref="f0016">Figure 6B</figref>). The dosages used are comparable to or lower than the commonly used 0.5 ~ 2% antibiotics in ointment preparations.

0422MD-124 was shown to restore the effectiveness of polymyxin B towards E. coli expressing mcr-1. Specifically, it was investigated whether a MD-124-polymyxin B combination would be effective in treating MCR-1 bacterial infection in this skin-burn model (<figref idref="f0017">Figure 6C</figref>). Polymyxin B alone (3‰, w/w) only had minor effects as compared with vehicle group (<figref idref="f0017">Figure 6C</figref>). In contrast, the MD-124-polymyxin B combination (3‰ (w/w) polymyxin B and 1.5‰ (w/w)) reduced the bacterial load by ~ 200-fold (<figref idref="f0017">Figure 6C</figref>). Taken together, these results showed that the sensitization effect of MD-124 allows the use of narrow-spectrum antibiotics in treating Gram-negative bacterial infection and restores the sensitivity of drug-resistant strains towards tested certain antibiotics.

0423The effect of phosphatidylcholine on MD-124 sensitization activity was also determined. E. coli was treated with 10 µM MD-124 (about 5 µg/ml) and rifampicin combination with varying concentrations of phosphatidylcholine (from 0 to 320 µM) for 20 h at 37 °C, then the OD600 was measured and the sensitization folds were calculated as mentioned above. The results are shown in <figref idref="f0020">Figure 9</figref>.

Example 7. Antibacterial Activity against MRSA

0424The sensitization fold of select compounds described herein on Gram-positive bacteria was determined. <chemistry id="chem0364" num="0364"><img file="EP4603484A2_D0380.tif" /></chemistry>

0425DB2560 (also refered as MD-100 herein and shown above) sensitizes Gram-positive bacteria such as B. subtilis towards traditional antibiotics. The MIC of DB2560 on wild type B. subtilis is 50 µg/ml. As shown in <figref idref="f0021">Figure 10A</figref>,<figref idref="f0013 f0014 f0015">5.5</figref> µg/ml of DB2560 alone (i.e., without any additional antibiotic) failed to significantly impact bacterial growth (80% growth density compared with the control (no treatment) group). The MIC of rifampicin on B. subtilis in the presence of 5.5 µg/ml of DB2560 was 0.037 µg/ml, a concentration at which rifampicin has little inhibition effect. The sensitization fold and FIC index was calculated to be 256-fold and 0.11. The MIC of erythromycin in the presence of and absence of DB2560 was determined to be 1.5 and 50 µg/mL, which gave DB2560 a 32-fold sensitization and a FIC index of 0.14. A concentration of 5.5 µg/ml DB2560 sensitizes B. subtilis towards a wide range of antibiotics with distinct anti-microbial mechanisms, such as clindamycin (16-fold), clarithromycin (32-fold), novobiocin (4-fold), methicillin (4-fold), entrapenem (4-fold), trovafloxacin (8-fold).

0426The fact that DB2560 significantly sensitizes B. subtilis towards rifampicin, erythromycin and clindamycin indicates Gram-positive bacteria membrane are a very effective barrier for those antibiotics. DB2560, at a concentration of 2.7 µg/ml, sensitized MRSA towards existing antibiotics such as rifampicin (32-fold) (<figref idref="f0021">Figure 10B</figref>) and trovafloxacin (16-fold). Rifampicin is the first line of defense against MRSA and many MRSA strains become resistant to rifampicin through overexpression of efflux pumps and other mechanisms. The combination of the bacterial sensitizers as described herein, such as DB2560, and rifampicin can be used more as a more effective therapeutic against MRSA.

0427The MIC of many antibiotics such as erythromycin, rifampicin, and trovafloxacin on MRSA is significantly higher than wild type E. coli, which means even narrow-spectrum antibiotics such as rifampicin, a first-line of defense of MRSA, can cause severe collateral damage to benign Gram-negative bacteria like E. coli before it can kill MRSA. As a proof of concept, the relative ratio of E. coli and MRSA or B. subtilis and MRSA was measured with and without MD-108 (<figref idref="f0022">Figure 11A and B</figref>). Trovafloxacin (16 ng/ml) would prefer the inhibition of E. coli, leaving MRSA the dominant species (78% of the bacteria population). When supplied with 1.5 µg/ml MD-108 and 8 ng/ml trovafloxacin, the MRSA inhibition was achieved, leaving E. coli as the dominant species (89% of the bacteria population). Under 16 ng/ml trovafloxacin, the relative survival ratio between B. subtilis and MRSA is 1:1, while under 8 ng/ml trovafloxacin and 1.5 µg/ml MD-108, B. subtilis would dominate the composition (99.5 %).

0428Although the foregoing invention has been described in some detail by way of illustration and example for the purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teaching of this invention that certain changes and modifications may be made thereto without departing from the spirit and scope of the invention as defined in the appended.

CLAUSETHE PRESENT INVENTION CAN FURTHER BE DESCRIBED BY THE FOLLOWING CLAUSES:

0429<ol id="ol0002"><li>1. A compound of Formula I <chemistry id="chem0365" num="0365"><img file="EP4603484A2_D0381.tif" /></chemistry> or a pharmaceutically acceptable salt thereof wherein: <ul id="ul0017" list-style="none" compact="compact"><li>m and o are independently selected from 0, 1, 2, or 3;</li><li>n is 0, 1, 2, 3, or 4;</li><li>X1 is O, S, or NR4;</li><li>X3 is independently at each occurrence selected from the group consisting of C(R3)2, O, S, and NR4;</li><li>X4 is independently at each occurrence selected from the group consisting of CR3 and N;</li><li>X5 is C(R3)2, O, or S;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R1 and R2 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0366" num="0366"><img file="EP4603484A2_D0382.tif" /></chemistry> and <chemistry id="chem0367" num="0367"><img file="EP4603484A2_D0383.tif" /></chemistry></li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine; and R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl.</li></ul></li><li>2. The compound of clause 1, wherein R1 and R2 are selected from <chemistry id="chem0368" num="0368"><img file="EP4603484A2_D0384.tif" /></chemistry></li><li>3. The compound of clause 1 or 2, wherein R4 and R5 are hydrogen.</li><li>4. The compound of any one of clauses 1-3, wherein R is hydrogen.</li><li>5. The compound of any one of clause 1-4, wherein X3 and X4 are NR4 and R4 is hydrogen.</li><li>6. The compound of clause 1 of the structure selected from <chemistry id="chem0369" num="0369"><img file="EP4603484A2_D0385.tif" /></chemistry><chemistry id="chem0370" num="0370"><img file="EP4603484A2_D0386.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>7. A method for the treatment of a bacterial infection comprising administering a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V <chemistry id="chem0371" num="0371"><img file="EP4603484A2_D0387.tif" /></chemistry><chemistry id="chem0372" num="0372"><img file="EP4603484A2_D0388.tif" /></chemistry> or a pharmaceutically acceptable salt to a host in need thereof wherein <ul id="ul0018" list-style="none" compact="compact"><li>L1 is selected from <chemistry id="chem0373" num="0373"><img file="EP4603484A2_D0389.tif" /></chemistry></li><li>L2 is selected from <chemistry id="chem0374" num="0374"><img file="EP4603484A2_D0390.tif" /></chemistry></li><li>v and w are independently selected from 0, 1, 2, 3, and 4;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>X3 is independently at each occurrence selected from the group consisting of C(R3)2, O, S, and NR4;</li><li>X4 is independently at each occurrence selected from the group consisting of CR3 and N;</li><li>X6, X7, X8, and X9 are independently selected from O, S, NH, and Se;</li><li>X10 is selected from Se, S, or NH;</li><li>R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl; and</li><li>R6 and R7 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0375" num="0375"><img file="EP4603484A2_D0391.tif" /></chemistry></li></ul></li><li>8. The method of clause 7, wherein Formula II is selected from <chemistry id="chem0376" num="0376"><img file="EP4603484A2_D0392.tif" /></chemistry><chemistry id="chem0377" num="0377"><img file="EP4603484A2_D0393.tif" /></chemistry><chemistry id="chem0378" num="0378"><img file="EP4603484A2_D0394.tif" /></chemistry> and <chemistry id="chem0379" num="0379"><img file="EP4603484A2_D0395.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>9. The method of clause 7, wherein Formula III is selected from <chemistry id="chem0380" num="0380"><img file="EP4603484A2_D0396.tif" /></chemistry><chemistry id="chem0381" num="0381"><img file="EP4603484A2_D0397.tif" /></chemistry><chemistry id="chem0382" num="0382"><img file="EP4603484A2_D0398.tif" /></chemistry><chemistry id="chem0383" num="0383"><img file="EP4603484A2_D0399.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>10. The method of clause 7, wherein Formula III is a compound of the structure: <chemistry id="chem0384" num="0384"><img file="EP4603484A2_D0400.tif" /></chemistry> and <chemistry id="chem0385" num="0385"><img file="EP4603484A2_D0401.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>11. The method of clause 7, wherein Formula IV is selected from <chemistry id="chem0386" num="0386"><img file="EP4603484A2_D0402.tif" /></chemistry><chemistry id="chem0387" num="0387"><img file="EP4603484A2_D0403.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>12. The method of clause 7, wherein Formula IV is a compound of the structure: <chemistry id="chem0388" num="0388"><img file="EP4603484A2_D0404.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>13. The method of clause 7, wherein Formula V is selected from <chemistry id="chem0389" num="0389"><img file="EP4603484A2_D0405.tif" /></chemistry><chemistry id="chem0390" num="0390"><img file="EP4603484A2_D0406.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>14. The method of clause 7, wherein Formula V is a compound of the structure: <chemistry id="chem0391" num="0391"><img file="EP4603484A2_D0407.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>15. A method for the treatment of a bacterial infection comprising administering a compound selected from Compound A, Compound B, or Compound C: <chemistry id="chem0392" num="0392"><img file="EP4603484A2_D0408.tif" /></chemistry><chemistry id="chem0393" num="0393"><img file="EP4603484A2_D0409.tif" /></chemistry><chemistry id="chem0394" num="0394"><img file="EP4603484A2_D0410.tif" /></chemistry> or a pharmaceutically acceptable salt thereof to a host in need thereof.</li><li>16. A method of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection comprising administering a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V <chemistry id="chem0395" num="0395"><img file="EP4603484A2_D0411.tif" /></chemistry><chemistry id="chem0396" num="0396"><img file="EP4603484A2_D0412.tif" /></chemistry> or a pharmaceutically acceptable salt to a host in need thereof wherein <ul id="ul0019" list-style="none" compact="compact"><li>L1 is selected from <chemistry id="chem0397" num="0397"><img file="EP4603484A2_D0413.tif" /></chemistry></li><li>L2 is selected from <chemistry id="chem0398" num="0398"><img file="EP4603484A2_D0414.tif" /></chemistry></li><li>v and w are independently selected from 0, 1, 2, 3, and 4;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>X3 is independently at each occurrence selected from the group consisting of C(R3)2, O, S, and NR4;</li><li>X4 is independently at each occurrence selected from the group consisting of CR3 and N;</li><li>X6, X7, X8, and X9 are independently selected from O, S, NH, and Se;</li><li>X10 is selected from Se, S, or NH;</li><li>R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl; and</li><li>R6 and R7 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0399" num="0399"><img file="EP4603484A2_D0415.tif" /></chemistry></li></ul></li><li>17. The method of clause 16, wherein Formula III is a compound of the structure: <chemistry id="chem0400" num="0400"><img file="EP4603484A2_D0416.tif" /></chemistry> and <chemistry id="chem0401" num="0401"><img file="EP4603484A2_D0417.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>18. The method of clause 16, wherein Formula IV is a compound of the structure: <chemistry id="chem0402" num="0402"><img file="EP4603484A2_D0418.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>19. The method of clause 16, wherein Formula V is a compound of the structure: <chemistry id="chem0403" num="0403"><img file="EP4603484A2_D0419.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>20. A method of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection comprising administering a compound selected from Compound A, Compound B, or Compound C:<chemistry id="chem0404" num="0404"><img file="EP4603484A2_D0420.tif" /></chemistry><chemistry id="chem0405" num="0405"><img file="EP4603484A2_D0421.tif" /></chemistry><chemistry id="chem0406" num="0406"><img file="EP4603484A2_D0422.tif" /></chemistry> or a pharmaceutically acceptable salt thereof to a host in need thereof.</li><li>21. The method of any one of clauses 7-20, wherein the bacterial infection is caused by a gram-positive bacterial infection.</li><li>22. The method of any one of clauses 7-20, wherein the bacterial infection is caused by a gram-negative bacterial infection.</li><li>23. The method of any one of clauses 7-20, wherein the bacterial infection is caused by a mycobacterium.</li><li>24. A method for the treatment of a gram-positive or gram-negative bacterial infection comprising administering a compound selected from Compound D or Compound E<chemistry id="chem0407" num="0407"><img file="EP4603484A2_D0423.tif" /></chemistry><chemistry id="chem0408" num="0408"><img file="EP4603484A2_D0424.tif" /></chemistry> or a pharmaceutically acceptable salt thereof to a host in need thereof.</li><li>25. A method of potentiating the therapeutic effect of an antibiotic during the treatment of a gram-positive or gram-negative bacterial infection comprising administering a compound selected from Compound D or Compound E<chemistry id="chem0409" num="0409"><img file="EP4603484A2_D0425.tif" /></chemistry><chemistry id="chem0410" num="0410"><img file="EP4603484A2_D0426.tif" /></chemistry> or a pharmaceutically acceptable salt thereof to a host in need thereof.</li><li>26. A method for the treatment of a bacterial infection comprising administering a compound or pharmaceutically acceptable salt thereof selected from any one of clauses 1-6.</li><li>27. A method of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection comprising administering a compound or pharmaceutically acceptable salt thereof selected from any one of clauses 1-6.</li><li>28. A method for the treatment of a gram-positive or gram-negative bacterial infection comprising administering a compound of Formula VI <chemistry id="chem0411" num="0411"><img file="EP4603484A2_D0427.tif" /></chemistry> or a pharmaceutically acceptable salt thereof wherein <ul id="ul0020" list-style="none" compact="compact"><li>R9 and R12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano; and</li><li>R10 and R11 are independently at each occurrence selected from the group consisting of hydroxyl, C1-C6alkanoyl, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, - C(O)R, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)S2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano.</li></ul></li><li>29. The method of clause 28, wherein Formula VI is a compound of the formula: <chemistry id="chem0412" num="0412"><img file="EP4603484A2_D0428.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>30. The method of clause 28, wherein Formula VI is selected from: <chemistry id="chem0413" num="0413"><img file="EP4603484A2_D0429.tif" /></chemistry><chemistry id="chem0414" num="0414"><img file="EP4603484A2_D0430.tif" /></chemistry><chemistry id="chem0415" num="0415"><img file="EP4603484A2_D0431.tif" /></chemistry><chemistry id="chem0416" num="0416"><img file="EP4603484A2_D0432.tif" /></chemistry><chemistry id="chem0417" num="0417"><img file="EP4603484A2_D0433.tif" /></chemistry> and <chemistry id="chem0418" num="0418"><img file="EP4603484A2_D0434.tif" /></chemistry></li><li>31. The method of any one of clauses 7-30, wherein the host is a human.</li><li>32. A compound selected from Compound F - Compound L <chemistry id="chem0419" num="0419"><img file="EP4603484A2_D0435.tif" /></chemistry><chemistry id="chem0420" num="0420"><img file="EP4603484A2_D0436.tif" /></chemistry><chemistry id="chem0421" num="0421"><img file="EP4603484A2_D0437.tif" /></chemistry><chemistry id="chem0422" num="0422"><img file="EP4603484A2_D0438.tif" /></chemistry><chemistry id="chem0423" num="0423"><img file="EP4603484A2_D0439.tif" /></chemistry><chemistry id="chem0424" num="0424"><img file="EP4603484A2_D0440.tif" /></chemistry><chemistry id="chem0425" num="0425"><img file="EP4603484A2_D0441.tif" /></chemistry> or a pharmaceutically acceptable salt thereof.</li><li>33. A method for the treatment of a bacterial infection comprising administering a compound or pharmaceutically acceptable salt thereof of clause 32.</li><li>34. A method of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection comprising administering a compound or pharmaceutically acceptable salt thereof of clause 32.</li><li>35. The method of clause 26, 27, 33, or 34, wherein the bacterial infection is caused by gram-positive bacteria.</li><li>36. The method of clause 26, 27, 33, or 34, wherein the bacterial infection is caused by gram-negative bacteria.</li><li>37. The method of clause 26, 27, 33, or 34, wherein the bacterial infection is caused by mycobacterium.</li><li>38. A pharmaceutical composition comprising a compound of any one of clauses 1-6, optionally in a pharmaceutically acceptable carrier.</li><li>39. A pharmaceutical composition comprising a compound of clause 32, optionally in a pharmaceutically acceptable carrier.</li><li>40. A pharmaceutical composition comprising a compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI: <chemistry id="chem0426" num="0426"><img file="EP4603484A2_D0442.tif" /></chemistry><chemistry id="chem0427" num="0427"><img file="EP4603484A2_D0443.tif" /></chemistry><chemistry id="chem0428" num="0428"><img file="EP4603484A2_D0444.tif" /></chemistry><chemistry id="chem0429" num="0429"><img file="EP4603484A2_D0445.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in combination with an effective amount of an antibiotic for the treatment of a bacterial infection in a host in need thereof wherein: <ul id="ul0021" list-style="none" compact="compact"><li>m and o are independently selected from 0, 1, 2, or 3;</li><li>n is 0, 1, 2, 3, or 4;</li><li>L1 is selected from <chemistry id="chem0430" num="0430"><img file="EP4603484A2_D0446.tif" /></chemistry></li><li>L2 is selected from <chemistry id="chem0431" num="0431"><img file="EP4603484A2_D0447.tif" /></chemistry></li><li>v and w are independently selected from 0, 1, 2, 3, and 4;</li><li>X1 is O, S, or NR4;</li><li>X3 is independently at each occurrence selected from the group consisting of C(R3)2, O, S, and NR4;</li><li>X4 is independently at each occurrence selected from the group consisting of CR3 and N;</li><li>X5 is C(R3)2, O, or S;</li><li>X6, X7, X8, and X9 are independently selected from O, S, NH, and Se;</li><li>X10 is selected from Se, S, or NH;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R1 and R2 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0432" num="0432"><img file="EP4603484A2_D0448.tif" /></chemistry> and <chemistry id="chem0433" num="0433"><img file="EP4603484A2_D0449.tif" /></chemistry></li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;</li><li>R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl; and</li><li>R6 and R7 are independently at each occurrence selected from the group consisting of: <chemistry id="chem0434" num="0434"><img file="EP4603484A2_D0450.tif" /></chemistry></li><li>R9 and R12 are independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano; and</li><li>R10 and R11 are independently at each occurrence selected from the group consisting of hydroxyl, C1-C6alkanoyl, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, - C(O)R, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, bromine, iodine, thiol, and cyano.</li></ul></li><li>41. A pharmaceutical composition comprising a compound selected from Compound A, Compound B, Compound C, or Compound D<chemistry id="chem0435" num="0435"><img file="EP4603484A2_D0451.tif" /></chemistry><chemistry id="chem0436" num="0436"><img file="EP4603484A2_D0452.tif" /></chemistry><chemistry id="chem0437" num="0437"><img file="EP4603484A2_D0453.tif" /></chemistry><chemistry id="chem0438" num="0438"><img file="EP4603484A2_D0454.tif" /></chemistry> or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, in combination with an effective amount of an antibiotic for the treatment of a bacterial infection in a host in need thereof.</li><li>42. A compound of Formula VII: <chemistry id="chem0439" num="0439"><img file="EP4603484A2_D0455.tif" /></chemistry> wherein: <ul id="ul0022" list-style="none" compact="compact"><li>m and n are independently selected from 1, 2, 3, or 4;</li><li>p is 0, 1, 2, or 3;</li><li>q and t are independently at each occurrence 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>L3 and L4 are each independently C(R3)2, O, or S;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, - N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, - SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;</li><li>R13 and R14 are independently at each occurrence selected from the group consisting of <chemistry id="chem0440" num="0440"><img file="EP4603484A2_D0456.tif" /></chemistry> and -C(R3)oNR4R5</li><li>wherein R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl and o is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>X11 and X12 are each independently selected from the group consisting of C(R3)2, O, NH, or S;</li><li>Y1 and Y2 are each independently selected from the group consisting of C(R3)2, O, NH, or S; and</li><li>Z is CR3 or N.</li></ul></li><li>43. The compound of clause 42, wherein R4 and R5 are hydrogen.</li><li>44. The compound of clause 42 or 43, wherein X11 and X12 are the same.</li><li>45. The compound of any one of clauses 42-44, wherein X11 and X12 are selected from the group consisting of O, CH2, and S.</li><li>46. The compound of any one of clauses 42-45, wherein Y1 and Y2 are the same.</li><li>47. The compound of any one of clauses 42-46, wherein Y1 and Y2 are selected from the group consisting of O and CH2.</li><li>48. The compound of any one of clauses 42-47, wherein each R is independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and fluorine.</li><li>49. The compound of clause 42, wherein the compound has the following structure: <chemistry id="chem0441" num="0441"><img file="EP4603484A2_D0457.tif" /></chemistry></li><li>50. The compound of clause 42, wherein the structure is selected from: <chemistry id="chem0442" num="0442"><img file="EP4603484A2_D0458.tif" /></chemistry><chemistry id="chem0443" num="0443"><img file="EP4603484A2_D0459.tif" /></chemistry><chemistry id="chem0444" num="0444"><img file="EP4603484A2_D0460.tif" /></chemistry><chemistry id="chem0445" num="0445"><img file="EP4603484A2_D0461.tif" /></chemistry><chemistry id="chem0446" num="0446"><img file="EP4603484A2_D0462.tif" /></chemistry><chemistry id="chem0447" num="0447"><img file="EP4603484A2_D0463.tif" /></chemistry><chemistry id="chem0448" num="0448"><img file="EP4603484A2_D0464.tif" /></chemistry><chemistry id="chem0449" num="0449"><img file="EP4603484A2_D0465.tif" /></chemistry><chemistry id="chem0450" num="0450"><img file="EP4603484A2_D0466.tif" /></chemistry><chemistry id="chem0451" num="0451"><img file="EP4603484A2_D0467.tif" /></chemistry><chemistry id="chem0452" num="0452"><img file="EP4603484A2_D0468.tif" /></chemistry><chemistry id="chem0453" num="0453"><img file="EP4603484A2_D0469.tif" /></chemistry><chemistry id="chem0454" num="0454"><img file="EP4603484A2_D0470.tif" /></chemistry><chemistry id="chem0455" num="0455"><img file="EP4603484A2_D0471.tif" /></chemistry><chemistry id="chem0456" num="0456"><img file="EP4603484A2_D0472.tif" /></chemistry><chemistry id="chem0457" num="0457"><img file="EP4603484A2_D0473.tif" /></chemistry><chemistry id="chem0458" num="0458"><img file="EP4603484A2_D0474.tif" /></chemistry><chemistry id="chem0459" num="0459"><img file="EP4603484A2_D0475.tif" /></chemistry><chemistry id="chem0460" num="0460"><img file="EP4603484A2_D0476.tif" /></chemistry><chemistry id="chem0461" num="0461"><img file="EP4603484A2_D0477.tif" /></chemistry><chemistry id="chem0462" num="0462"><img file="EP4603484A2_D0478.tif" /></chemistry><chemistry id="chem0463" num="0463"><img file="EP4603484A2_D0479.tif" /></chemistry><chemistry id="chem0464" num="0464"><img file="EP4603484A2_D0480.tif" /></chemistry><chemistry id="chem0465" num="0465"><img file="EP4603484A2_D0481.tif" /></chemistry><chemistry id="chem0466" num="0466"><img file="EP4603484A2_D0482.tif" /></chemistry><chemistry id="chem0467" num="0467"><img file="EP4603484A2_D0483.tif" /></chemistry></li><li>51. The compound of clause 42, wherein the compound is <chemistry id="chem0468" num="0468"><img file="EP4603484A2_D0484.tif" /></chemistry></li><li>52. A compound of Formula VIII: <chemistry id="chem0469" num="0469"><img file="EP4603484A2_D0485.tif" /></chemistry> wherein: <ul id="ul0023" list-style="none" compact="compact"><li>m and n are independently selected from 1, 2, 3, or 4;</li><li>p is 0, 1, 2, or 3;</li><li>q and t are independently at each occurrence 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>L3 and L4 are each independently C(R3)2, O, or S;</li><li>R is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, aliphatic, carbocyclic, C1-C6hydroxyalkyl, C1-C6haloalkyl, N(R3)2, -NHSO2alkyl, -N(alkyl)SO2alkyl, -NHSO2aryl, -N(alkyl)SO2aryl, -NHSO2alkenyl, -N(alkyl)SO2alkenyl, -NHSO2alkynyl, -N(alkyl)SO2alkynyl, NO2, -COOH, -CONH2, -P(O)(OH)2, -S(O)R3, -SO2R3, -SO3R3, -SO2N(R3)2, -OSO2R3, -N(R3)SO2R3, azide, aryl, heteroaryl, heterocyclyl, fluorine, chlorine, bromine, iodine, thiol, and cyano;</li><li>R3 is independently at each occurrence selected from the group consisting of hydrogen, hydroxyl, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkanoyl, carbocyclic, C2-C6alkenyl, C2-C6alkynyl, heteroaryl, aryl, heterocyclyl, -COOR, -C(O)R, fluorine, chlorine, bromine, and iodine;</li><li>R13 and R14 are independently at each occurrence selected from the group consisting of <chemistry id="chem0470" num="0470"><img file="EP4603484A2_D0486.tif" /></chemistry> and -C(R3)oNR4R5</li><li>wherein R4 and R5 are independently at each occurrence selected from the group consisting of hydrogen and C1-C6alkyl and o is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;</li><li>X11 and X12 are each independently selected from the group consisting of C(R3)2, O, NH, or S;</li><li>Y1 and Y2 are each independently selected from the group consisting of C(R3)2, O, NH, or S; and</li><li>Z is CR3 or N.</li></ul></li><li>53. The compound of clause 52, wherein R4 and R5 are hydrogen.</li><li>54. The compound of clause 52 or 53, wherein X11 and X12 are the same.</li><li>55. The compound of any one of clauses 52-54, wherein X11 and X12 are selected from the group consisting of O, CH2, and S.</li><li>56. The compound of any one of clauses 52-55, wherein Y1 and Y2 are the same.</li><li>57. The compound of any one of clauses 52-56, wherein Y1 and Y2 are selected from the group consisting of O and CH2.</li><li>58. The compound of any one of clauses 52-57, wherein each R is independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6alkoxy, C1-C6haloalkyl, and fluorine.</li><li>59. The compound of clause 52, wherein the compound has the following structure: <chemistry id="chem0471" num="0471"><img file="EP4603484A2_D0487.tif" /></chemistry></li><li>60. The compound of clause 52, wherein the compound is <chemistry id="chem0472" num="0472"><img file="EP4603484A2_D0488.tif" /></chemistry></li><li>61. A method for the treatment of a bacterial infection comprising administering a compound or pharmaceutically acceptable salt thereof of any one of clauses 42-60.</li><li>62. A method of potentiating the therapeutic effect of an antibiotic during the treatment of a bacterial infection comprising administering a compound or pharmaceutically acceptable salt thereof of any one of clauses 42-60.</li><li>63. The method of clause 61 or 62, wherein the bacterial infection is caused by gram-positive bacteria.</li><li>64. The method of clause 61 or 62, wherein the bacterial infection is caused by gram-negative bacteria.</li><li>65. The method of clause 61 or 62, wherein the bacterial infection is caused by a mycobacterium.</li><li>66. A pharmaceutical composition comprising a compound of any one of clauses 42-60, optionally in a pharmaceutically acceptable carrier.</li></ol>

Contents15

569 sheets

Sheet 1
Sheet 2
Sheet 3
Sheet 4
Sheet 5
Sheet 6
Sheet 7
Sheet 8
Sheet 9
Sheet 10
Sheet 11
Sheet 12
Sheet 13
Sheet 14
Sheet 15
Sheet 16
Sheet 17
Sheet 18
Sheet 19
Sheet 20
Sheet 21
Sheet 22
Sheet 23
Sheet 24
Sheet 25
Sheet 26
Sheet 27
Sheet 28
Sheet 29
Sheet 30
Sheet 31
Sheet 32
Sheet 33
Sheet 34
Sheet 35
Sheet 36
Sheet 37
Sheet 38
Sheet 39
Sheet 40
Sheet 41
Sheet 42
Sheet 43
Sheet 44
Sheet 45
Sheet 46
Sheet 47
Sheet 48
Sheet 49
Sheet 50
Sheet 51
Sheet 52
Sheet 53
Sheet 54
Sheet 55
Sheet 56
Sheet 57
Sheet 58
Sheet 59
Sheet 60
Sheet 61
Sheet 62
Sheet 63
Sheet 64
Sheet 65
Sheet 66
Sheet 67
Sheet 68
Sheet 69
Sheet 70
Sheet 71
Sheet 72
Sheet 73
Sheet 74
Sheet 75
Sheet 76
Sheet 77
Sheet 78
Sheet 79
Sheet 80
Sheet 81
Sheet 82
Sheet 83
Sheet 84
Sheet 85
Sheet 86
Sheet 87
Sheet 88
Sheet 89
Sheet 90
Sheet 91
Sheet 92
Sheet 93
Sheet 94
Sheet 95
Sheet 96
Sheet 97
Sheet 98
Sheet 99
Sheet 100
Sheet 101
Sheet 102
Sheet 103
Sheet 104
Sheet 105
Sheet 106
Sheet 107
Sheet 108
Sheet 109
Sheet 110
Sheet 111
Sheet 112
Sheet 113
Sheet 114
Sheet 115
Sheet 116
Sheet 117
Sheet 118
Sheet 119
Sheet 120
Sheet 121
Sheet 122
Sheet 123
Sheet 124
Sheet 125
Sheet 126
Sheet 127
Sheet 128
Sheet 129
Sheet 130
Sheet 131
Sheet 132
Sheet 133
Sheet 134
Sheet 135
Sheet 136
Sheet 137
Sheet 138
Sheet 139
Sheet 140
Sheet 141
Sheet 142
Sheet 143
Sheet 144
Sheet 145
Sheet 146
Sheet 147
Sheet 148
Sheet 149
Sheet 150
Sheet 151
Sheet 152
Sheet 153
Sheet 154
Sheet 155
Sheet 156
Sheet 157
Sheet 158
Sheet 159
Sheet 160
Sheet 161
Sheet 162
Sheet 163
Sheet 164
Sheet 165
Sheet 166
Sheet 167
Sheet 168
Sheet 169
Sheet 170
Sheet 171
Sheet 172
Sheet 173
Sheet 174
Sheet 175
Sheet 176
Sheet 177
Sheet 178
Sheet 179
Sheet 180
Sheet 181
Sheet 182
Sheet 183
Sheet 184
Sheet 185
Sheet 186
Sheet 187
Sheet 188
Sheet 189
Sheet 190
Sheet 191
Sheet 192
Sheet 193
Sheet 194
Sheet 195
Sheet 196
Sheet 197
Sheet 198
Sheet 199
Sheet 200
Sheet 201
Sheet 202
Sheet 203
Sheet 204
Sheet 205
Sheet 206
Sheet 207
Sheet 208
Sheet 209
Sheet 210
Sheet 211
Sheet 212
Sheet 213
Sheet 214
Sheet 215
Sheet 216
Sheet 217
Sheet 218
Sheet 219
Sheet 220
Sheet 221
Sheet 222
Sheet 223
Sheet 224
Sheet 225
Sheet 226
Sheet 227
Sheet 228
Sheet 229
Sheet 230
Sheet 231
Sheet 232
Sheet 233
Sheet 234
Sheet 235
Sheet 236
Sheet 237
Sheet 238
Sheet 239
Sheet 240
Sheet 241
Sheet 242
Sheet 243
Sheet 244
Sheet 245
Sheet 246
Sheet 247
Sheet 248
Sheet 249
Sheet 250
Sheet 251
Sheet 252
Sheet 253
Sheet 254
Sheet 255
Sheet 256
Sheet 257
Sheet 258
Sheet 259
Sheet 260
Sheet 261
Sheet 262
Sheet 263
Sheet 264
Sheet 265
Sheet 266
Sheet 267
Sheet 268
Sheet 269
Sheet 270
Sheet 271
Sheet 272
Sheet 273
Sheet 274
Sheet 275
Sheet 276
Sheet 277
Sheet 278
Sheet 279
Sheet 280
Sheet 281
Sheet 282
Sheet 283
Sheet 284
Sheet 285
Sheet 286
Sheet 287
Sheet 288
Sheet 289
Sheet 290
Sheet 291
Sheet 292
Sheet 293
Sheet 294
Sheet 295
Sheet 296
Sheet 297
Sheet 298
Sheet 299
Sheet 300
Sheet 301
Sheet 302
Sheet 303
Sheet 304
Sheet 305
Sheet 306
Sheet 307
Sheet 308
Sheet 309
Sheet 310
Sheet 311
Sheet 312
Sheet 313
Sheet 314
Sheet 315
Sheet 316
Sheet 317
Sheet 318
Sheet 319
Sheet 320
Sheet 321
Sheet 322
Sheet 323
Sheet 324
Sheet 325
Sheet 326
Sheet 327
Sheet 328
Sheet 329
Sheet 330
Sheet 331
Sheet 332
Sheet 333
Sheet 334
Sheet 335
Sheet 336
Sheet 337
Sheet 338
Sheet 339
Sheet 340
Sheet 341
Sheet 342
Sheet 343
Sheet 344
Sheet 345
Sheet 346
Sheet 347
Sheet 348
Sheet 349
Sheet 350
Sheet 351
Sheet 352
Sheet 353
Sheet 354
Sheet 355
Sheet 356
Sheet 357
Sheet 358
Sheet 359
Sheet 360
Sheet 361
Sheet 362
Sheet 363
Sheet 364
Sheet 365
Sheet 366
Sheet 367
Sheet 368
Sheet 369
Sheet 370
Sheet 371
Sheet 372
Sheet 373
Sheet 374
Sheet 375
Sheet 376
Sheet 377
Sheet 378
Sheet 379
Sheet 380
Sheet 381
Sheet 382
Sheet 383
Sheet 384
Sheet 385
Sheet 386
Sheet 387
Sheet 388
Sheet 389
Sheet 390
Sheet 391
Sheet 392
Sheet 393
Sheet 394
Sheet 395
Sheet 396
Sheet 397
Sheet 398
Sheet 399
Sheet 400
Sheet 401
Sheet 402
Sheet 403
Sheet 404
Sheet 405
Sheet 406
Sheet 407
Sheet 408
Sheet 409
Sheet 410
Sheet 411
Sheet 412
Sheet 413
Sheet 414
Sheet 415
Sheet 416
Sheet 417
Sheet 418
Sheet 419
Sheet 420
Sheet 421
Sheet 422
Sheet 423
Sheet 424
Sheet 425
Sheet 426
Sheet 427
Sheet 428
Sheet 429
Sheet 430
Sheet 431
Sheet 432
Sheet 433
Sheet 434
Sheet 435
Sheet 436
Sheet 437
Sheet 438
Sheet 439
Sheet 440
Sheet 441
Sheet 442
Sheet 443
Sheet 444
Sheet 445
Sheet 446
Sheet 447
Sheet 448
Sheet 449
Sheet 450
Sheet 451
Sheet 452
Sheet 453
Sheet 454
Sheet 455
Sheet 456
Sheet 457
Sheet 458
Sheet 459
Sheet 460
Sheet 461
Sheet 462
Sheet 463
Sheet 464
Sheet 465
Sheet 466
Sheet 467
Sheet 468
Sheet 469
Sheet 470
Sheet 471
Sheet 472
Sheet 473
Sheet 474
Sheet 475
Sheet 476
Sheet 477
Sheet 478
Sheet 479
Sheet 480
Sheet 481
Sheet 482
Sheet 483
Sheet 484
Sheet 485
Sheet 486
Sheet 487
Sheet 488
Sheet 489
Sheet 490
Sheet 491
Sheet 492
Sheet 493
Sheet 494
Sheet 495
Sheet 496
Sheet 497
Sheet 498
Sheet 499
Sheet 500
Sheet 501
Sheet 502
Sheet 503
Sheet 504
Sheet 505
Sheet 506
Sheet 507
Sheet 508
Sheet 509
Sheet 510
Sheet 511
Sheet 512
Sheet 513
Sheet 514
Sheet 515
Sheet 516
Sheet 517
Sheet 518
Sheet 519
Sheet 520
Sheet 521
Sheet 522
Sheet 523
Sheet 524
Sheet 525
Sheet 526
Sheet 527
Sheet 528
Sheet 529
Sheet 530
Sheet 531
Sheet 532
Sheet 533
Sheet 534
Sheet 535
Sheet 536
Sheet 537
Sheet 538
Sheet 539
Sheet 540
Sheet 541
Sheet 542
Sheet 543
Sheet 544
Sheet 545
Sheet 546
Sheet 547
Sheet 548
Sheet 549
Sheet 550
Sheet 551
Sheet 552
Sheet 553
Sheet 554
Sheet 555
Sheet 556
Sheet 557
Sheet 558
Sheet 559
Sheet 560
Sheet 561
Sheet 562
Sheet 563
Sheet 564
Sheet 565
Sheet 566
Sheet 567
Sheet 568
Sheet 569

Every citation, both ways

Citations
Document	Relation	Office	Cited during
WO0031068A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO02055025A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO03017994A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO03103598A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
EP1726589A2	Cites	European Patent Office (EPO)	Applicant
US2003202944A1	Cites	United States of America	Applicant
WO2005033065A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2005040132A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2005044186A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2005086754A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2005086808A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2005089738A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
US2005152849A1	Cites	United States of America	Applicant
WO2006021833A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2006033584A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
US2006293540A1	Cites	United States of America	Applicant
US2007043030A1	Cites	United States of America	Applicant
WO2008090831A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
US2008132457A1	Cites	United States of America	Applicant
WO2009051796A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2009105691A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
US2009269412A1	Cites	United States of America	Applicant
WO2010133748A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
US2010249175A1	Cites	United States of America	Applicant
US2010285142A1	Cites	United States of America	Applicant
US2010330188A1	Cites	United States of America	Applicant
US2012114709A1	Cites	United States of America	Applicant
WO2013038170A2	Cites	World Intellectual Property Organization (WIPO)	Applicant
US2013287854A1	Cites	United States of America	Applicant
US2014037737A1	Cites	United States of America	Applicant
US2014352690A1	Cites	United States of America	Applicant
US2015050350A1	Cites	United States of America	Applicant
US2015165137A1	Cites	United States of America	Applicant
US2015174343A1	Cites	United States of America	Applicant
WO2017223260A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2018045104A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO2018045106A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
US4034010A	Cites	United States of America	Applicant
US4619942A	Cites	United States of America	Applicant
US4983593A	Cites	United States of America	Applicant
US5013557A	Cites	United States of America	Applicant
US5456923A	Cites	United States of America	Applicant
US5576025A	Cites	United States of America	Applicant
US5723269A	Cites	United States of America	Applicant
US5858411A	Cites	United States of America	Applicant
US6221338B1	Cites	United States of America	Applicant
US6254889B1	Cites	United States of America	Applicant
US6303148B1	Cites	United States of America	Applicant
US6395302B1	Cites	United States of America	Applicant
US6497903B1	Cites	United States of America	Applicant
US6582678B2	Cites	United States of America	Applicant
US6948496B2	Cites	United States of America	Applicant
US6989155B1	Cites	United States of America	Applicant
US7060296B2	Cites	United States of America	Applicant
US7078057B2	Cites	United States of America	Applicant
US7383837B2	Cites	United States of America	Applicant
US7404828B1	Cites	United States of America	Applicant
US7541022B2	Cites	United States of America	Applicant
US7744855B2	Cites	United States of America	Applicant
US7845349B2	Cites	United States of America	Applicant
US8101160B2	Cites	United States of America	Applicant
US8137657B2	Cites	United States of America	Applicant
US8202912B2	Cites	United States of America	Applicant
US8205611B2	Cites	United States of America	Applicant
US8257741B2	Cites	United States of America	Applicant
US8263128B2	Cites	United States of America	Applicant
US8337899B2	Cites	United States of America	Applicant
US8431159B2	Cites	United States of America	Applicant
US8580306B2	Cites	United States of America	Applicant
US8910625B2	Cites	United States of America	Applicant
US9028870B2	Cites	United States of America	Applicant
US9060938B2	Cites	United States of America	Applicant
US9095670B2	Cites	United States of America	Applicant
US9211261B2	Cites	United States of America	Applicant
US9265731B2	Cites	United States of America	Applicant
US9358478B2	Cites	United States of America	Applicant
US9387252B2	Cites	United States of America	Applicant
WO9628427A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
WO9729067A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
US9960588B2	Cites	United States of America	Applicant
SANDS ET AL.: "Pentamidine: A Review", REVIEWS OF INFECTIOUS DISEASES, vol. 7, no. 5, 1985, pages 625 - 634	Non-patent	–	Applicant
STOKES ET AL.: "Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance", NAT. MICROBIOL., vol. 2, 2017, pages 17028	Non-patent	–	Applicant
BEAN ET AL.: "Pentamidine: a drug to consider re-purposing in the targeted treatment of multi-drug resistant bacterial infections?", J. LAB. PRECIS. MED., vol. 2, 2017, pages 49	Non-patent	–	Applicant
GERATZ ET AL.: "Novel Bis(benzamidino) Compounds with an Aromatic Central Link. Inhibitors of Thrombin, Pancreatic Kallikrein, Trypsin, and Complement", J. MED. CHEM., vol. 19, no. 5, 1976, pages 634, XP000573915, DOI: 10.1021/jm00227a011	Non-patent	–	Applicant
PARRISH ET AL.: "Structure-Activity Relationships for the Inhibition of Acrosin by Benzamidine Derivatives", J. MED. CHEM., vol. 21, no. 11, 1978, pages 1132, XP000573914, DOI: 10.1021/jm00209a008	Non-patent	–	Applicant
PATRICK ET AL.: "Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyoxy)naphthalenes", EUR. J. MED. CHEM., vol. 44, 2009, pages 3543, XP026322180, DOI: 10.1016/j.ejmech.2009.03.014	Non-patent	–	Applicant
GIORDANI ET AL.: "Green Fluorescent Diamidine as Diagnostic Probes for Trypanosomes", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 58, 2014, pages 1793	Non-patent	–	Applicant
MUNDE ET AL.: "The Unusual Monomer Recognition of Guanine-Containing Mixed Sequence DNA by a Dithiophene Heterocyclic Diamidine", BIOCHEMISTRY, vol. 53, 2014, pages 1218	Non-patent	–	Applicant
ARAFA: "Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozal agents", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, 2008, pages 2901 - 2908, XP025714737, DOI: 10.1016/j.ejmech.2008.02.008	Non-patent	–	Applicant
STEPHENS ET AL.: "Diguanidino and ''Reversed'' Diamidino 2,5-Diarylfurans as Antimicrobial Agents", J. MED. CHEM, vol. 44, 2001, pages 1741, XP002955210, DOI: 10.1021/jm000413a	Non-patent	–	Applicant
MUNDE ET AL.: "Structure-dependent inhibition of the ETS-family transcription factor PU.1 by novel heterocyclic diamidines", NUCLEIC ACIDS RESEARCH, vol. 42, 2014, pages 1379, XP055335515, DOI: 10.1093/nar/gkt955	Non-patent	–	Applicant
GONZALEZ: "Synthesis and antiparasitic evaluation of bis-2,5-[4-guanidinophenyl]thiophenes", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, 2007, pages 552 - 557, XP022015937, DOI: 10.1016/j.ejmech.2006.11.006	Non-patent	–	Applicant
WANG ET AL.: "Evaluation of the Influence of Compound Structure on Stacked-Dimer Formation in the DNA Minor Groove", BIOCHEMISTRY, vol. 40, 2001, pages 2511, XP002333540, DOI: 10.1021/bi002301r	Non-patent	–	Applicant
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418	Non-patent	–	Applicant
ISMAIL MABOYKIN DWSTEPHENS CE: "An efficient synthesis of 2,5'-diarylbichalcophenes", TETRAHEDRON LETTERS, vol. 47, 2006, pages 795 - 797	Non-patent	–	Applicant

7 members in 4 offices

This recordMember, by publication date

Members7

Family members, oldest first
Document	Office	Kind
WO2021127452A1	World Intellectual Property Organization (WIPO)	A1	2021-06-24
CN114845708A	China	A	2022-08-02
EP4076420A1	European Patent Office (EPO)	A1	2022-10-26
US2023105108A1	United States of America	A1	2023-04-06
EP4076420A4	European Patent Office (EPO)	A4	2024-03-13
CN119837855A	China	A	2025-04-18
EP4603484A2This record	European Patent Office (EPO)	A2	2025-08-20

13 legal events, as 2 offices reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code	Office
2026-01-21	Designated contracting statesAK	AK	EP
2026-01-21	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2026-01-21	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2026-01-21	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2025-12-19	Search report despatchedORIGINAL CODE: 0009013PUAL	PUAL	EP
2025-10-29	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2025-10-29	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2025-10-29	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2025-09-25	Amendment of ipc main classPREVIOUS MAIN CLASS: C07D0345000000R079	R079	DE
2025-08-20	Divisional application: reference to earlier applicationAC	AC	EP
2025-08-20	Designated contracting statesAK	AK	EP
2025-07-18	Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI	PUAI	EP
2025-07-18	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION HAS BEEN PUBLISHEDSTAA	STAA	EP